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General introduction 
The primary aim of this thesis was to investigate whether asthma could be 
prevented in children with a genetic predisposition by educating parents about 
multiple measures for simultaneously optimising their child’s exposure to 
environmental exposures associated with asthma. The measures focused upon 
were lowering the exposure to inhalant allergens and food allergens, 
breastfeeding promotion and reducing exposure to environmental tobacco 
smoke. 
Asthma  
Asthma is a chronic disease of the respiratory system that is characterized by 
excessive inflammatory response to specific and non-specific exposures like 
allergens and physical exercise.1,2 Wheezing, night-time coughing and 
dyspnoea are the symptoms that are associated with asthma.  
Usually the treatment advised, is environmental control and medication use 
(inhaled corticosteroids, beta2sympatico-mimetics, anticholinergics, anti-
histamines).2,3 Although asthma can often be treated successfully, it can have 
major consequences for children’s well-being.4 It is the most common chronic 
disease in childhood that can lead to teasing in primary school.5 Growth and 
development can be disadvantaged by periods of symptoms and medication 
use,5,6 and often children are not able to go to school because of respiratory 
complaints and visits to doctors.5, 7  
Prevalence  
A five-fold increase in the prevalence of asthma has been observed in 
developed countries between 1980 and 2000.8 This tendency seems to have 
reversed thereafter.8 The most recently observed (2006) prevalence of asthma 
in children aged five to eight years was approximately 5.7 to 10.5%.9,10  
Asthma is known to be a disease that is associated with both genetic and 
environmental factors.11 As a consequence, genetically predisposed children 
may not develop asthma when environmental exposures are adequately 
reduced.  
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Hypotheses concerning the primary prevention of 
asthma in children by means of environmental exposure 
There are several hypotheses concerning the prevention of asthma. One of 
these is the hygiene hypothesis, which assumes that a high infection load for 
children aged 0-2 years is associated with a proper development of the immune 
system.12 The hygiene hypothesis implies that in children exposed to infectious 
agents a skewing of the immune response towards a healthy balance of the 
T-helper cells (Th) type 1 and 2 will be reached. This view has been shown to 
be an over-simplification of the complexity of the immune system, since recently 
a third T-cell population (Treg) has been shown to regulate the function of both 
‘players’ in the Th1/Th2 paradigm.13-15 One consequence of this hypothesis has 
been that some parents have decided not to vaccinate their child because they 
shared the opinion that the immune system of children needed to be exposed to 
infectious agents in order to eventually develop an adequately reacting immune 
system. The hygiene hypothesis has never been proved thus far. It seems 
plausible, however, that certain elements of the hygiene hypothesis may be 
correct. 
Not only viruses and bacteria but also pro-biotics – products containing inactive 
infectious agents – are the subject of research.16 The major topic in recent 
research into pro-biotics is the prevention of atopy and more specifically atopic 
dermatitis.16,17 Pro-biotics are known for their presumed positive influence on 
the microbial balance of the intestine.  
Another environmental factor that has been the focus of asthma research is the 
influence of the supplementation of poly-unsaturated fatty acids of the n-3 and 
n-6 family. Most research on fatty acid supplementation is carried out in terms 
of its influence on atopic dermatitis, but asthma research regarding this topic is 
expanding.18-20 
Allergen exposure is the main subject of research as far as the primary 
prevention of asthma is concerned. It is hypothesized that children raised in an 
environment with low exposure will less frequently develop asthma as 
compared to children exposed to high levels of allergens. The studies on 
interventions based on allergen reduction are aimed at reducing exposure to 
either 1) single allergen levels (mono-faceted interventions) or 2) multiple 
allergens simultaneously (multi-faceted interventions). Several studies have 
been carried out on allergen reduction as primary preventive intervention aimed 
at the development of asthma in children. Results so far suggest that multi-
faceted interventions have promising effects on reducing the prevalence of 
asthma.21-26 Mono-faceted interventions however were no more effective than 
controls in the reduction of asthma.27-30 
Sometimes multi-faceted allergen-reducing interventions have been combined 
with reduction in other exposures like environmental tobacco smoke (ETS).31 It 
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is known that ETS exposure has a negative influence on the development of the 
lungs.32,33 
Stimulation of exclusive breastfeeding during the first months of life is an often-
used intervention for reducing food allergens in mono- as well as multi-faceted 
intervention studies. Human milk contains immunological components such as 
immune globulin G (IgG), secretory immune globulin A (sIgA) and cytokines.34-37 
Non-immunological components in breastfeeding that might possibly influence 
the development of the immune system are the anti-bacterial enzyme lysosym, 
oligosaccharides (prebiotics), hormones and growth factors.34-37 
Main subject of the present thesis 
The study described in this thesis is the PREVASC study on the primary 
prevention of asthma in children susceptible to the development of asthma.  
The intervention used in the PREVASC study was based on a simultaneous 
lowering of exposure to environmental factors such as inhalant and food 
allergens, as well as ETS. It is expected that these measures will reduce the 
risk of developing asthma in susceptible children.  
Those children susceptible to developing asthma on grounds of familial 
predisposition were included during their prenatal life. These children were 
randomly assigned to an intervention group (n=213) or a control group (n=219) 
and followed from prenatal life until the age of six. The main outcome was the 
asthma status at age six as categorized by a predefined algorithm (no asthma, 
possible asthma, current asthma). Categorization of their asthma status was 
based on spirometry and symptoms, as prospectively reported by parents and 
general practitioners. The exposure outcome was evaluated by standardized 
measurements and questionnaires completed by parents. 
Duration of intervention offered is one of the secondary research questions the 
PREVASC study focuses on. 
The designs of (ongoing) birth cohort studies on the primary prevention of 
asthma through reduction in exposure to house dust mite allergens is described 
in Chapter 2. Chapter 3 focuses on the description of the PREVASC study 
design. The abbreviation PREVASC (PREVention of Asthma in Children) refers 
not only to the current trial, but also to the research programme on prevention of 
asthma in children. Two RCTs and one cohort study are part of the PREVASC 
programme. The study described in this thesis is the first project initiated in this 
research programme. Another trial carried out by Gijsbers et al. is part of the 
programme as well, and assessed whether optimising the breastfeeding 
intervention as used in the PREVASC project would lead to increased 
adherence.  
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The cohort study included in the PREVASC-program is carried out by Kuiper 
et.al. Data on the PREVASC-trial control group (children familial predisposed for 
asthma in first degree family members) and the cohort of non-familial 
predisposed children was evaluated on differences related to familial 
predisposition by comparing group outcome.  
 
The objective of the Cochrane review described in Chapter 4 was to determine 
if there were any differences between the outcomes of two types of allergen-
reducing interventions for the primary prevention of asthma in children at high 
risk of developing asthma. The types of interventions we were interested in 
were interventions aimed at reducing exposure to 1) single allergen levels 
(mono-faceted intervention studies) and 2) multiple allergens simultaneously 
(multi-faceted intervention studies). Based on the theoretical consideration that 
asthma is a multi-factorial disease, it was hypothesized that prevention might 
only prove effective if most or all relevant environmental factors are 
simultaneously avoided.  
 
Chapter 5 describes a pilot study on house dust mite allergen sampling in 
settled dust in homes with smooth floor coverings.  
 
The results of a post-hoc research question on the influence of infections on the 
development of asthma, asthma symptoms and increase of total and specific 
IgE is described in Chapter 6. Episodes of the common cold and episodes of 
diarrhoea associated with fever were tested in this chapter as independent 
proxy variables for infection. The results did offer some information on the 
plausibility of the assumptions made in the hygiene hypothesis. 
 
The outcomes at age four and six years are the subject of Chapter 7. In this 
chapter the answer to the main research question is described concerning the 
effect of the PREVASC study intervention on preventing the development of 
asthma in susceptible children whose lung function measurements were taken 
at six years of age. Possible differences between these effects based on the 
differences in intervention duration have been described in this chapter as well 
(secondary research question). We also describe the results of a secondary 
research question on the influence on asthma outcome of the individual 
exposures the intervention was focussed on.  
 
A general discussion is presented in Chapter 8. 
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Abstract 
Background 
In past decades the prevalence of asthma in children has substantially increased but this rising 
trend seems not tot have persisted into the twenty-first century. What could have caused the rise in 
prevalence is not well understood. With the expectation the prevalence may be decreased by 
reducing exposure to environmental factors, several birth cohort studies are being (or have been) 
carried out all over the world.  
 
Objectives 
Although many studies are still ongoing, decisions on data gathered by these studies will be of great 
importance for clinical practice. An overview of designs of available studies will be essential in 
constructing a meta-analysis.  
We describe the similarities and differences between designs and variable sets of birth cohort 
studies focusing on the relationship between allergen exposure (solely or in combination with other 
environmental exposures) and development of childhood asthma. Also we evaluate which studies 
are particularly qualified for inclusion in a meta-analysis relating asthma prevention to environmental 
exposures. 
 
Method 
Ongoing birth cohort studies on allergen exposure (solely or in combination with other 
environmental exposures) in relation to asthma development in children were identified and all 
available information on study designs was collected and compared.  
 
Results 
From the 19 studies selected, 13 are prospective cohort studies and six are Randomised Clinical 
Trials (RCTs). All six RCTs included children during prenatal life whereas all but five prospective 
cohort studies started after birth. The exposures almost all studies focus on HDM allergens, pet 
allergens, food allergens and environmental tobacco smoke (ETS). 
 
Conclusions 
We concluded randomised clinical trials (RCTs) are best candidates for inclusion in a meta-analysis 
(an individual subject data analysis) in the future. Four RCTs we evaluated to be particularly 
suitable for inclusion in a meta-analysis on grounds of similarities in their study designs: The Isle of 
Wight study, the Canadian Allergy and Asthma Project (CAAP), the CAPS-study and the 
PREVASC-project. Of these four all recommend multifaceted interventions and differences in there 
designs are expected to be to overcome by stratification and restriction to homogeneous clusters.  
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Introduction 
In past decades the prevalence of asthma in children increased substantially1 
but this rising trend seems not tot have persisted into the twenty-first century.2 
What could have caused the rise in prevalence is not well understood.  
Genetics as well as environmental factors play important parts in asthma 
development.3 Children with genetic predisposition to develop asthma are 
therefore particularly at risk. Changing environmental factors could be an 
effective tool in preventing asthma.  
The immune system and respiratory tract of humans mature and change greatly 
during early life, possibly even from the prenatal period on.4,5 Environmental 
factors may cause permanent changes in physiology of the respiratory tract and 
immune system, resulting in asthma.4,5 Which environmental factors are 
important in the aetiology of asthma in particular are not exactly known up until 
now. Some environmental factors are easy to adjust. Reducing exposure to 
certain environmental factors (tobacco smoke) have immediate health 
promoting effects.3,6,7 Birth cohort studies on asthma in children are carried out 
all over the world.8-29 Some study one environmental factor, other studies follow 
a more multi-factorial approach. Designs vary from cohort studies to 
randomised clinical trials (RCTs). Cohort studies are of particular importance as 
explorative studies on the role of certain exposures. Knowledge resulting from 
these studies is used in RCTs primarily focused on effectiveness of specific 
interventions (mono- or multi-faceted). Meta-analysis of these RCT data will be 
valuable. 
The current article does not describe a meta-analysis, as many studies did not 
yet publish the effects of certain exposures in relation to asthma development. 
Our aim here is to present an overview of similarities and differences of designs 
of ongoing birth cohort studies, including intervention studies, on the subject of 
the relationship between allergen exposure, (solely or in combination with other 
environmental exposures) and development of childhood asthma. This overview 
will be of use for carrying out a meta-analysis or collaborative individual subject 
data analysis in the future.  
Next to presenting an overview of similarities and differences in designs of birth 
cohort studies focusing on the relationship between allergen exposure (solely or 
in combination with other environmental exposures) and development of 
childhood asthma, we evaluated which studies seem to be particularly qualified 
for inclusion in a meta-analysis relating asthma prevention to environmental 
exposures. 
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Method 
A Medline-database literature search was carried out for birth cohort studies 
focusing on allergen exposure (solely or in combination with other 
environmental exposures) in relation to asthma development in children. 
Keywords used were: birth cohort, asthma, and allergen*. Study centres we 
found as result of this literature search, as well as others known to the authors 
were approached by letter. An appendix containing all research groups we 
contacted was included, as well as a structured description of study designs of 
studies already published, prepared on base of literature. The description of 
study designs contained the research question(s), type of design RCT or cohort, 
recruitment (inclusion period, number of children included / needed and 
inclusion and exclusion criteria), as well as specifics about follow-up and 
variables measured in the scope of the study with special attention to the 
exposure variables. We asked the researchers of all groups contacted to check 
the appendix for completeness and, if not complete, to supply us with names of 
missed studies and corresponding researchers. All corresponding authors of 
selected studies were also asked to check and complete the description of their 
study design as drafted by the authors and to send back the revised description 
of their study design.  
The final descriptions of study designs were used to compose chronologically 
numbered tables that contain the information on the study designs, recruitment, 
inclusion, and similarities and differences of the various studies. References of 
published study information used for gathering information are listed in Table 
2.1. If no published information on the study design was available, no 
references are mentioned. 
Results 
The number of birth cohort studies relevant to this article on which information 
was available, is 19 of which six RCTs (four multi-faceted, two mono 
intervention studies) mainly focused on effectiveness, and 13 prospective 
cohort studies. Specifics on the studies included are presented in Table 2.1 
Study designs, Table 2.2 Recruitment & Inclusion and Table 2.3 Similarities & 
Differences.  
Birth cohort studies presented in the current article originated from all over the 
world except from the continents of Asia and Africa. The studies that started first 
are the prospective cohort studies named British cohort in 1976, Tucson 
children’s Respiratory Study in 1980 and the Danish cohort (we indicated with 
A) in 1985. The ECA-study is the only included case control study nested in a 
cohort. 
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Table 2.3 Similarities & differences 
In this table a selection of topics studied in birth cohort studies is presented in the column named 
‘topic’. In the column ‘is studied’ the numbers of cohort studies that studied the corresponding topics 
are presented (according to the numbering as used in all tables in this article). In the column ‘n’ the 
number of studies that studied the corresponding topics are presented as N/total separate for 
prospective cohort studies (C) and RCTs (R) 
Topic Is studied  n 
Intervention (RCT) 4, 9-13 6 
Multi-faceted intervention 4, 9, 12, 13 4/6 
Mono intervention 10, 11 2/6 
Intervention & cohort 10, 11, 13 3/6 
Intervention mainly focused on effectiveness 4, 9, 11-13 5/6 
Prospective cohort study 1-3, 5-8, 14-19 13 
TOPIC  Is studied: 
In RCTs (R) or Cohorts (C)
N/total 
For R or C 
Inclusion of children during prenatal life R: all C: 1, 15-17, 19 R: 6/6 C: 5/13 
Presence or absence of family history of atopy is 
inclusion criterion 
R: all  
C: 1, 5, 8, 18 
R: 6/6  
C: 4/13 
Presence or absence of family history of asthma is 
inclusion criterion 
R: 10, 12 & 13  
C: none 
R: 3/6  
C: 0/13 
Asthma and/or atopy as diagnosed and reported by 
medical doctor is inclusion criterion  
R: 13 C: none R: 1/6  
C: 0/13 
Proven family history of atopy on grounds of IgE 
levels or skin prick testing in the scope of the study 
R: 4, 10  
C: none 
R: 2/6  
C: 0/13 
Vegan or strict vegetarian or alternative diet is 
inclusion or exclusion criterion 
R: 4, 12 
C: 16 
R: 2/6 
C: 1/13 
Usage of HDM impermeable covers  R: 9-13 C: none R: 5/6 C: 0/13 
HDM allergens including Der p 1 measured in dust R: 4, 9-11, 13 
C: 1, 5 & 6, 8, 14-19 
R: 5/6 
C: 9/13 
HDM allergens Der p1 & f1 measured in dust  R: 9 & 11 
C: 5, 6, 8, 14, 16, 18, 19 
R: 2/6 
C: 7/13 
Breast feeding and formula feeding  R: all C: 2 & 3, 5-8, 14-19 R: 6/6 C: 12/13 
Introduction of solid foods R: 9-13  
C: 3, 6-8, 14, 15, 17, 19 
R: 5/6 
C: 8/13 
Pet allergens measured in house dust samples Fel d1 
& Can f1 
R: 10, 11, 13  
C: 5, 6, 14, 16, 19 
R: 3/6 
C: 5/13 
Of pet allergens solely Fel d1 measured in dust  R: 9  
C: 8, 15, 17, 18 
R: 1/6  
C: 4/13 
Pet exposure measured solely from parental report R: none C: 1-3, 16, 19 R: 0/6 C: 5/13 
ETS exposure by self report parents R and C: all  R: 6/6 C: 13/13 
Cotinine levels measured as validation of ETS  R: none C: 2, 5 R: 0/6 2/13 
CO levels measured as validation of ETS  R: 13 C: none R: 1/6 C: 0/13 
Nitric oxide exposure measured R: none C: 6 R: 0/6 C: 1/13 
Fatty acid content of milk R: 12 C: 16 R: 1/6 C: 1/13 
Endotoxin measured as exposure variable R: none C: 15, 17, 19 R: 0/6 C: 3/13 
Special interest in pre and probiotics and organic 
foods 
R: none  
C: 16 
R: 0/6  
C: 1/13 
Special interest in farming exposure R: none C: 19 R: 0/6 C: 1/13 
Special interest in traffic exposure R: none C: 6 R: 0/6 C: 1/13 
Special interest in respiratory and/or gastro intestinal 
infections objectified by laboratory analyses 
R: 9  
C: 2 & 16 
R: 1/6  
C: 2/13 
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Inclusion and exclusion criteria 
All RCTs started inclusion during prenatal life and used presence or absence of 
family history of atopy as inclusion criterion. More specific, the inclusion criterion 
presence or absence of family history of asthma is used in two of six RCTs here 
presented. Five of 13 cohort studies started inclusion during prenatal life, and 
four used presence or absence of atopy in first degree relatives as inclusion 
criterion. All other cohort studies did include children from the general 
population without selecting a high-risk group. The number of children included 
in the cohort studies varied from 100 in the British cohort to 4089 in the BAMSE 
study. Follow up in cohort studies varies from >4 years in the New York study to 
22 years of age in the British cohort. 
The use of a vegan or strict vegetarian or alternative diet was an inclusion 
criterion for a subgroup in the KOALA cohort but an exclusion criterion in the 
Isle of Wight and CAPS RCTs.  
Designs of specific RCTs 
Mono- and multi-faceted interventions: Mono-interventions are those 
interventions that include one measure, for example the use of house dust mite 
(HDM) allergen impermeable mattress encasings. Multi-faceted interventions 
include measures on a variety of exposures.  
The nacMaas-study and the Dutch studies PREVASC and PIAMA are not only 
designed as RCT but have a cohort included in their design as well. These 
studies are not included in the total number of 13 prospective cohort studies as 
described in tables and results. The prospective cohorts in the studies PIAMA 
and nacMaas concern children from the general population, while in the 
PREVASC study, the prospective cohort is a low risk group. 
Isle of Wight study 
The Isle of Wight study started in 1990. One hundred thirty six children are 
followed from the prenatal period until the age of eight years. This study is a 
multi-faceted intervention study in which measures are focused on 
environmental tobacco smoke (ETS) exposure and food allergens as well as 
HDM allergens and pet allergens reduction. Extra attention is given to the food 
allergen intervention. The intervention is focused mainly on effectiveness, not 
efficacy, which makes the results of direct relevance for parents where 
implementation in daily life is concerned. 
The Canadian Allergy and Asthma Project (CAAP) 
This RCT again is a multi-faceted intervention study that is focused on reduction 
of exposure to indoor- (HDM and pets) and food allergens as well as ETS. Main 
30⏐Chapter 2 
goal of this study is establishing the effectiveness of the intervention. Five 
hundred forty-five children are being followed up from the prenatal period until 
the age of seven years.   
nacMAAS-study 
The nacMaas study is designed to study the efficacy of a HDM allergen 
avoidance intervention (mono intervention) in a high risk group (both parents 
are atopic) in which no pets are present from the time of inclusion as opposed 
to a group of high risk children not exposed to the allergen avoidance 
intervention. In total 291 children are included in this primary prevention part of 
the study and they are being followed up from the prenatal period until the age 
of 8 years. Efficacy and not effectiveness is the main focus of this intervention. 
Another mono intervention included is focused on the clinical effectiveness of 
corticosteroid use as compared to placebo medication in children at medium 
risk of developing atopy (one atopic parent). Children are allocated to the 
intervention group (fluticasone propionate) or control group (placebo 
medication) when they met inclusion criteria regarding number of wheezing 
episodes (stratified to treatment by exposure to ETS, pets exposure, maternal 
asthma and age of onset of wheeze). Early corticosteroid use is presumed to 
lessen the number of children that finally develop asthma (secondary 
prevention). None of the families included in the corticosteroid intervention part 
of the study are exposed to the allergen avoidance intervention. The total 
number of children at medium risk of developing atopy is 547 but not all of them 
were included in the secondary prevention study part because not all of them 
wheezed. 
Next to these two RCTs the nacMaas-study contains a prospective cohort of 
children at low risk of developing atopy, children at medium risk without 
wheezing episodes and children at high risk with pets. All children in the 
nacMaas-study (n=1065) are followed from the prenatal period until the age of 
eight years. 
Piama-study 
The Piama study is designed to study the clinical effect of the use of HDM 
allergen impermeable versus placebo covers on mattresses (mono 
intervention). This primary prevention intervention is mainly focused on 
effectiveness not efficacy and 810 children are followed from the prenatal period 
until the age of eight years. A total number of 3291 children are followed in two 
prospective cohorts (one of 472 children with atopic parent(s) and one of 2819 
children with non-allergic parents) are part of the design as well. 
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CAPS-study 
The CAPS-study is designed not only as a multi-faceted intervention study 
focused on allergen avoidance as well as diet parameters (n=308, follow-up 
from prenatal period until age five years) but has included two mono 
interventions in the (factorial) design as well (each n=308, follow-up from 
prenatal period until age five years). One of these mono-interventions is 
focused on environmental allergen exposure and one includes only the diet-part 
of the multi-faceted intervention. Although composed of two mono intervention 
studies and one multi-faceted RCT, this study is included in the current article 
as multi-faceted intervention study as presented in the tables. All intervention 
parts of the study are focused mainly on effectiveness, not efficacy. 
PREVASC study 
This most recent started RCT as included in our tables (1997) can be 
distinguished from other designs as the effectiveness of two multi-faceted 
interventions is studied; one is focused on clinical effectiveness of the 
intervention (n=443, follow-up from prenatal period until age six years) and one 
on the adherence to the intervention (n=92, follow-up from prenatal period until 
age one year). In this study the general practitioner has a central role because 
he/she is involved in checking the inclusion criterion family history of asthma 
and registers all relevant outcome on symptoms and diagnoses of asthma and 
allergy prospectively. In the low risk cohort-part of the PREVASC-study 309 
children are being followed-up from the prenatal period preferably until age 6 
years. 
Indoor allergen exposure 
In all studies the exposure to HDM-allergens as well as allergens from cats and 
dogs are measured on grounds of questionnaire data and in 14 studies (five 
RCTs, nine cohorts) the HDM allergen Dermatophagoides Pteronyssinus (Der 
p1) exposure was also measured in dust samples. In nine studies (two RCTs, 
seven cohorts) the HDM allergen Dermatophagoides Farinae (Der f1) was 
measured in dust samples. Pet allergen exposure from cat (Fel d1) and/or dog 
(Can f1) is measured in dust samples in 13 out of 19 studies presented (four 
RCTs, nine cohorts). 
Food allergen exposure 
In all RCTs and in all cohort studies except for the British cohort, data on 
breast-feeding and formula feeding was measured using questionnaires. Time 
of introduction of solid foods is measured in 13 of 19 studies presented (five 
RCTs, eight cohorts). 
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Exposure to environmental tobacco smoke (ETS) 
In all studies the exposure to ETS is measured, at least by self-report of 
parents. Cotinine levels were measured as validation of parental reports in only 
two out of 19 studies (both prospective cohort studies). The PREVASC study is 
the only study that used carbon monoxide (CO) in exhaled air of mother and 
father expressed as %COHb to validate the parental reports of smoking 
behaviour.  
Exposures seldom studied 
In cohort studies in particular, some parameters are less often studied. 
Exposure to Nitric Oxide for example is studied in only the ECA-study. 
Exposure to lipopolysaccharide (LPS) is another example of a seldom-studied 
parameter and is measured in only the KOALA study. Three of 13 cohort 
studies included exposure to endotoxin(s) in their study. This is the case in the 
New Zealand, PAULA and PASTURE cohorts, all studies that were started in 
1998 or more recently. The PASTURE cohort is the only study with special 
interest in farming exposure. Special interest in vehicular (traffic) exposure is 
specific for the ECA-study. 
Although all studies evaluate exposure to infections on basis of parental or 
general practitioners reports, only three studies (CAAP, Tuscon Respiratory 
Study and the KOALA cohort) measure exposure to respiratory- and gastro-
intestinal infections objectively by laboratory analysis.  
The only seldom-studied parameter included in an RCT as part of an 
intervention is the Fatty Acid content of milk (CAPS-study). The KOALA-cohort 
study did also include this parameter. 
Discussion 
In this paper similarities and differences between designs and variable sets of 
birth cohort studies focusing on the relationship between allergen exposure 
(solely or in combination with other environmental exposures) and asthma 
development in children are described as basis for carrying out a meta-analysis 
in the future. Nineteen birth cohort studies were identified and their designs 
were compared. These studies concern RCTs as well as prospective cohort 
studies. These two different design types are both important. In cohort studies 
participants need not be selected as stringently as is the case in RCTs. Results 
of cohort studies can more often be translated to the general population what 
makes them suitable for finding out what exposures are of particular importance 
in asthma development. Results of cohort studies are often used as preliminary 
data on which RCTs can be based. RCTs have the advantage of yielding direct 
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information on the effectiveness of interventions, of being substantially less 
biased, and of being more easily interpreted. However they usually have a more 
stringent inclusion policy and may thus have limited generalizability. RCTs 
probably are the best candidates for a meta-analysis. 
Interventions on allergen reduction as presented in the current article that are 
used more often than others are multi-faceted interventions focused on 
exposure of high risk infants to indoor allergens (HDM- and pet allergens) as 
well as food allergens (focused on breastfeeding and/or hypoallergenic formula 
feeding and introduction of solid foods) and ETS. The studies, in which such an 
intervention is studied, although at some aspects slightly different, are the Isle 
of Wight study, CAAP, CAPS and PREVASC study. These studies might be 
suitable candidates for meta-analysis of multi-faceted interventions. All these 
studies use an intervention that aims at effectiveness more than efficacy, which 
makes the results of direct relevance for parents where implementation in daily 
life is concerned.  
The differences in interventions studied in the four RCTs we considered as 
most suitable for inclusion in a meta-analysis concern mainly selection of high-
risk children and the food allergen reduction part of multi-faceted interventions. 
In the CAPS and PREVASC study not presence of family history of atopy in 
first-degree relatives of the children, but more stringently, family history of 
asthma is used as inclusion criterion. The PREVASC study is the only RCT in 
which not only questionnaire data are used to screen eligible families on family 
history of asthma. In this study general practitioners recruited eligible families 
and checked this specific inclusion criterion. The Isle of Wight study based their 
inclusion criterion ‘family history of atopy’ initially on questionnaire data but if 
this indicated that no dual heredity was evident but only single heredity, total 
IgE in cord blood was measured as tool for determining eligibility for inclusion. 
In all selected RCTs but The Isle of Wight study single heredity of atopy or 
asthma in first-degree relatives is the primary inclusion criterion. Concerning the 
diet part of the intervention in the Isle of Wight study exclusive breast-feeding is 
advised in the first nine months, whereas this is the case until minimally four 
(CAAP) or six months (CAPS and PREVASC) in the other comparable RCTs. 
Use of partially hydrolysed formula feeding, as alternative for breast-feeding is 
advised in three of the four selected RCTs (CAAP, CAPS, PREVASC). Mothers 
of infants included in The Isle of Wight-study as well as the CAAP and CAPS-
study were advised to follow dietary instructions given as part of the intervention 
during the period they breast-fed their child. The dietary advice for mothers is 
very different because they are, respectively, focused on reduction of food 
allergen exposure of the children in the Isle of Wight and CAAP-study whereas 
achieving a desirable fatty acid ratio of breast milk by using fatty acid 
supplements is the main goal of the dietary intervention in the CAPS-study. In 
the PREVASC study no specific measures are advised on the mother’s diet. 
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Concerning the introduction of solid foods parents were advised to delay 
introduction until their children had reached the age of six months in the CAAP, 
CAPS and PREVASC study. In the Isle of Wight study solid foods were to be 
introduced stepwise where potentially allergenic foods were concerned, starting 
with introduction at age nine months. Before the age of nine months non-
allergenic foods were allowed to be used without dietary restrictions other than 
usual care. 
HDM impermeable covers were supplied as part of the intervention in all but 
one (The Isle of Wight study) of the four considered RCTs.  
Interventions on allergen reduction more often used than others are multi-
faceted interventions focused on exposure of high-risk infants to indoor 
allergens as well as food allergens and ETS. 
We conclude that the RCTs most suitable for inclusion in a meta-analysis or a 
collaborative individual subject data analysis on birth cohort studies focusing on 
allergen exposure (solely or in combination with other environmental exposures) 
in relation to asthma development are The Isle of Wight study, CAAP, CAPS 
and the PREVASC study. A few important differences in study design of these 
four studies might cause some difficulties when starting the pooling of data in a 
meta-analysis, but these difficulties are expected to be to overcome by making 
use of stratification and restriction to homogeneous clusters.  
As most studies did not publish their results on asthma outcome yet, the meta-
analysis could not be exerted at this moment in time. 
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Abstract 
The PREVASC study addresses the primary prevention of asthma in infants and small children. The 
objective of this study is to investigate whether a multifaceted prenatally started intervention 
strategy in high-risk infants leads to a decrease in the occurrence of (severe) asthma and whether a 
refinement of the prevention strategy leads to an increase in the adherence to the prevention 
program. 
 
The primary prevention program includes house dust mite impermeable bed coverings, education 
on breastfeeding, hypoallergenic feeding, timing of introduction of solid food, and smoking 
cessation. 
 
Eight hundred and eighty-eight infants were prenatally included. By the time of inclusion the 
mothers were 3-7 months pregnant. Twenty seven infants were excluded from the study and 18 
dropped out. Of the remaining 843 infants 535 had a first-degree familial predisposition of asthma 
(high-risk group), whereas a reference group of 308 (162 boys) infants was not predisposed for 
asthma in the first degree (low-risk group). To evaluate the (cost-) effectiveness of the preventive 
intervention, 222 (118 boys) infants of the high-risk group allocated to the intervention group and 
221 (112 boys) allocated to a control group are followed-up. The low-risk infants serve as controls to 
evaluate the predictive value of high risk (1st degree familial predisposition of asthma). The infants 
are followed from the prenatal stage until they reach the age of six years. The remaining 92 high-
risk infants were included in an optimised randomised clinical adherence trial’ (RCAT). Of these 92 
infants 45 (20 boys) were allocated to an intervention group and 47 (24 boys) to a control group. 
Until now all infants have been followed for at least 1 year. 
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Introduction 
Childhood asthma, a chronic disease of the airways, is predominantly newly 
diagnosed in infants and small children. Asthma is the main cause of school 
absence,1,2 involves high costs and is known to reduce the quality of life of 
children and their parents. During the last decades there has been a substantial 
increase in the prevalence of asthma worldwide,3,4 which emphasizes the need 
to prevent its development. It is generally thought that genetic as well as 
environmental factors are involved in the development of asthma.5,6 Since it is 
not yet possible to influence the genetic factors, prevention programs should 
focus on influencing the environmental factors. There are reasons to believe 
that the first signs of sensitisation occur already in the prenatal stage by the 
interaction between the maternal environment and the foetus.7 Therefore it is 
important to start intervention in the prenatal stage. Several primary prevention 
studies are being performed, and are still in progress. In most primary 
prevention studies only one8-10 intervention was tested whereas in others two 
single interventions with or without a factorial design were tested,11-13 which 
may lead to underestimation of the effect of prevention. To our knowledge there 
are three multifaceted primary prevention studies,14-16 in which several 
interventions are combined into one program and compared to one other 
modality, like usual care. 
We report on the objectives and the design of the PREVASC (Prevention of 
Asthma in Children) program, a research program focused on primary 
prevention of asthma in children. The objectives of this program are to estimate 
the predictive value of a positive family history of asthma assessed in the 
prenatal period by the general practitioner (GP) for the development of 
childhood asthma and, to assess the effectiveness of a prenatally started multi-
faceted primary prevention program focused on reducing the exposure to 
indoor- and food allergens and environmental tobacco smoke in children at 
high-risk of developing asthma. Furthermore it will be assessed whether the 
duration of the prevention program has any effect on the development of 
asthma as measured at six years of age and whether optimising the intervention 
leads to increased adherence. Finally the health-economic benefits of high-risk 
identification and primary prevention of asthma will be assessed. 
Research plan 
General design 
Our study comprised of three parts, one observational cohort and two 
intervention studies. 
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To assess the clinical effectiveness of the PREVASC prevention program, a 
randomised clinical prevention trial (RCPT) was started in a group of prenatally 
selected high-risk infants. Additionally a cohort of prenatally selected low-risk 
infants was composed for a natural history study, to assess the clinical course 
of asthma and allergies in high- and low risk children and to assess the 
predictive value of ‘high-risk’. To be able to identify whether (the parents of) the 
infants were compliant to the prevention program, the adherence to the 
intervention was evaluated. In addition, to get a better insight into the 
determinants of adherence and to improve the preventive program, a ‘focus’ 
group approach was applied in a subgroup of trial participants. In addition an 
‘optimised randomised clinical adherence trial’ (RCAT) was evaluated in a 
newly recruited group of prenatally selected infants with a family history of 
asthma. Cost-effectiveness of the prevention program will be studied on the 
basis of the RCPT, taking adherence aspects and validity of screening into 
account.  
In the participants section a general description will be given of how the 
participants were included in the study. In the section concerning the 
intervention studies and the natural history study the outline of both intervention 
studies and the natural history study will be described. 
Participants 
The infants were recruited prenatally when their mothers were in their first two 
trimesters of pregnancy. The community based recruitment started in January 
1997 and continued until February 2000. For the RCPT this was performed by 
the primary caregivers (GP and midwives) and by advertisements. For the 
natural history study recruitment was exclusively performed by the GP, whereas 
for the optimised RCAT recruitment was performed by midwifes and by 
advertisements. These complementary ways of recruitment were necessary to 
include 888 participants. 
‘High-risk’ was defined as ‘at least one first-degree family member (i.e. the 
pregnant woman, the biological father of the unborn child or a sibling) suffering 
from GP registered asthma’, whereas ‘low-risk’ was defined as ‘absence of GP 
registered asthma in first-degree family members’. Asthma was defined 
according to the International Classification of Primary Care (ICPC)17 as 
recurrent episodes of reversible acute bronchial obstruction with wheeze and/or 
dry cough. This was checked by the GP and screening questionnaires.  
For the RCPT, the natural history study and the RCAT, a family was excluded 
from the study when there was intra-uterine or neonatal death, major language 
problems, serious birth defects (illness or malformation) and moving abroad.  
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Intervention studies 
In the following specific elements of the various study parts are described. 
Thereafter aspects that relate to all the three study parts are presented 
together. 
Randomised Clinical Prevention Trial 
The goal of this study was to assess the effectiveness of (the duration of) a 
prenatally started multi-faceted primary prevention program in children at high 
risk for development of asthma. The study was designed to follow the high-risk 
children until they reach the age of six. By that time lung function measurement 
can reliably be performed which makes an objective diagnosis of asthma 
possible. 
Recruitment 
In the first part of the study (the period from the prenatal stage until the age of 
two) 476 pregnant women were included (Figure 3.1) and after randomisation 
equally divided over two study groups: an intervention group and a control 
group. Four hundred forty three of the descendants could be followed up, 222 
(118 boys) of the intervention group and 221 (112 boys) of the control group.  
Intervention first part 
The intervention started prenatally in order to reach a low house dust mite and 
pet allergen exposure level at the time the child was born. In addition, the 
intervention focused on avoidance of prenatal and postnatal passive smoking 
and on avoidance of food allergens postnatal.  
House dust mite (HDM) reduction intervention started before the 7th month of 
pregnancy. This intervention consisted of advice on ventilation and cleaning as 
well as application of HDM impermeable covers on the parents and children’s 
bed. To prevent exposure to pet allergens, the advice was given to keep pets 
outdoors from the 6th month of pregnancy. Smoking intervention consisted of 
advice on smoking cessation of the mother as early as possible in pregnancy 
and no smoking of the father as well as the mother in the presence of the baby 
postnatal. Dietary intervention contained advice on exclusively breastfeeding 
(and/or hypo-allergen formula feeding) for at least six months and postponing 
introduction of solid food until six months after birth. The high-risk control group 
received usual care, according to the Guidelines of the Dutch College of 
General Practitioners that include criteria based diagnosis and an initial 
treatment with short acting bronchodilatators and when no adequate asthma 
control is achieved with a step-up approach with inhaled corticosteroids in 
increasing dosage.18  
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Intervention second part  
In the second part of the study the children are followed from 2-6 years of age. 
For this part of the study the children in the original intervention group were 
randomised again into two groups (Figure 3.1). One group was no longer 
exposed to advice and HDM impermeable mattress covers (short intervention 
period). The other group still received an intervention program focused on 
diminishing allergen and irritant exposure and to keep on using HDM 
impermeable mattress covers (extended intervention period). The children that 
participated in the control group in the first part continue to participate in the 
control group in the second part of the study as well and receive usual care. 
Randomised Clinical Adherence Trial 
Eighty-one randomly selected families who participated in the intervention group 
of the RCPT received an invitation letter for a focus-group interview to 
investigate which determinants influenced the actual adherence behaviour. For 
these interviews the stepwise guidelines of van Assema et al.19 for conducting a 
focus-group interview were used. 
Recruitment focus groups 
43 Households (59 participants) were scheduled to meet at times and locations 
that might be convenient for the participants. Six groups were mixed as to 
gender and one group was formed containing only fathers, since fathers may 
have different opinions and thoughts about breastfeeding and postponement of 
solid foods, which might be missed in the presence of women.  
Focus group observations 
The reasons for the 39 non-respondent households were:  interested, but date 
not convenient (n=14), no time (n=7), location of interview not convenient (n=3), 
on holiday (n=2), unknown (n=13). No significant differences were found 
between the participation and no-participation group with respect to level of 
education, feeding behaviour and family history of asthma. 
On the basis of the results of the determinant-analysis, a refined prevention 
educational program was developed.  
Recruitment refined intervention program 
In this phase, the RCAT study, 92 families expecting a child at high-risk of 
developing asthma were selected. 45 Families received intervention and 47 
served as controls (Figure 3.1). 
Intervention measures 
Educational materials and the educational message to be provided orally by 
research nurses were refined. The effect of the renewed education on the 
degree of adherence with the advised measures (HDM, tobacco smoke, 
breastfeeding) was evaluated in the next phase of this program.  
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Natural history study 
The goal of this study was to assess the clinical course of asthma and allergies 
in high- and low risk children and to assess the predictive value of ‘high-risk’. 
Recruitment 
For this study 317 pregnant women, without asthma or asthma in the family, 
were included. 308 (162 boys) of the descendants could be followed up (Figure 
3.1). 
Clinical follow-up 
The clinical course of symptoms of asthma and allergies over the first two years 
of life in this cohort was compared with the RCPT control group in order to 
evaluate the predictive value of the family history. The low-risk infants received 
usual care.  
Randomisation, withdrawal procedures and blinding 
For those women who were recruited by the GP, randomisation was done in 
ZIP-code clusters on practice level and not on patient level in order to minimize 
the probability of exchange of information between participants.  
Families who were recruited by the GP were screened by the GP. Families who 
were recruited for the RCPT study by midwives or advertisements completed 
questionnaires concerning the presence of asthma in their family. Whenever it 
turned out from the questionnaire that there was no asthma in a ‘high-risk’ 
family, the GP was contacted. When the GP confirmed the questionnaire 
outcome, the family was withdrawn from the study. Families who were recruited 
by midwives or advertisements for the RCAT study were screened by the GP. 
For the RCPT and the RCAT, blinding for group assignment was performed at 
family level. 
Economical evaluation 
To assess the efficiency of ‘high-risk’ identification and the cost effectiveness of 
the PREVASC intervention, it will be evaluated whether cost savings 
(associated with a decrease in (severe) asthma cases and an increase in the 
quality of life) outweigh the costs of the prevention program. This will be 
achieved in two steps, by assessing 1. the cost-effectiveness of the PREVASC 
intervention among the high-risk group, and 2. the cost-effectiveness of the 
complete PREVASC RCPT program including the high-risk identification at the 
population level. Ad (1): It will be assessed what the PREVASC preventive 
intervention with its allied costs yields in terms of health outcome and savings 
concerning direct and indirect health related costs in the high-risk group. For 
this purpose, the clinical course, health outcomes and costs of primary 
prevention of asthma (PREVASC intervention group) will be compared with the 
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clinical course, health outcomes and costs of usual care (PREVASC control 
group). To be able to assess the cost-effectiveness, information concerning the 
direct and indirect medical costs, the costs of the prevention program, and the 
health status of the children will be collected, using information from 
questionnaires that will be completed by the parents. By use of these 
questionnaires the use of medical care and products can be measured. This 
use will be valued against national recommended prices20 to be able to 
determine the costs of care per individual. The health status of the children will 
be measured using the ISAAC questionnaire as well as the morbidity 
registration of the GP. When the children have reached the age of six years 
asthma will objectively be diagnosed, which makes it possible to express 
asthma as a dichotomous variable. In this way the costs per asthma case 
prevented can be determined. 
Ad (2): By connecting the results ad (1) (the cost-effectiveness of the primary 
prevention program among the high-risk group) to the predictive value of the 
‘high-risk’ identification, the costs of prenatal high-risk identification, the 
prevalence of a positive family history, and the observed disease course in the 
absence of intervention in both the high-risk control group and the low-risk 
group, the expected cost-effectiveness of the complete PREVASC program at 
population level will be assessed.   
Data collection procedure 
Symptoms/diagnosis 
First-degree familial predisposition of asthma was determined by the GP and by 
use of a questionnaire directly at the inclusion. For the RCPT and the ‘natural 
history’ study this was re-evaluated at the age of two years. Information on 
complaints, diagnosis, laboratory tests and medication concerning respiratory 
morbidity are prospectively registered by the GP at every consultation. 
Additionally the parents were asked to complete weekly reports, concerning 
questions about asthma related complaints, OTC medication and asthma 
related costs, during the first two years of the infants’ life and to complete the 
internationally accepted ISAAC questionnaire21 yearly until the age of six 
(Tables 3.1, 3.2, 3.3). 
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Table 3.1 Timing schedule of the measurements of environmental exposures and outcome 
variables in the RCPT. 
Time point Environmental exposures Outcome measures 
3rd–5th month of 
pregnancy 
• Dust (derp1, canf1, feld1) 
• Humidity  
• CO  
 
7th–8th month of 
pregnancy (intervention 
group only) 
• Humidity  
• CO  
 
Weekly from birth  
until 2 years of age 
• Type of feeding 
• Day-care attendance 
• Asthma related complaints 
• Health-care consumption 
• Absence from work 
Around 4 weeks after 
birth (intervention group 
only)  
• Humidity  
• CO  
 
3-5 days after birth   • Total IgE   
6 months after birth  • Type of feeding 
 
• Amount of wheezing episodes in the last 6 months 
• Nightly wheezing in the last 6 months  
• Nocturnal coughing in the last 6 months  
• Doctors diagnosed asthma  
• Constitutional eczema  
• Food allergy  
• Non-viral rhinitis  
• Other upper airway infections  
• Other lower airway infections  
• Dyspnoea  
7-9 months after birth 
(exactly 1 year after first 
dust sampling) 
• Dust (derp1, canf1, feld1) 
• Humidity 
• CO 
 
1 year after birth • Humidity 
• CO 
• ETS 
• Exposure to house dust mite 
   and animal allergens 
• Amount of wheezing episodes in the last 6 months 
• Nightly wheezing in the last 6 months  
• Nocturnal coughing in the last 6 months  
• Total IgE  
• Specific IgE (derp1, feld1, canf1)  
• Doctors diagnosed asthma  
• Constitutional eczema  
• Food allergy  
• Non-viral rhinitis  
• Other upper airway infections  
• Other lower airway infections  
• Dyspnoea  
2 years after birth • Humidity  
• CO  
• Amount of wheezing episodes in the last year 
• Nightly wheezing in the last year  
• Nocturnal coughing in the last year 
• Specific IgE (derp1, feld1, canf1)  
• Doctors diagnosed asthma  
• Total IgE  
• Constitutional eczema in the last year 
• Food allergy in the last year 
• Non-viral rhinitis in the last year 
• Other upper airway infections  
• Other lower airway infections  
• Dyspnoea  
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Time point Environmental exposures Outcome measures 
3 years after birth • ETS 
• Allergen exposure 
• Amount of wheezing episodes in the last year  
• Nightly wheezing in the last year   
• Nocturnal coughing in the last year  
• Doctors diagnosed asthma  
• Doctors diagnosed cows milk allergy 
• Other food related allergies diagnosed by a doctor 
• Doctors diagnosed inhalation allergies 
• Non-viral rhinitis in the last year  
• Other upper airway infections in the last year  
• Other lower airway infections in the last year  
• Dyspnoea in the last year  
4 years after birth • Dust (derp1, canf1, feld1) 
• Humidity  
• CO 
• ETS 
 
• Tidal airway resistance (microRint) 
• Amount of wheezing episodes in the last year  
• Nightly wheezing in the last year   
• Nocturnal coughing in the last year 
• Specific IgE (derp1, feld1, canf1)  
• Doctors diagnosed asthma  
• Doctors diagnosed cows milk allergy 
• Other food related allergies diagnosed by a doctor 
• Doctors diagnosed inhalation allergies 
• Total IgE  
• Non-viral rhinitis in the last year  
• Other upper airway infections in the last year  
• Other lower airway infections in the last year  
• Dyspnoea in the last year  
5 years after birth • ETS 
• Allergen exposure  
• Amount of wheezing episodes in the last year  
• Nightly wheezing in the last year   
• Nocturnal coughing in the last year  
• Doctors diagnosed asthma  
• Doctors diagnosed cows milk allergy 
• Other food related allergies diagnosed by a doctor 
• Doctors diagnosed inhalation allergies 
• Non-viral rhinitis in the last year  
• Other upper airway infections in the last year  
• Other lower airway infections in the last year  
• Dyspnoea in the last year 
6 years after birth  • ETS 
• Allergen exposure 
• Asthma  
• Specific IgE (derp1, feld1, canf1)  
 
Mite collection and humidity 
Dust samples were collected (Table 3.1) to measure the compliance with the 
intervention advice in the intervention group (RCPT and RCAT) and to correlate 
the intensity of exposure to inhalant allergens with respiratory morbidity (RCPT, 
RCAT and natural history study) and to evaluate the validity of using the low-
risk infants as control group. The collection was performed in a standardized 
manner. Samples were taken, using a vacuum cleaner (Bosch BSA1100 1300 
Watt) with a special cassette (ALK Abello) containing a Whatman GF/F 70 mm 
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filter, from the living room floor (2 x 1 m2), the parents’ mattress (1 m2) and the 
mattress of the baby (whole mattress). The samples were kept on 4°C until they 
were analysed for mite, cat and dog allergens by use of ELISA.22-24 Humidity 
was measured by use of a hygrometer in the parents’ bedroom and, when in 
use, the infants’ bedroom. 
 
Table 3.2 Timing schedule of the measurements of environmental exposures and outcome 
variables in the Natural history study. 
Time point Environmental exposures Primary (1) and secondary (2) outcome measures 
Weekly from birth until 2 
years of age 
• Day-care attendance 
 
• Asthma related complaints 
• Health-care consumption 
• Absence from work 
3-5 days after birth  • Total IgE  
6 months after birth • Type of feeding 
 
• Amount of wheezing episodes in the last 6 months 
• Nightly wheezing in the last 6 months  
• Nocturnal coughing in the last 6 months  
• Doctors diagnosed asthma  
• Constitutional eczema in the last 6 months 
• Food allergy in the last 6 months 
• Non-viral rhinitis in the last 6 months 
• Other upper airway infections  
• Other lower airway infections  
• Dyspnoea  
7-9 months after birth  • Dust (derp1, canf1, feld1)  
1 year after birth • ETS 
• Exposure to house dust mite 
and animal allergens  
  
 
• Amount of wheezing episodes in the last 6 months 
• Nightly wheezing in the last 6 months  
• Nocturnal coughing in the last 6 months  
• Doctors diagnosed asthma  
• Constitutional eczema in the last 6 months 
• Food allergy in the last 6 months 
• Non-viral rhinitis in the last 6 months 
• Other upper airway infections  
• Other lower airway infections  
• Dyspnoea  
2 years after birth  • Amount of wheezing episodes in the last year 
• Nightly wheezing in the last year  
• Nocturnal coughing in the last year 
• Doctors diagnosed asthma 
• Constitutional eczema in the last year 
• Food allergy in the last year 
• Non-viral rhinitis in the last year 
• Other upper airway infections  
• Other lower airway infections  
• Dyspnoea  
 
Type of feeding and ETS exposure 
The parents completed questionnaires concerning the type of feeding, 
environmental allergen exposure and environmental tobacco smoke (ETS) 
exposure. 
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Table 2.3 Timing schedule of the measurements of environmental exposures and outcome 
variables in the RCAT. 
Time point Environmental exposures Primary and secondary outcome measures 
3rd month of pregnancy • Dust (derp1) 
• Humidity  
• CO 
 
7th month of pregnancy • Humidity  
• CO 
 
2-3 weeks after birth • Humidity  
• CO  
• Compliance with dietary advices 
 
6 months after birth • Dust (derp1) 
• Humidity  
• CO  
• Compliance with dietary advices 
• Amount of wheezing episodes in the last 6 months 
• Nightly wheezing in the last 6 months  
• Nocturnal coughing in the last 6 months  
• Doctors diagnosed asthma  
• Constitutional eczema in the last 6 months 
• Non-viral rhinitis in the last 6 months 
• Other upper airway infections  
• Other lower airway infections  
1 year after birth • Humidity  
• CO 
• Amount of wheezing episodes in the last 6 months 
• Nightly wheezing in the last 6 months  
• Nocturnal coughing in the last 6 months  
• Doctors diagnosed asthma  
• Constitutional eczema in the last 6 months 
• Non-viral rhinitis in the last 6 months 
• Other upper airway infections  
• Other lower airway infections  
 
IgE 
Blood samples were collected in the RCPT and natural history group to 
measure the concentration of total immunoglobulin E (IgE). IgE was analysed 
using the method of Aalberse et al.25  
Carbon Monoxide 
To study the compliance with the smoking advice in the intervention group, to 
detect spontaneous smoking cessation by the mother during pregnancy in the 
control groups and to correlate the intensity of exposure to smoke with 
respiratory morbidity, Carbon Monoxide was measured in expired air. 
Tidal airway resistance and lung function 
To assess the tidal airway resistance by means of an interrupter technique, 
microRint measurements are performed when the children are four and six 
years of age, while lung function (FEV1, FVC), reversibility on β2-mimetics 
(change in FEV1 after 600 μg salbutamol through a spacer) and bronchial 
responsiveness to increasing doses of histamine (PC20) will be assessed when 
the children reach the age of six years. 
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Statistical aspects 
Power calculation 
The power calculation of the RCPT study was based on a study of Saarinen et 
al.26, the only longitudinal asthma prevention trial that reported results on 
objective asthma outcome by the time the PREVASC trial was designed. In the 
Saarinen study it was shown that breastfeeding as preventive measure, in a 
comparable group of infants as in the RCPT, resulted in a 30% reduction in the 
development of asthma. This percentage was chosen in the RCPT as the 
minimum clinically relevant difference. A minimum amount of 194 infants in the 
intervention as well as in the control group was required to reduce the asthma 
incidence with at least 30% (taking a type I error of 0.05 and a power of 0.80 
into account). 
The power calculation of the RCAT was based on the number of parents 
required to measure the compliance of the parents with the optimised 
prevention program. Based on literature studies27 an effect-size of 0.46 was 
expected. With a minimum of 38 participants in each group a power of 0.80 
could be reached (taking a type I error of 0.05 and a drop out of at the most 
18% into account). 
The power calculation of the natural history study was based on a sample size 
that would be large enough to show a statistically significant difference, 
between the high- and low-risk groups, in the development of asthma at six 
years of age.28 An odds ratio of at least two was assumed for the association of 
a first-degree family history of asthma with the risk to develop asthma in 
descendants. Taking a cumulative asthma incidence of 10%, a maximum drop 
out of 10% and a type I error of 0.05 into account a power of 0.80 could be 
reached with an addition of 308 low-risk infants. 
Data analysis 
In the RCPT compliance will be evaluated in terms of reduced exposure to 
HDM, cat and dog allergens as well as reduced smoking and increased 
breastfeeding. 
Differences in proportions between groups in bi-variate analyses will be tested 
with the χ2 test. Differences in means for continuous normally distributed 
variables are analysed using the Student’s t-test. Multiple logistic and linear 
regression techniques are used for multivariate analyses with a fixed follow-up 
time, while Cox proportion hazard analyses will be performed when the follow-
up time is variable. 
Concerning the cost-effectiveness one way sensitivity analyses regarding 
important assumptions will be performed. In addition, statistical uncertainty 
regarding the cost-effectiveness estimates will be assessed using non 
parametric bootstrap resample methods. By means of the analysis of effect 
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modification it will be evaluated whether the effect differs between subgroups. 
For most analyses a p-value smaller than 0.05 is considered as significant. 
Statistical analyses are performed using the Statistical Package for the Social 
Sciences (SPSS) version 10.0. 
Ethics approval and informed consent 
Ethical approval for this study was obtained from the ethics committees of the 
participating institutes. All participants gave written, informed consent. 
Preliminary results of the RCPT 
Preliminary results indicate that infants in the intervention group were 
significantly more breast-fed (p=0.001) and/or received significantly more 
hypoallergenic formula feeding than infants in the control group. The first intake 
of solid food was significantly more often postponed to the age of six months in 
the intervention group compared to the control group (p=0.001). No difference 
was found in the intervention compared to the control group concerning the 
exposure to tobacco smoke. Measurement of environmental exposure to house 
dust mite, cat and dog allergens was performed during pregnancy (baseline) 
and exactly one year later. One year after baseline measurements the 
concentration of house dust mite, cat and dog allergens, measured at the living 
room floor (except for dog allergens), the mattress of the parents and the 
mattress of the baby, were statistically significant decreased in the intervention 
group, but not in the control group.29 
Discussion 
The PREVASC study is a longitudinal prospective birth cohort study with its 
focus on the development of a primary prevention program for asthma in 
children. The main goal of the PREVASC study is to assess the effectiveness of 
(the duration of) an intervention program focused on reducing the exposure to 
indoor and food allergens and environmental tobacco smoke in children at high-
risk of developing asthma. This is investigated in a RCPT. To be able to define 
to what extent first-degree familial predisposition for asthma is predictive for the 
development of asthma, a natural history study was started with children with a 
high- or low-risk of developing asthma.  
Whether the participants are compliant to the prevention program and whether 
optimising the intervention leads to an increase in adherence is investigated in a 
RCAT. The health-economic benefits of ‘high-risk’ identification and primary 
prevention of asthma will be assessed on the basis of the RCPT, taking 
compliance aspects and validity of screening into account. 
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There are few prospective birth cohort studies in which the effect of primary 
prevention of asthma is studied.8-16 Most of these studies focus on one or two 
preventive measures.8-13 To our knowledge there are four multi-facetted 
intervention studies, the Isle of Wight study30 the study of Halken et al.14, the 
CAAP15 study and SPACE16 study. The PREVASC study differs from these 
studies in several aspects. In contrast to these studies a low-risk group was 
included in the PREVASC study, which enables an estimation of the high-risk 
prediction and in addition facilitates the evaluation of the external validity of the 
primary prevention study. In the PREVASC study ‘high-risk’ was defined as 
presence of asthma in 1st degree family members. This definition was chosen 
since asthma in 1st degree family members is expected to be the most 
predictive risk factor for the development of asthma in descendants31 although 
this is often based on retrospective and cross-sectional data. We expect the 
strongest effect of the intervention program in children with a first-degree 
hereditary predisposition of asthma. Concerning the intervention program, in the 
PREVASC study the dietary advices for the baby were exclusively 
breastfeeding for at least six months as well as delay of solid food until six 
months of age. 32 The mother was not advised to follow a diet. Since the goal of 
the prevention program was that it should be easy to implement into practice, 
prevention was based on easily applicable intervention measures. Recruitment 
was performed predominantly by the GP. The Dutch health care system is 
organized in such a way that the GP keeps complete medical records of all 
registered families which makes the GP the most appropriate health care 
worker to assess whether an unborn child is at high-risk of developing future 
asthma. 
There are however some limitations to our study. Although there is a well-
defined cleaning regimen some exposure could not be avoided. However by 
keeping the cleaning regimen close to daily practice, the HDM reduction that will 
be reached is realistic and can easily be obtained. In general, we expect that 
people will better adhere to the intervention program when the intervention is as 
close to daily practice as possible. In studying a multi-faceted intervention 
strategy it is impossible to directly investigate the effectiveness of all single 
intervention measures in all possible combinations (like would be done in a 
factorial design), since this should result in a sample size that is far too large for 
in one trial. Moreover synergistic effects can be missed in comparing single 
interventions only, while the most pronounced clinical effect possible should be 
expected from a combined intervention. Finally the GP and the parents could 
not be blinded to the intervention, which might result into classification bias and 
reporting bias with respect to medical records and questionnaires in relation to 
health outcome. Therefore it is important to follow the cohort until the children 
have reached the age of six years, at which age lung function measurement can 
be performed. 
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Synopsis 
Mono and multifaceted allergen reduction interventions for the primary prevention of asthma in 
children at high risk of developing asthma.  
This review asks whether asthma, being a multi-factorial disease, can be prevented by reducing 
single allergen levels in children with genetic susceptibility, and whether reduction of multiple 
exposures lead to better outcome than control. In children who have a family history of atopy or 
asthma it is possible that early exposure to allergens may lead to their development of asthma. The 
objective of the current review was to determine if there were any differences between the 
outcomes of two types of allergen reducing interventions in primary prevention of asthma in children 
at high risk of developing asthma. The types of interventions we were interested in were 
interventions aiming at reducing exposure to 1) single allergen levels (mono-faceted intervention 
studies) 2) multiple allergens simultaneously (multifaceted intervention studies).  
The current meta-analyses provide evidence that multi-faceted interventions, characterised by 
dietary allergen reduction and environmental remediation, reduce the odds of a physician diagnosis 
of asthma later in childhood, in children who are at risk of developing childhood asthma by a half. 
This translates to a number needed to treat (NNT) of 16. However, the effect of multi-faceted 
interventions on parent reported wheeze was inconsistent and it had no beneficial effect on 
nocturnal cough or dyspnoea. Mono-faceted interventions were no more effective than controls in 
the reduction of all outcomes but there remains uncertainty as to whether multiple interventions are 
more effective than mono-component interventions. 
Abstract 
Background 
Based on the theoretical consideration that asthma is a multi-factorial disease, it is hypothesised 
that prevention might only prove effective if most or all relevant environmental factors are 
simultaneously avoided. Allergen exposure is one of the environmental factors seemingly 
associated with the development of asthma. 
 
Objectives 
The objective of this review was to assess effect(s) of mono-faceted and multi-faceted interventions 
when compared with control interventions, in preventing asthma and asthma symptoms in children. 
 
Search strategy 
A computer aided search was performed of the Cochrane Central Register of Controlled trials 
(Central) issue 1, 2006, Medline (from January 1966 to October 2006) and EMBASE (from January 
1989 to October 2006) and the Cochrane Airways Trial Register (until January 2008). 
 
Selection criteria 
Randomised controlled trials on primary prevention of asthma in children by allergen exposure 
reduction were identified and results of mono-faceted and multi-faceted intervention studies were 
separately pooled. We stipulated that the follow-up had to be from birth (or even during pregnancy) 
up to a minimum of two years of age. 
 
Data collection & analysis 
Eligible studies were screened on relevant results for the current meta-analysis. When the primary 
outcome 'current diagnosis asthma' and/or one of the secondary outcomes' current respiratory 
symptoms wheezing, nocturnal cough and dyspnoea' were described, studies were included in the 
analyses. Multi-faceted and mono-faceted intervention studies were pooled separately. We made 
an indirect comparison of their effects with Z-tests. 
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Main results 
Three multi-faceted and six mono-faceted intervention studies that described their results at various 
intervals met the entry criteria. These studies randomised 3271 children. Physician diagnosed 
asthma in children less than five years and asthma as defined by respiratory symptoms and lung 
function criteria in children aged five years and older both favoured treatment of multi-faceted 
intervention studies (<5 years OR 0.73, CI 0.55 0.97 and >5 years OR 0.52, CI 0.32 0.84). 
However, there was no difference in outcome between mono-faceted intervention and control study 
results (<5 years OR 1.22, CI 0.83 1.78 and >5 years OR 0.93, CI 0.66 1.31). Indirect comparison 
between these treatments via Z-test scores suggested that multiple interventions were more 
successful than mono-interventions in reducing the frequency of asthma diagnosis in children under 
five years (Z-score -2.118 ). Z-test comparison in diagnosis of asthma in children five years and 
older was not significant between multiple and mono-interventions (Z-score -1.925). There was no 
significant difference between either mono- and multi-faceted intervention and control in reducing 
the likelihood of symptoms at follow-up (multi: 0.7, CI 0.43 to 1.17). 
 
Reviewers' conclusions 
The available evidence suggest that the reduction of exposure to multiple allergens reduces the 
likelihood of a current diagnosis of asthma at ages <5 years, whereas the evidence mono-
intervention studies does not indicate a statistically significant difference with control. Multi-faceted 
interventions, characterised by dietary allergen reduction and environmental remediation, reduce 
the odds of a physician diagnosis of asthma later in childhood, in children who are at risk of 
developing childhood asthma by a half. This translates to a number needed to treat (NNT) of 16. 
However, the effect of multi-faceted interventions on parent reported wheeze was inconsistent and it 
had no beneficial effect on nocturnal cough or dyspnoea. Mono-faceted interventions were no more 
effective than controls in the reduction of all outcomes. There remains uncertainty as to whether 
multiple interventions are more effective than mono-component interventions. The non-significant 
between mono- and multi-faceted interventions on outcome diagnosis asthma at ages five years 
and older might be true but may have been caused by lack of power or the difference in study 
outcome used in the of studies compared. The findings warrant further direct comparison between 
multiple- and mono-faceted intervention at reducing the prevalence of asthma in children. Since the 
current meta analyses are not randomised comparisons, we recommend that a new study which 
assesses both types of interventions is undertaken. There are no studies ongoing to our knowledge 
in which both intervention strategies are randomly compared. Such a study will be of great 
importance for shedding new light on preventing the development of asthma in genetically 
susceptible children. 
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Background 
Asthma is a multi-factorial disease that in the main develops in individuals with 
genetic susceptibility. Genetically predisposed children exposed to specific 
environmental factors (such as allergens) are believed to be at increased risk of 
developing asthma. It is generally accepted that the interaction between 
genotype and environment plays a crucial role.1 In this line of thinking it is 
assumed that reduction of exposure to inhalant as well as food allergens could 
lead to a reduction in the risk of developing asthma, although current evidence 
on maternal dietary antigen avoidance is equivocal.2  
 
Information leading to this assumption is mainly based on results of secondary 
prevention strategies.3,4 Many have speculated that reduction of exposure to 
inhalant or food allergens could lead to a reduction in the risk of developing 
asthma. It has however proven very difficult to translate these insights into 
effective primary prevention strategies.5-8 Up until now the reasons behind the 
lack of effectiveness of these carefully designed studies remain unclear. Based 
on theoretical considerations that asthma is a multi-factorial disease, prevention 
might only prove effective if most or all relevant environmental factors for a 
specific child are simultaneously avoided. To investigate this hypothesis we 
undertook a systematic review of mono- and multi-faceted allergen avoidance 
interventions compared with controls aiming to prevent asthma in high risk 
children. As we were aware that there are at present no randomised controlled 
trials directly comparing mono- and multi-faceted interventions we considered 
that this approach would offer the possibility of an indirect comparison between 
these two intervention strategies.  
Objectives 
The objective of this review was to compare the effectiveness of mono- and 
multi-faceted allergen reduction interventions in the primary prevention of 
asthma and asthma symptoms in children judged to be at high risk of 
developing asthma, by pooling the results of individual studies.  
Criteria for considering studies for this review 
Types of studies 
Birth cohort randomised controlled trials (RCTs) with follow-up of children from 
birth onwards. The interventions tested are either multifaceted or mono faceted 
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and focused on allergen exposure reduction (inhalant allergens and/or food 
allergens). 
Types of participants 
Children at high risk of developing atopy or asthma recruited at or before birth 
with the aim of preventing asthma. High risk of developing atopy or asthma was 
defined as a family history of atopy or asthma in at least one first degree (i.e. 
biologic parent or, full sibling) relative. We stipulated that the family history 
should be confirmed by parents, general practitioner (GP) or biological marker 
of hypersensitivity (specific IgE or skin prick test).  
Types of interventions 
Allergen reducing interventions focused on inhalant allergens and/or food 
allergens, either as part of a multi-faceted or mono-faceted intervention 
strategy. Co-interventions included in multi-faceted or mono-faceted 
interventions (not aimed at allergen reduction) were permitted.  
We categorised studies as either multi-faceted or mono-faceted depending on 
whether they aimed at reducing exposure to inhalant allergens AS WELL AS 
food allergens (multi-faceted) or whether they aimed at reducing exposure to 
EITHER inhalant allergens OR food allergens (mono-faceted).  
Allergen reduction measures started either during pregnancy or from birth 
onwards, and continued during postnatal life. Minimum duration of intervention 
was four months. We anticipated some variation in the length of follow-up 
beyond this time point.  
For optimal contrast in interventions the control group measures were either 
placebo strategies or usual care.  
Another Cochrane review of pre and post-natal dietary intervention focused on 
maternal diet.2 However, in the current review we extend the focus to post-natal 
intervention in infants, and prenatal environmental allergen reducing 
interventions. 
Types of outcome measures 
Outcomes of interest needed to be assessed at a minimum age of two years. At 
least one clinical outcome measure (asthma or respiratory symptoms wheezing, 
nocturnal cough and/or dyspnoea) had to be evaluated for studies to be eligible.  
As a diagnosis of asthma at ages younger than five years is driven more by 
symptoms than a diagnosis asthma at age five and older we did separate 
analyses for these outcomes. Asthma cannot be determined objectively children 
under five years of age since lung function measurements cannot be performed 
reliably in these children. Nevertheless we chose to include this outcome, 
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because doctors do diagnose children as being asthmatic at these young ages. 
The diagnosis in these cases is usually confirmed by medication usage.  
Current nocturnal cough is also included although it is known that nocturnal 
cough is likely to be a manifestation of asthma in only a minority of cases. This 
makes the use of the outcome nocturnal cough as asthma symptom less 
reliable.9 As most studies in the field of asthma prevention use this criterion 
however, we have included nocturnal cough in the current meta-analyses. 
Primary outcome 
1. Current Asthma (defined as doctor diagnosis) in children aged <5 years; 
2. Current asthma (defined as current respiratory symptoms (wheeze and/or 
nocturnal cough and/or dyspnoea) plus lung function criteria corresponding 
with clinical diagnosis asthma (BHR and/or reversibility) in children aged ≥5 
years; 
Secondary outcome 
3. Current respiratory symptoms (wheeze, nocturnal cough and dyspnoea) as 
reported by parents in questionnaires; 
4, Adverse events. 
Search strategy for identification of studies 
Eligible studies were identified by searching the Cochrane Central Register of 
Controlled trials (Central) issue 1, 2006, MEDLINE (from January 1966 to 
October 2006), EMBASE (from January 1989 to October 2006) and the 
Cochrane Airways Trial Register (until January 2008) no limitation on language 
of publication. 
 
Design related terms: clinical trial, random (in Cochrane Central search only), 
intervention*, control*; 
Illness related terms: asthma; 
Topic related terms: prevent*, reduct*, allergen*; 
Screening references of relevant reviews and identified studies. 
 
In order to retrieve unpublished or un-identified studies experts in the field were 
contacted via a letter and a standardized e-mail. 
Methods of the review 
Based on title and abstract one reviewer (TM) selected studies by applying the 
inclusion criteria to the studies identified by the literature search. In case of 
uncertainty, a second reviewer (CPvS) was consulted. Both reviewers did 
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assess the full paper version of the selected studies. Disagreements about 
inclusion were resolved by consensus. 
Quality assessment 
The articles were not blinded for authors, institutions or journal title. The 
methodological quality of the included studies was assessed by using the 
Delphi List,10 which also contains all items of the list developed by Jadad.11 The 
Delphi List contains nine items: 1) method of randomisation performed, 2) 
allocation concealed, 3) blinding of 'patient' /parents, 4) blinding of health care 
provider 5) blinding of outcome assessor, 6) inclusion and exclusion criteria 
specified, 7) comparability at baseline regarding the most important prognostic 
indicators (e.g. gender, familial predisposition of child, number of older siblings, 
pets), 8) intention to treat analysis performed 9) point estimates and measures 
of variability presented for primary outcome measure(s). In addition to the 
Delphi List, we considered another item to be important: 10) specification of 
outcome measures. Two reviewers (TM and CPvS) independently assigned a 
score for criteria 1-10.  
 
In a consensus meeting, disagreements between the two reviewers were 
discussed and resolved. If a study did not contain sufficient information on 
methodological criteria, the authors were contacted for additional information. 
 
Inclusion criterion on methodological quality we used for the current meta-
analyses is that at least item number 1, 2, 5 and 10 had to be described and 
fulfilled and of item nine point estimates had to be presented.  
Data extraction 
Data from the included studies were extracted by two reviewers (TM and 
CPvS). Any discrepancies between the two reviewers were resolved by 
discussion.  
Data were extracted according to the following criteria: 
− Methods: setting (location of intervention extramural, at home or hospital, 
country, year of study) and study design; 
− Participants and /or health care providers: method of recruitment, inclusion 
criteria, characteristics of study population (gender, familial predisposition, 
number of older siblings); 
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− Interventions: description of the intervention for each group (mono- versus 
multi-faceted interventions); 
− Outcome measures: for each outcome measure (diagnosis asthma and 
respiratory symptoms (wheezing, night-time cough and dyspnoea) the 
definition of outcome and specific outcome assessor. 
Data analysis 
Review Manager 4.2 of the Cochrane Collaboration we used for pooling data to 
assess the effects of specific interventions and report data on the same 
outcome measure. A formal test for statistical heterogeneity, the natural 
approximate Chi square test, assessed whether the observed variability in effect 
sizes was greater than would be expected to occur by chance. For dichotomous 
endpoints, an Odds Ratio (OR) and 95% Confidence Interval (CI) was 
presented by using a random effects model. Also we re-analysed the data by 
using a fixed effects model and compared the two types of modelling. When no 
or only small differences were observed we presented the data using the 
random effects model. 
 
We calculated a NNT to express the number of children required to be treated 
in order for one to avoid the outcome of interest (Visual Rx).12  
 
Due to the nature of the question addressed in this review, it is likely that there 
would be some variation in the length of follow-up carried out in each of the 
studies. We therefore aimed to analyse data on diagnosis and symptoms of 
asthma in two ways. Firstly we analysed data from multiple age categories (as 
age-pooled subgroups). For every outcome we also analysed data from the last 
published observation available in each of the studies irrespective of time point. 
The results pooled as last observation available were the most recent results of 
every study resulting in a larger amount of studies pooled (n/N), making the 
pooling of these results the most valid ones for every outcome presented.  
 
We used intention to treat analyses for all studies, even if they did not report 
these data. For all studies we assumed that cases lost to follow-up did not 
satisfy the criteria for the outcome tested.  
 
To test the difference between the two separate meta-analyses (mono- and 
multi-faceted) Z tests were carried out for every outcome variable when data 
was available for both types of intervention studies. 
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Description of studies 
A total of 1184 articles were screened. 335 articles resulted from the literature 
search we did ourselves and 849 articles resulted from the Cochrane search in 
the Airways Group Register, including duplicates. After we screened on title and 
abstract 41 remained. We screened the full paper versions of these 41 on 
inclusion criteria as defined for the current meta-analyses and broadened our 
search by checking relevant references.  
Included studies 
A total of nine studies were included. Some studies reported results on multiple 
age-time moments. Of the included studies, three were classified as multi-
faceted intervention studies in the current Meta-analyses: Canadian study13,14, 
Isle of Wight study15-17, PREVASC18 and six were classified as mono-faceted 
intervention studies19-27 (Table 4.1).  
Excluded studies 
Two studies, Kjellman and Johnstone,28,29 that did initially seem to fit the 
inclusion criteria were excluded because of insufficient methodological quality 
(outcome assessors not blinded). The study of Chandra30 initially did fit the 
inclusion criteria but was excluded because of evidence that the published data 
may have been fabricated.2 The study of Koopman et al.8 did fit the inclusion 
criteria but no information was supplied on prevalence of outcomes, the only 
results described in the paper were those of a multiple regression analysis. 
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 a
s 
po
st
iv
e 
sk
in
 te
st
 
to
 >
1a
lle
rg
en
s.
  
C
A
P
S
 H
D
M
 
20
04
19
 
Lo
ng
itu
di
na
l b
irt
h 
co
ho
rt 
in
te
rv
en
tio
n 
st
ud
y 
w
ith
 fo
llo
w
-u
p 
of
 
ch
ild
re
n 
fro
m
 p
re
gn
an
cy
 to
 5
 y
ea
rs
;
P
at
ië
nt
s 
an
d 
pr
ov
id
er
s 
w
er
e 
bl
in
de
d,
 o
ut
co
m
e 
as
se
ss
or
s 
no
t 
cl
ea
r i
f b
lin
de
d 
or
 n
aï
ve
; 
N
um
be
r o
f d
ro
p-
ou
ts
 a
t a
ge
 3
 y
ea
rs
: 
n=
62
 
R
ec
ru
itm
en
t i
n 
6 
an
te
na
ta
l c
lin
ic
s 
an
d 
pr
iv
at
e 
ob
st
et
ric
 ro
om
s 
in
 th
e 
st
ud
y 
re
gi
on
. 
P
ar
en
ts
 w
er
e 
as
ke
d 
to
 fi
ll 
in
 
qu
es
tio
nn
ai
re
s 
on
 a
st
hm
a 
sy
m
pt
om
s 
in
 th
e 
fa
m
ily
. 
In
cl
us
io
n 
cr
ite
ria
: 
- A
t l
ea
st
 o
ne
 p
ar
en
t o
r s
ib
lin
g 
w
ith
 
cu
rre
nt
 a
st
hm
a 
sy
m
pt
om
s;
 
- L
iv
in
g 
in
 s
tu
dy
 a
re
a;
 
- R
ea
so
na
bl
e 
flu
en
cy
 in
 E
ng
lis
h;
 
- T
el
ep
ho
ne
 a
t h
om
e.
 
E
xc
lu
si
on
 c
rit
er
ia
: 
- P
et
 c
at
 in
 th
e 
ho
us
e;
 
- S
tri
ct
 v
eg
et
ar
ia
n 
di
et
; 
- B
irt
h 
<3
6 
w
ks
 g
es
ta
tio
n;
 
- M
ul
tip
le
 b
irt
h;
 
- B
irt
h 
w
ei
gh
t <
2.
5k
g;
 
- S
ig
ni
fic
an
t n
eo
na
ta
l d
is
ea
se
, 
im
pa
irm
en
t o
r m
al
fo
rm
at
io
n;
 
- H
os
pi
ta
lis
at
io
n 
>1
 w
ee
k;
 
- B
ab
ie
s 
in
 n
ee
d 
of
 s
ur
ge
ry
. 
N
um
be
r o
f p
ar
tic
ip
an
ts
: 6
16
 o
f 
w
hi
ch
 n
=3
08
 in
 th
e 
H
D
M
 
in
te
rv
en
tio
ng
ro
up
 a
nd
 n
=3
08
 in
 th
e 
H
D
M
 c
on
tro
lg
ro
up
 
H
D
M
 re
du
ci
ng
 in
te
rv
en
tio
n:
 
M
on
o-
fa
ce
te
d 
in
te
rv
en
tio
n 
on
 
re
du
ct
io
n 
of
 H
D
M
 a
lle
rg
en
 e
xp
os
ur
e 
U
se
 o
f i
m
pe
rm
ea
bl
e 
m
at
tre
ss
 
en
ca
si
ng
 fo
r c
hi
ld
; 
A
dv
ic
e 
on
 re
du
ci
ng
 fu
rry
 p
et
s 
in
 
ch
ild
s 
be
d 
an
d 
av
oi
di
ng
 s
he
ep
sk
in
 
un
de
rla
ys
 in
 c
hi
ld
s 
be
d;
 
La
te
x 
fre
e 
pl
ay
 m
at
 w
as
 p
ro
vi
de
d 
to
 
re
du
ce
 c
on
ta
ct
 w
ith
 c
ar
pe
te
d 
flo
or
s;
W
ha
sh
in
g 
ad
vi
ce
 fo
r b
ed
di
ng
 a
nd
 
pl
ay
 m
at
 (a
ca
ric
id
e 
w
as
hi
ng
); 
C
le
an
in
g 
ad
vi
ce
.  
C
on
tro
l g
ro
up
 in
te
rv
en
tio
n:
 
O
nl
y 
cl
ea
ni
ng
 a
dv
ic
e.
 
C
lin
ic
al
 o
ut
co
m
es
 (c
lin
ic
al
 
ex
am
in
at
io
n 
an
d 
qu
es
tio
nn
ai
re
): 
- N
o 
as
th
m
a;
 
- T
riv
ia
l a
st
hm
a,
 d
ef
in
ed
 a
s 
w
he
ez
e 
in
 la
st
 1
8 
m
on
th
s;
 
- I
nf
re
qu
en
t e
pi
so
di
c 
as
th
m
a,
 
de
fin
ed
 a
s 
1 
or
 m
or
e 
ep
is
od
es
 o
f 
w
he
ez
e 
w
ith
 a
tta
ck
s 
m
or
e 
th
an
 6
 
w
ee
ks
 a
pa
rt;
 
- F
re
qu
en
t e
pi
so
di
c 
as
th
m
a,
 d
ef
in
ed
 
as
 3
 o
r m
or
e 
ep
is
od
es
 o
f w
he
ez
e 
w
ith
 a
tta
ck
s 
le
ss
 th
an
 6
 w
ee
ks
 
ap
ar
t; 
- P
er
si
st
en
t a
st
hm
a 
de
fin
ed
 a
s 
3 
or
 
m
or
e 
ep
is
od
es
 o
f w
he
ez
e 
an
d 
at
 
le
as
t 1
 e
pi
so
de
 o
f n
ig
ht
 ti
m
e 
co
ug
h 
la
st
in
g 
m
or
e 
th
an
 3
 n
ig
ht
s 
an
d 
w
he
ez
e 
at
ta
ck
s 
le
ss
 th
an
 6
 w
ee
ks
 
ap
ar
t a
nd
 d
ai
ly
 u
se
 o
f a
st
hm
a 
m
ed
ic
at
io
n;
 
- n
o 
co
ug
h;
 
- M
ild
 c
ou
gh
, d
ef
in
ed
 a
s 
co
ug
h 
fo
r 
m
or
e 
th
an
 1
 w
ee
k 
or
 c
ou
gh
 w
ith
ou
t 
co
ld
 o
r n
oc
tu
rn
al
 c
ou
gh
 o
r c
ou
gh
 
du
rin
g 
ex
er
ci
se
 a
nd
 p
hy
si
ca
l 
ac
tiv
ity
; 
- M
od
er
at
e 
co
ug
h 
de
fin
ed
 a
s 
pr
es
en
ce
 o
f a
ll 
4 
ty
pe
s 
of
 c
ou
gh
; 
- N
o 
w
he
ez
e;
 
- N
on
 a
to
pi
c 
w
he
ez
e;
 
O
ut
co
m
e 
as
th
m
a 
as
 in
cl
ud
ed
 in
 
cu
rre
nt
 m
et
a-
an
al
ys
is
 is
 re
po
rte
d 
in
 
ar
tic
le
 a
s 
pe
rs
is
te
nt
 a
st
hm
a.
 W
e 
co
nc
lu
de
d 
th
is
 o
ut
co
m
e 
di
d 
fit
 th
e 
in
cl
us
io
n 
cr
ite
rio
n 
'C
ur
re
nt
 a
st
hm
a 
(d
ef
in
ed
 a
s 
do
ct
or
 d
ia
gn
os
is
) i
n 
ch
ild
re
n 
ag
ed
 <
5 
ye
ar
s 
si
nc
e 
th
is
 
ou
tc
om
e 
w
as
 th
e 
re
su
lt 
of
 c
lin
ic
al
 
ex
am
in
at
io
n 
(d
oc
to
r?
). 
O
ut
co
m
e 
tri
vi
al
 a
st
hm
a 
(w
he
ez
e 
in
 
la
st
 1
8 
m
on
th
s)
 a
s 
re
po
rte
d 
in
 
ar
tic
le
 fi
ts
 in
cl
us
io
n 
cr
ite
ria
 o
ut
co
m
e 
'c
ur
re
nt
 w
he
ez
e'
 (w
he
ez
e 
in
 la
st
 1
2 
m
on
th
s)
 a
s 
in
cl
ud
ed
 in
 c
ur
re
nt
 
m
et
a-
an
al
ys
is
.  
A
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- A
to
pi
c 
w
he
ez
e;
 
- N
o 
ec
ze
m
a;
 
- N
on
at
op
ic
 e
cz
em
a;
 
- A
to
pi
c 
ec
ze
m
a;
 
- A
to
py
 to
 in
ge
st
ed
 a
lle
rg
en
s;
 
- A
to
py
 to
 in
ha
la
nt
 a
lle
rg
en
s;
 
- H
ou
se
 d
us
t m
ite
 a
to
py
 
C
A
P
S
 H
D
M
 
20
06
20
 
N
um
be
r o
f d
ro
p-
ou
ts
 p
er
io
d 
3 
to
 5
 
ye
ar
s 
n=
15
, e
ve
nl
y 
di
vi
de
d 
ov
er
 
gr
ou
ps
 
S
ee
 a
bo
ve
 
S
ee
 a
bo
ve
 
C
lin
ic
al
 o
ut
co
m
es
: 
- P
ro
ba
bl
e 
cu
rre
nt
 a
st
hm
a 
de
fin
ed
 
as
 p
ar
en
ta
l r
ep
or
t o
f a
ny
 w
he
ez
e 
in
 
la
st
 1
2 
m
on
th
s 
an
d 
ei
th
er
 a
 p
ar
en
ta
l 
re
po
rt 
of
 a
ny
 w
he
ez
e 
in
 la
st
 1
2 
m
on
th
s 
an
d 
pr
ev
io
us
 p
ar
en
ta
l r
ep
or
t 
of
 d
ia
gn
os
ed
 a
st
hm
a 
(1
8 
m
on
th
s,
 3
 
ye
ar
s,
 5
 y
ea
rs
) o
r 1
2%
 in
cr
ea
se
 o
f 
FE
V
1 
af
te
r b
ro
nc
ho
di
la
to
r a
t a
ge
 5
 
ye
ar
s;
 
- F
re
qu
en
t e
pi
so
di
c 
w
he
ez
e 
de
fin
ed
 
as
 3
 o
r m
or
e 
ep
is
od
es
 a
nd
 m
or
e 
th
an
 e
ve
ry
 6
 w
ee
ks
 o
ve
r a
 p
er
io
d 
of
 
12
 m
on
th
s;
 
- I
nf
re
qu
en
t e
pi
so
di
c 
w
he
ez
e 
de
fin
ed
 a
s 
le
ss
 w
he
ez
in
g 
ep
is
od
es
 
th
an
 fr
eq
ue
nt
 e
pi
so
di
c 
w
he
ez
e;
 
- O
th
er
 w
he
ez
e;
 
- N
o 
w
he
ez
e;
 
- P
er
si
st
en
t w
he
ez
e 
de
fin
ed
 a
s 
w
he
ez
e 
pr
es
en
t a
t a
ge
 1
8 
m
on
th
s 
an
d/
or
 3
 y
ea
rs
 a
nd
 a
ls
o 
pr
es
en
t a
t 
ag
e 
5 
ye
ar
s;
 
- L
at
e 
on
se
t w
he
ez
e 
de
fin
ed
 a
t 
w
he
ez
e 
ab
se
nt
 a
t 1
8 
m
on
th
s 
an
d 
3 
ye
ar
s 
bu
t p
re
se
nt
 a
t a
ge
 5
 y
ea
rs
; 
- T
ra
ns
ie
nt
 e
ar
ly
 w
he
ez
e 
de
fin
ed
 a
s 
w
he
ez
e 
pr
es
en
t a
t a
ge
 1
8 
m
on
th
s 
an
d 
3 
ye
ar
s 
bu
t a
bs
en
t a
t a
ge
 5
 
ye
ar
s;
 
- N
ev
er
 w
he
ez
ed
; 
O
ut
co
m
e 
pe
rs
is
te
nt
 w
he
ez
e 
di
d 
fit
 
th
e 
in
cl
us
io
n 
cr
ite
ria
 o
f c
ur
re
nt
 
w
he
ez
e 
(w
he
ez
e 
at
 5
 y
ea
rs
 o
f a
ge
, 
qu
es
tio
nn
ai
re
 d
at
a)
 a
lth
ou
gh
 th
e 
sy
m
pt
om
s 
in
 th
is
 s
tu
dy
 w
er
e 
th
e 
re
su
lt 
of
 a
n 
in
te
rv
ie
w
 in
cl
ud
in
g 
qu
es
tio
ns
 u
si
ng
 a
 p
ro
 fo
rm
a 
qu
es
tio
nn
ai
re
. 
A
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- C
ou
gh
 w
ith
ou
t c
ol
d 
de
fin
ed
 a
s 
pa
re
nt
al
 re
po
rte
d 
co
ug
h 
la
st
in
g 
>=
 1
 
w
ee
k 
no
t a
ss
oc
ia
te
d 
w
ith
 c
ol
d;
 
- R
hi
ni
tis
; 
- C
ur
re
nt
 e
cz
em
a;
 
- S
P
T:
 a
ny
 a
to
py
, i
nh
al
an
t a
to
py
, 
H
D
M
 a
to
py
, I
gE
 IU
/l;
 
- B
as
el
in
e 
sp
iro
m
et
ry
: F
E
V
1 
l, 
FE
V
1/
FV
C
 ra
tio
; 
-p
os
tb
ro
nc
ho
di
la
to
r s
pi
ro
m
et
ry
: 
FE
V
1 
l, 
FE
V
1/
FV
C
 ra
tio
, %
 c
ha
ng
e 
FE
V
1;
 
- F
O
T 
ba
se
lin
e:
 R
rs
 (c
m
 H
2O
/l/
s)
; 
- F
O
T 
af
te
r b
ro
nc
ho
di
la
to
r: 
R
rs
 (c
m
 
H
2O
/l/
s)
, %
 c
ha
ng
e 
R
rs
 
Is
le
 o
f W
ig
ht
 
19
94
15
 
Lo
ng
itu
di
na
l b
irt
h 
co
ho
rt 
st
ud
y 
w
ith
 
fo
llo
w
-u
p 
of
 c
hi
ld
re
n 
fro
m
 
pr
eg
na
nc
y 
to
 8
 y
ea
rs
; 
P
at
ie
nt
s,
 p
ro
vi
de
rs
 a
nd
 o
ut
co
m
e 
as
se
ss
or
s 
w
er
e 
bl
in
de
d;
 
N
um
be
r o
f d
ro
p-
ou
ts
 a
t a
ge
 2
 y
ea
rs
: 
n=
16
, o
f w
hi
ch
 n
=1
1 
in
 th
e 
in
te
rv
en
tio
n 
gr
ou
p 
an
d 
n=
5 
in
 th
e 
co
nt
ro
l g
ro
up
. 
R
ec
ru
ite
m
en
t a
t o
ne
 d
is
tri
ct
 h
os
pi
ta
l 
at
 2
8 
w
ee
ks
 g
es
ta
tio
n;
 
In
cl
us
io
n 
cr
ite
ria
: 
- P
re
gn
an
t w
om
en
 m
ax
im
um
 
ge
st
at
io
na
l a
ge
 c
hi
ld
 3
2 
w
ee
ks
; 
- R
ep
or
te
d 
du
al
 a
lle
rg
ic
 h
er
ed
ity
 
(p
ar
en
t(s
), 
si
bl
in
g(
s)
); 
- O
r s
in
gl
e 
al
le
rg
ic
 h
er
ed
ity
 A
N
D
 
co
rd
 b
lo
od
 Ig
E
 >
0.
5 
kU
/l.
 
E
xc
lu
si
on
 c
rit
er
ia
: 
- L
iv
in
g 
ou
ts
id
e 
re
se
ar
ch
 a
re
a;
 
- p
re
m
at
ur
ity
; 
- M
ov
in
g 
fro
m
 re
se
ar
ch
 a
re
a;
 
- N
on
 c
om
pl
ia
nc
e 
to
 in
te
rv
en
tio
n;
 
- N
on
 c
om
pl
ia
nc
e 
to
 p
ar
tic
ip
at
in
g 
in
 
fo
llo
w
-u
p 
vi
si
ts
; 
N
um
be
r o
f p
ar
tic
ip
an
ts
: 1
36
 o
f 
w
hi
ch
 in
cl
ud
ed
 in
 th
e 
in
te
rv
en
tio
n 
gr
ou
p:
 n
=6
7 
an
d 
in
cl
ud
ed
 in
 th
e 
co
nt
ro
l g
ro
up
: n
=6
9 
S
ee
 a
bo
ve
 
M
ul
ti-
fa
ce
te
d 
in
te
rv
en
tio
n 
on
 
re
du
ci
ng
 e
xp
os
ur
e 
to
 H
D
M
 a
nd
 
en
co
ur
ag
em
en
t o
f b
re
as
tfe
ed
in
g,
 
st
ric
t d
ie
ta
ry
 re
gi
m
en
 fo
r l
ac
ta
tin
g 
m
ot
he
rs
 a
nd
 d
el
ay
 o
f i
nt
ro
du
ci
ng
 
ch
ild
 to
 a
lle
rg
en
ic
 s
ol
id
 fo
od
s 
un
til
 9
 
m
on
th
s 
an
d 
st
ep
w
is
e 
st
an
da
rd
is
ed
 
in
tro
du
ct
io
n 
fro
m
 th
at
 m
om
en
t o
n.
 
C
in
ic
al
 O
ut
co
m
es
 a
s 
ev
al
ua
te
d 
at
 
re
gu
la
r v
is
its
 b
y 
pa
ed
ia
tri
c 
al
le
rg
is
t:
- D
ia
gn
os
is
 a
st
hm
a;
 
- D
ia
gn
os
is
 c
on
st
itu
tio
na
l e
cz
em
a 
(S
C
O
R
A
D
); 
- A
lle
rg
ic
 rh
in
iti
s;
 
- F
oo
d 
in
to
le
ra
nc
e;
 
- P
os
iti
ve
 S
PT
 s
in
gl
e 
al
le
rg
en
 
(H
D
M
, c
at
 d
an
de
r, 
do
g 
da
nd
er
, 
m
ol
ds
, c
ow
's
 m
ilk
, e
gg
, w
he
at
); 
- P
os
iti
ve
 S
PT
 >
1 
al
le
rg
en
; 
- A
ny
 a
lle
rg
y.
 
 
A
 
Is
le
 o
f W
ig
ht
 
19
97
16
 
S
ee
 a
bo
ve
  
N
o 
pa
rti
ci
pa
nt
s 
lo
st
 to
 fo
llo
w
-u
p 
af
te
r t
he
 c
hi
ld
re
n 
ha
d 
re
ac
he
d 
th
e 
S
ee
 a
bo
ve
 
S
ee
 a
bo
ve
 
C
in
ic
al
 O
ut
co
m
es
 a
s 
ev
al
ua
te
d 
at
 
re
gu
la
r v
is
its
 b
y 
pa
ed
ia
tri
c 
al
le
rg
is
t:
- D
ia
gn
os
is
 a
st
hm
a;
 
 
A
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ag
e 
of
 tw
o 
ye
ar
s 
- D
ia
gn
os
is
 c
on
st
itu
tio
na
l e
cz
em
a;
- A
lle
rg
y 
(a
ny
 p
os
iti
ve
 S
PT
); 
- D
ef
in
ite
 a
lle
rg
y 
(a
lle
rg
y 
sy
m
pt
om
s 
pl
us
 p
os
iti
ve
 S
P
T)
; 
- R
hi
ni
tis
; 
- F
oo
d 
In
to
le
ra
nc
e;
 
- P
os
iti
ve
 S
PT
. 
Is
le
 o
f W
ig
ht
 
20
03
17
 
S
ee
 a
bo
ve
  
N
o 
pa
rti
ci
pa
nt
s 
lo
st
 to
 fo
llo
w
-u
p 
af
te
r t
he
 c
hi
ld
re
n 
ha
d 
re
ac
he
d 
th
e 
ag
e 
of
 tw
o 
ye
ar
s 
S
ee
 a
bo
ve
 
S
ee
 a
bo
ve
 
C
in
ic
al
 o
ut
co
m
e 
m
ea
su
re
s:
 
-C
ur
re
nt
 a
st
hm
a,
 d
ef
in
ed
 a
s 
cu
rre
nt
 
w
he
ez
e 
pl
us
 B
H
R
 <
8m
g/
m
l; 
- C
ur
re
nt
 w
he
ez
e 
as
 re
po
rte
d 
in
 
IS
A
A
C
 q
ue
st
io
nn
ai
re
; 
- N
oc
tu
rn
al
 c
ou
gh
 a
s 
re
po
rte
d 
in
 
IS
A
A
C
 q
ue
st
io
nn
ai
re
; 
- E
xe
rc
is
e 
in
du
ce
d 
w
he
ez
e 
as
 
re
po
rte
d 
in
 IS
A
A
C
 q
ue
st
io
nn
ai
re
; 
- B
H
R
 d
ef
in
ed
 a
s 
P
C
20
<8
m
g/
m
l; 
 
Lu
ng
fu
nc
tio
n 
re
su
lts
: 
- F
E
V
1 
(%
pr
ed
ic
te
d)
; 
- P
ea
kf
lo
w
 (%
pr
ed
ic
te
d)
; 
- F
E
F2
5-
75
 (%
pr
ed
ic
te
d)
; 
- B
ro
nc
hi
al
 re
sp
on
si
ve
ne
ss
 (m
ax
 
ch
an
ge
 in
 F
E
V
1 
di
vi
de
d 
by
 
cu
m
ul
at
iv
e 
do
se
 o
f m
et
ac
ho
lin
e 
gi
ve
n 
fo
r e
ac
h 
su
bj
ec
t);
 
- S
ki
n 
te
st
 o
ut
co
m
e,
 h
ou
se
 d
us
t 
m
ite
, g
ra
ss
 p
ol
le
n,
 tr
ee
 p
ol
le
n,
 c
at
, 
an
y 
ae
ro
al
le
rg
en
, c
ow
's
 m
ilk
, 
pe
an
ut
, a
ny
 fo
od
 a
lle
rg
en
, a
ny
 
al
le
rg
en
 (a
to
py
); 
- I
gE
 o
ut
co
m
e:
 T
ot
al
 Ig
E
 (g
eo
m
et
ric
 
m
ea
ns
 (S
D
), 
m
ea
ns
 d
iff
er
en
ce
 a
nd
 
95
%
 C
I);
 
- I
gE
 in
ha
la
nt
 s
cr
ee
n 
po
si
tiv
e.
 
 
A
 
M
al
le
t 
19
92
21
 
Lo
ng
itu
di
na
l b
irt
h 
co
ho
rt 
st
ud
y 
w
ith
 
fo
llo
w
-u
p 
of
 c
hi
ld
re
n 
fro
m
 b
irt
h 
to
 4
 
ye
ar
s;
 
P
at
ië
nt
 w
er
e 
bl
in
de
d,
 p
ro
vi
de
r w
as
 
R
ec
ru
ite
m
en
t i
n 
on
e 
m
at
er
ni
ty
 
ho
sp
ita
l o
f i
nf
an
ts
 a
t h
ig
h 
ris
k 
of
 
de
ve
lo
pi
ng
 a
to
py
 o
n 
gr
ou
nd
s 
of
 
hi
st
or
y 
of
 a
to
pi
c 
di
se
as
e 
in
 fi
rs
t 
Th
e 
pr
op
hy
la
ct
ic
 g
ro
up
 re
ce
iv
ed
 a
 
fo
rm
ul
a 
ba
se
d 
on
 a
 c
as
ei
n 
hy
dr
ol
ys
at
e 
fo
r 4
 m
on
th
s 
(s
up
pl
ie
d 
by
 th
e 
ho
sp
ita
l) 
ei
th
er
 e
xc
lu
si
ve
ly
 o
r 
C
lin
ic
al
 o
ut
co
m
e 
as
 id
en
tif
ie
d 
at
 
cl
in
ic
al
 a
ss
es
sm
en
t: 
- D
ia
gn
os
is
 a
st
hm
a(
tic
 b
ro
nc
hi
tis
) 
de
fin
ed
 a
s 
m
ild
, t
w
o 
to
 fo
ur
 
M
ild
 a
nd
 s
ev
er
e 
as
th
m
a(
tic
)b
ro
nc
hi
tis
 a
s 
de
sc
rib
ed
 in
 
ar
tic
le
 w
er
e 
cu
m
ul
at
iv
el
y 
in
cl
ud
ed
 in
 
'o
uc
om
e 
as
th
m
a 
de
fin
ed
 a
s 
do
ct
or
 
A
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na
ïv
e,
 o
f p
ro
vi
de
rs
 o
nl
y 
th
e 
pe
di
at
ric
ia
n 
w
as
 n
ot
 b
lin
d 
no
r n
aï
ve
. 
B
lin
di
ng
 o
f o
ut
co
m
e 
as
se
ss
or
 
un
cl
ea
r; 
n=
38
 d
ro
p-
ou
ts
 a
t a
ge
 2
 y
ea
rs
 o
f 
w
hi
ch
 n
=1
4 
in
 th
e 
pr
op
hy
la
ct
ic
 
gr
ou
p 
an
 2
4 
in
 th
e 
co
nt
ro
l g
ro
up
. A
t 
4 
ye
ar
s 
th
er
e 
w
er
e 
an
ot
he
r 1
4 
dr
op
-
ou
ts
 o
f w
hi
ch
 8
 in
 th
e 
pr
op
hy
la
ct
ic
 
gr
ou
p 
an
d 
7 
in
 th
e 
co
nt
ro
l g
ro
up
.  
de
gr
ee
 fa
m
ily
 m
em
be
rs
, c
on
fir
m
ed
 
by
 m
ed
ic
al
 re
co
rd
s.
 
In
fa
nt
s 
w
er
e 
ra
nd
om
ly
 a
ss
ig
ne
d 
to
 
on
e 
of
 tw
o 
gr
ou
ps
: p
ro
ph
yl
ac
tic
 
gr
ou
p 
(n
=9
2)
 o
r c
on
tro
l g
ro
up
 
(n
=8
5)
. 
as
 a
 c
om
pl
em
en
t t
o 
or
 s
ub
st
itu
te
 fo
r 
hu
m
an
 m
ilk
. N
o 
ot
he
r f
oo
d 
w
as
 
al
lo
w
ed
, i
nc
lu
di
ng
 fr
ui
t j
ui
ce
. N
o 
sp
ec
ifi
c 
in
st
ru
ct
io
ns
 w
er
e 
gi
ve
n 
re
ga
rd
in
g 
th
e 
m
ot
he
r's
 d
ie
ts
 d
ur
in
g 
pr
eg
na
nc
y 
an
d 
br
ea
st
-fe
ed
in
g.
 
P
ar
en
ts
 a
nd
 th
ei
r p
hy
si
ci
an
s 
w
er
e 
gi
ve
n 
an
 o
bs
er
va
tio
n 
sh
ee
t t
o 
re
co
rd
 a
nt
hr
op
om
et
ric
 d
at
a,
 
si
gn
ifi
ca
nt
 c
lin
ic
al
 re
ac
tio
ns
 
(c
ut
an
eo
us
, d
ig
es
tiv
e 
or
 re
sp
ira
to
ry
) 
an
d 
pe
di
at
ric
ia
ns
 k
ne
w
 w
hi
ch
 
fo
rm
ul
a 
w
as
 fe
d 
to
 th
e 
in
fa
nt
.  
C
on
tro
l g
ro
up
 in
te
rv
en
tio
n:
 
Th
e 
sa
m
e 
as
 th
e 
pr
op
hy
la
ct
ic
 g
ro
up
 
in
te
rv
en
tio
n 
w
ith
 th
e 
on
ly
 d
iff
er
en
ce
 
th
e 
ty
pe
 o
f f
or
m
ul
a 
su
pp
lie
d.
 T
he
 
co
nt
ro
l g
ro
up
 in
fa
nt
s 
re
ce
iv
ed
 
ad
ap
te
d 
co
w
's
 m
ilk
 fo
rm
ul
a.
 
oc
cu
rre
nc
es
 y
ea
rly
, s
ev
er
e 
de
fin
ed
 
as
 m
or
e 
th
an
 4
 o
cc
ur
re
nc
es
 y
ea
rly
;
- D
ia
gn
os
is
 E
cz
em
a:
 
- M
ild
 e
cz
em
a 
de
fin
ed
 a
s 
le
ss
 th
an
 
4 
pa
tc
he
s 
of
 e
cz
em
a;
 
- M
od
er
at
e 
ec
ze
m
a;
  
- D
ru
g-
re
si
st
an
t e
cz
em
a;
 
- S
ev
er
e 
ec
ze
m
a.
 
- O
bv
io
us
 c
ow
's
 m
ilk
 p
ro
te
in
 a
lle
rg
y 
ve
rif
ie
d 
by
 c
rit
er
ia
 o
f t
yp
e 
I r
ea
ge
ni
c 
al
le
rg
y 
of
 m
al
ab
so
rp
tio
n.
 
- T
ot
al
 Ig
E
 le
ve
ls
 w
er
e 
m
ea
su
re
d 
in
 
co
rd
 b
lo
od
 a
t b
irt
h 
an
d 
in
 b
lo
od
 
ob
ta
in
ed
 b
y 
ve
na
 p
un
ct
ur
e 
at
 4
 a
nd
 
12
 m
on
th
s 
of
 a
ge
. I
f a
bo
ve
 n
or
m
al
 
le
ve
ls
 w
er
e 
de
te
ct
ed
, c
ow
's
 m
ilk
 
pr
ot
ei
n 
sp
ec
ifi
c 
Ig
E
 w
er
e 
m
ea
su
re
d.
di
ag
no
si
s 
in
 c
hi
ld
re
n 
ag
ed
 <
5 
ye
ar
s)
 
as
 th
e 
de
sc
rib
ed
 o
ut
co
m
e 
w
as
 re
su
lt 
of
 c
lin
ic
al
 a
ss
es
sm
en
t. 
na
cM
A
A
S 
20
04
22
 
Lo
ng
itu
di
na
l b
irt
h 
co
ho
rt 
in
te
rv
en
tio
n 
st
ud
y 
w
ith
 fo
llo
w
-u
p 
of
 
ch
ild
re
n 
fro
m
 p
re
gn
an
cy
 to
 8
 y
ea
rs
;
P
at
ie
nt
s 
an
d 
ou
tc
om
e 
as
se
ss
or
s 
no
t c
le
ar
 if
 b
lin
de
d 
or
 n
aï
ve
. 
P
ro
vi
de
rs
 w
er
e 
bl
in
de
d;
 
N
um
be
r o
f d
ro
p-
ou
ts
 a
t 3
 y
ea
rs
 o
f 
ag
e:
 1
2 
(n
=5
 in
 in
te
rv
en
tio
n 
gr
ou
p 
an
d 
n=
7 
in
 c
on
tro
l g
ro
up
). 
A
ll 
pr
eg
na
nt
 w
om
en
 a
nd
 th
ei
r 
pa
rtn
er
s 
in
 6
54
 a
nt
en
at
al
 c
lin
ic
s 
w
er
e 
sc
re
en
ed
 fo
r e
lig
ib
ili
ty
 a
t 8
-1
0 
w
ee
ks
 p
re
gn
an
cy
 b
y 
S
P
T 
an
d 
st
ru
ct
ur
ed
 q
ue
st
io
nn
ai
re
; 
In
cl
us
io
n 
cr
ite
ria
: 
H
ig
h 
ris
k 
of
 d
ev
el
op
in
g 
al
le
rg
ic
 
di
se
as
e 
(b
ot
h 
pa
re
nt
s 
at
op
ic
); 
N
o 
pe
t c
at
 o
r d
og
 a
t h
om
e.
 
E
xc
lu
si
on
 c
rit
er
ia
: i
nc
lu
si
on
 c
rit
er
ia
 
no
t f
ul
fil
le
d.
 
N
um
be
r o
f i
nc
lu
de
d 
pa
rti
ci
pa
nt
s 
(m
in
us
 in
fa
nt
s 
w
ith
dr
aw
n 
be
fo
re
 
bi
rth
): 
25
6 
in
 th
e 
en
vi
ro
nm
en
ta
l 
co
nt
ro
l R
C
T,
 o
f w
hi
ch
 n
=1
33
 in
 th
e 
ac
tiv
e 
gr
ou
p 
an
d 
n=
12
3 
in
 th
e 
co
nt
ro
l g
ro
up
. 
In
te
rv
en
tio
n:
 E
nv
iro
nm
en
ta
l c
on
tro
l 
m
ea
su
re
s 
co
ns
is
tin
g 
of
 u
se
 o
f m
ite
 
im
pe
rm
ea
bl
e 
m
at
tre
ss
 e
nc
as
in
gs
 
fo
r p
ar
en
ta
l b
ed
 fr
om
 p
re
gn
an
cy
 o
n;
U
se
 o
f m
ite
 im
pe
rm
ea
bl
e 
m
at
tre
ss
 
co
ve
r f
or
 c
hi
ld
's
 b
ed
; 
A
dv
is
e 
to
 h
ot
 w
as
h 
be
d 
lin
ne
n 
w
ee
kl
y;
 
H
ig
h 
fil
tra
tio
n 
va
cu
um
 c
le
an
er
, 
w
as
ha
bl
e 
so
ft 
to
y 
an
d 
cr
ib
 m
at
tre
ss
 
pr
ov
id
ed
; 
C
ar
pe
ts
 o
f c
hi
ld
's
 b
ed
ro
om
 w
er
e 
re
m
ov
ed
 a
nd
 re
pl
ac
ed
 b
y 
sm
oo
th
 
flo
or
 c
ov
er
in
gs
; 
C
ar
pe
ts
 a
nd
 s
of
a'
s 
w
er
e 
3 
m
on
th
ly
 
tre
at
ed
 w
ith
 a
nt
i-m
ite
 fl
ui
d.
 
P
la
ce
bo
 in
te
rv
en
tio
n:
 U
su
al
 c
ar
e.
 
C
lin
ic
al
 o
ut
co
m
es
: 
- A
st
hm
a,
 p
hy
si
ci
an
 d
ia
gn
os
ed
; 
- W
he
ez
e 
ev
er
; 
- C
ur
re
nt
 w
he
ez
e 
(la
st
 3
 m
on
th
s)
 
- W
he
ez
e 
ag
e 
1 
to
 3
 y
ea
rs
; 
- W
he
ez
y 
at
ta
ck
s 
re
qu
iri
ng
 
m
ed
ic
at
io
n;
 
- >
3 
E
pi
so
de
s 
of
 s
ev
er
e 
w
he
ez
e;
 
- W
he
ez
e 
af
te
r e
xe
rti
on
; 
- N
ig
ht
-ti
m
e 
co
ug
h;
 
- C
ou
gh
 a
pa
rt 
fro
m
 c
ol
ds
; 
- C
ou
gh
 a
fte
r e
xe
rti
on
; 
- C
ou
gh
 w
ith
 e
xc
ite
m
en
t; 
- C
ur
re
nt
 a
st
hm
a 
m
ed
ic
at
io
n;
 
- R
hi
ni
tis
; 
- C
ur
re
nt
 e
cz
em
a;
 
- S
P
T 
po
si
tiv
e 
(D
er
 p
1,
 F
el
 d
1,
 C
an
 
f1
, m
ix
ed
 g
ra
ss
es
, m
ilk
, e
gg
, o
ve
ra
ll 
m
in
im
al
ly
 s
en
si
tis
ed
 fo
r 1
 a
lle
rg
en
 
te
st
ed
); 
O
ut
co
m
e 
'C
ur
re
nt
 w
he
ez
e 
as
 
pa
re
nt
al
 re
po
rte
d'
 w
e 
in
cl
ud
ed
 in
 
cu
rr
en
t m
et
a-
an
al
ys
is
 is
 'c
ur
re
nt
 
w
he
ez
e 
(la
st
 3
 m
on
th
s)
'. 
A
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- I
gE
 (D
er
 p
, F
el
 d
1,
 C
an
 f1
, m
ilk
, 
eg
g,
 o
ve
ra
ll 
m
in
im
al
ly
 s
en
si
tis
ed
 fo
r 
on
e 
al
le
rg
en
 te
st
ed
); 
- L
un
gf
un
ci
on
 (s
pe
ci
fic
 a
irw
ay
 
re
si
st
an
ce
 s
R
aw
). 
P
IA
M
A
 
20
06
23
,3
3 
Lo
ng
itu
di
na
l b
irt
h 
co
ho
rt 
in
te
rv
en
tio
n 
st
ud
y 
w
ith
 fo
llo
w
-u
p 
of
 
ch
ild
re
n 
fro
m
 p
re
gn
an
cy
 to
 2
 y
ea
rs
;
P
at
ië
nt
s,
 p
ro
vi
de
rs
 a
nd
 o
ut
co
m
e 
as
se
ss
or
s 
w
er
e 
bl
in
de
d;
 
N
um
be
r o
f d
ro
p-
ou
ts
 a
t a
ge
 4
 y
ea
rs
: 
n=
20
7,
 o
f w
hi
ch
 n
=9
2 
in
 th
e 
ac
tiv
e 
gr
ou
p 
an
d 
n=
11
5 
in
 th
e 
pl
ac
eb
o 
gr
ou
p.
 
R
ec
ru
itm
en
t: 
P
re
gn
an
t w
om
en
 in
 
th
ei
r t
hi
rd
 tr
im
es
te
r o
f p
re
gn
an
cy
 
w
er
e 
co
nt
ac
te
d 
w
ith
 h
el
p 
of
 
m
id
w
iv
es
 a
nd
 o
bs
te
tri
c 
cl
in
ic
s.
  
In
cl
us
io
n 
cr
ite
ria
: P
re
gn
an
t w
om
en
 
in
 th
ei
r t
hi
rd
 tr
im
es
te
r o
f p
re
gn
an
cy
;
A
lle
rg
ic
 m
ot
he
r o
n 
gr
ou
nd
s 
of
 
qu
es
tio
nn
ai
re
 d
at
a.
 
E
xc
lu
si
on
 c
rit
er
ia
: 
N
ot
 d
es
cr
ib
ed
. 
N
um
be
r o
f p
ar
tic
ip
an
ts
 in
 th
e 
In
te
rv
en
tio
n 
st
ud
y:
 n
=8
10
, o
f w
hi
ch
 
n=
 4
16
 in
 th
e 
ac
tiv
e 
gr
ou
p 
an
d 
n=
39
4 
in
 th
e 
pl
ac
eb
o 
gr
ou
p.
 
M
on
o-
fa
ce
te
d 
in
te
rv
en
tio
n 
on
 
re
du
ci
ng
 e
xp
os
ur
e 
to
 H
D
M
 
al
le
rg
en
s.
 
In
te
rv
en
tio
n:
 A
ct
iv
e 
H
D
M
 a
lle
rg
en
 
im
pe
rm
ea
bl
e 
en
ca
si
ng
 w
er
e 
su
pp
lie
d 
fo
r m
at
tre
ss
 a
nd
 p
illo
w
 o
f 
ch
ild
 a
nd
 p
ar
en
ts
 b
ed
; 
In
st
ru
ct
io
ns
 o
n 
w
as
hi
ng
 b
ed
 li
nn
en
 
at
 H
D
M
 k
illi
ng
 te
m
pe
ra
tu
re
; 
fa
m
ilie
s 
w
er
e 
su
pp
lie
d 
w
ith
 a
 
br
oc
hu
re
 o
f t
he
 D
ut
ch
 A
st
hm
a 
Fo
un
da
tio
n 
(N
A
F)
 o
n 
al
le
rg
en
 
av
oi
da
nc
e.
 
pl
ac
eb
o 
gr
ou
p 
in
te
rv
en
tio
n:
 
O
nl
y 
di
ffe
re
nc
e 
w
ith
 a
ct
iv
e 
in
te
rv
en
tio
n 
w
as
 th
e 
pl
ac
eb
o 
gr
ou
p 
re
ce
iv
ed
 p
la
ce
bo
 e
nc
as
in
gs
 b
ut
 
br
oc
hu
re
 a
nd
 w
as
hi
ng
 a
dv
is
e 
w
as
 
th
e 
sa
m
e.
 
C
lin
ic
al
 o
ut
co
m
es
: 
- 4
 W
he
ez
in
g 
ca
te
go
rie
s,
 1
 n
ev
er
 
w
he
ez
ed
, 2
 e
ar
ly
 tr
an
si
en
t w
he
ez
e,
 
3 
pe
rs
is
te
nt
 w
he
ez
e,
 4
 la
te
 w
he
ez
e;
- W
he
ez
e 
in
 fo
ur
th
 y
ea
r; 
- N
ig
ht
 ti
m
e 
co
ug
h 
in
 fo
ur
th
 y
ea
r; 
- A
to
pi
c 
de
rm
at
iti
s 
in
 fo
ur
th
 y
ea
r; 
- R
hi
ni
tis
 in
 fo
ur
th
 y
ea
r; 
- R
hi
ni
tis
 a
nd
 e
ye
 s
ym
pt
om
s 
in
 
fo
ur
th
 y
ea
r. 
- I
gE
 o
ut
co
m
e 
as
 m
ea
su
re
d 
at
 4
 y
rs
 
of
 a
ge
: T
ot
al
 Ig
E
 IU
/m
l, 
S
pe
ci
fic
 Ig
E
 
ag
ai
ns
t H
D
M
, c
at
, d
og
, g
ra
ss
po
lle
n,
 
bi
rc
hp
ol
le
n 
>=
0.
35
 IU
/m
l/t
ot
al
. 
D
at
a 
pr
es
en
te
d 
of
 d
es
cr
ib
ed
 s
tu
dy
-
ou
tc
om
e 
'w
he
ez
in
g 
in
 fo
ur
th
 y
ea
r '
 
in
cl
ud
ed
 fo
r o
ut
co
m
e 
'C
ur
re
nt
 
w
he
ez
in
g'
 in
 c
ur
re
nt
 m
et
a-
an
al
ys
is
. 
A
 
P
R
E
V
A
S
C
 
20
05
18
,3
4 
Lo
ng
itu
di
na
l b
irt
h 
co
ho
rt 
in
te
rv
en
tio
n 
st
ud
y 
w
ith
 fo
llo
w
-u
p 
of
 
ch
ild
re
n 
fro
m
 p
re
na
ta
l a
ge
 u
nt
il 
6 
ye
ar
s;
 
P
re
ra
nd
om
is
at
io
n 
of
 p
ar
tic
ip
an
ts
. 
P
at
ië
nt
s 
in
 in
te
rv
en
tio
n 
gr
ou
p 
in
fo
rm
ed
, n
ot
 b
lin
de
d,
 p
at
ië
nt
s 
in
 
co
nt
ro
l g
ro
up
 w
er
e 
bl
in
de
d;
 
G
P
 n
ot
 b
lin
de
d 
no
r n
aï
ve
, o
ut
co
m
e 
as
se
ss
or
s 
bl
in
de
d;
 
N
um
be
r o
f d
ro
p-
ou
ts
 a
t a
ge
 2
 y
ea
rs
 
n=
33
, o
f w
hi
ch
 n
=2
0 
in
 in
te
rv
en
tio
n 
gr
ou
p 
an
d 
n=
13
 in
 c
on
tro
l g
ro
up
, a
ll 
du
rin
g 
pr
en
at
al
 o
r d
el
iv
er
y 
pe
rio
d 
R
ec
ru
ite
m
en
t :
 G
P
s 
an
d 
m
id
w
iv
es
 
in
fo
rm
ed
 p
re
gn
an
t w
om
en
 a
nd
 
in
cl
us
io
n 
cr
ite
ria
 w
er
e 
ch
ec
ke
d 
by
 
G
P
 a
nd
 s
cr
ee
ni
ng
 q
ue
st
io
nn
ai
re
s;
 
In
cl
us
io
n 
cr
ite
ria
: P
re
gn
an
t w
om
en
 
in
cl
ud
ed
 d
ur
in
g 
fir
st
 o
r s
ec
on
d 
tri
m
es
te
r o
f p
re
gn
an
cy
; M
in
im
al
ly
 
on
e 
fir
st
 d
eg
re
e 
re
la
tiv
e 
of
 c
hi
ld
 is
 
di
ag
no
se
d 
as
 b
ei
ng
 a
st
hm
at
ic
 a
s 
re
po
rte
d 
by
 G
P
s;
 
Li
vi
ng
 in
 th
e 
so
ut
h 
of
 T
he
 
N
et
he
rla
nd
s;
 
E
xc
lu
si
on
 c
rit
er
ia
: 
M
aj
or
 la
ng
ua
ge
 p
ro
bl
em
; 
M
ul
ti-
fa
ce
te
d 
in
te
rv
en
tio
n 
on
 
re
du
ci
ng
 e
xp
os
ur
e 
to
 H
D
M
, p
et
s,
 
E
TS
 a
nd
 e
nc
ou
ra
ge
m
en
t o
f 
br
ea
st
fe
ed
in
g 
fo
r 6
 m
on
th
s 
an
d/
or
 
hy
po
-a
lle
rg
en
ic
 fo
rm
ul
a 
as
 w
el
l a
s 
de
la
y 
of
 in
tro
du
ct
io
n 
of
 s
ol
id
 fo
od
s.
C
on
tro
l g
ro
up
 in
te
rv
en
tio
n:
 
U
su
al
 c
ar
e,
 n
o 
st
ud
y 
in
te
rv
en
tio
n.
 
C
lin
ic
al
 o
ut
co
m
e 
m
ea
su
re
s:
 
- A
st
hm
a,
 a
s 
di
ag
no
se
d 
by
 G
P
;  
-A
st
hm
a 
sy
m
pt
om
s:
 w
he
ez
in
g 
(w
ith
 
or
 w
ith
ou
t f
ev
er
), 
no
ct
ur
na
l c
ou
gh
 in
 
th
e 
ab
se
ns
e 
of
 c
ol
d 
m
in
im
al
ly
 o
ne
s 
a 
w
ee
k,
 s
ho
rtn
es
s 
of
 b
re
at
h 
(d
ys
pn
oe
a)
 a
s 
re
po
rte
d 
by
 G
P
s 
an
d 
as
 re
po
rte
d 
by
 p
ar
en
ts
 in
 
w
ee
kr
ep
or
ts
;  
- C
on
st
itu
tio
na
l e
cz
em
a,
 a
s 
di
ag
no
se
d 
by
 G
P
; 
- T
ot
al
 a
nd
 s
pe
ci
fic
 Ig
e 
le
ve
l (
H
D
M
, 
ca
t, 
do
g)
 a
s 
m
ea
su
re
d 
in
 b
lo
od
 a
t 
ag
e 
2 
ye
ar
s;
 
G
P
 d
ia
gn
os
is
 a
st
hm
a 
in
cl
ud
ed
 fo
r 
ou
tc
om
e 
'C
ur
re
nt
 A
st
hm
a 
(d
ef
in
ed
 
as
 d
oc
to
r d
ia
gn
os
is
) i
n 
ch
ild
re
n 
ag
ed
 
<5
 y
ea
rs
; 
C
ur
re
nt
 re
sp
ira
to
ry
 s
ym
pt
om
s:
 
cu
rre
nt
 w
he
ez
in
g,
 c
ur
re
nt
 n
oc
tu
rn
al
 
co
ug
h 
an
d 
cu
rre
nt
 d
ys
pn
oe
a 
as
 
re
po
rte
d 
by
 p
ar
en
ts
 in
 w
ee
k 
re
po
rts
 
in
cl
ud
ed
 in
 c
ur
re
nt
 m
et
a-
an
al
ys
es
. 
A
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du
e 
to
 m
is
ca
rri
ag
es
, s
til
l b
irt
h,
 lo
ng
 
la
st
in
g 
ho
sp
ita
lis
at
io
n 
or
 m
ov
in
g.
 N
o 
da
ta
 o
n 
st
ud
y 
ou
tc
om
e 
w
er
e 
co
lle
ct
ed
. 
M
ov
in
g 
ou
ts
id
e 
th
e 
co
un
try
;  
S
ev
er
e 
illn
es
s/
m
al
fo
rm
at
io
n 
ch
ild
; 
N
um
be
r o
f p
ar
tic
ip
an
ts
 fo
llo
w
ed
 u
p:
 
n=
44
3,
 o
f w
hi
ch
 n
=2
22
 in
 th
e 
in
te
rv
en
tio
n 
gr
ou
p 
an
d 
n=
22
1 
in
 th
e 
us
ua
l c
ar
e 
gr
ou
p 
- A
to
py
 d
ef
in
ed
 a
s 
Ig
E
 le
ve
l f
or
 
H
D
M
, c
at
 o
r d
og
 a
lle
rg
en
 >
10
 U
/m
l.
S
P
A
C
E
 
20
04
27
,3
5 
Lo
ng
itu
di
na
l b
irt
h 
co
ho
rt 
in
te
rv
en
tio
n 
st
ud
y 
w
ith
 fo
llo
w
-u
p 
of
 
ch
ild
re
n 
fro
m
 p
re
gn
an
cy
 to
 2
 y
ea
rs
;
P
at
ië
nt
s,
 p
ro
vi
de
rs
 w
er
e 
ke
pt
 n
aï
ve
, 
ou
tc
om
e 
as
se
ss
or
s 
bl
in
de
d;
 
N
um
be
r o
f d
ro
p-
ou
ts
 a
t a
ge
 2
 y
ea
rs
: 
n=
13
3,
 o
f w
hi
ch
 5
8 
in
 th
e 
in
te
rv
en
tio
n 
gr
ou
p 
an
d 
75
 in
 th
e 
co
nt
ro
l g
ro
up
. 
R
ec
ru
itm
en
t: 
A
ll 
pr
eg
na
nt
 w
om
en
 a
t 
th
re
e 
ce
nt
re
s 
(in
 G
er
m
an
y,
 A
us
tri
a 
an
d 
U
K
) w
er
e 
sc
re
en
ed
 o
n 
al
ig
eb
ilit
y 
fo
r i
nc
lu
si
on
 in
 a
 1
2-
m
on
th
 p
er
io
d.
 T
he
 m
aj
or
ity
 o
f 
w
om
en
 w
er
e 
ap
pr
oa
ch
ed
 d
ur
in
g 
ro
ut
in
e 
vi
si
ts
 to
 o
bs
te
tri
c 
w
ar
d 
or
 
an
te
na
ta
l c
lin
ic
s 
du
rin
g 
pr
eg
na
nc
y.
 
IS
A
A
C
-q
ue
st
io
nn
ai
re
s 
an
d 
qu
es
tio
nn
ai
re
s 
of
 th
e 
M
A
S
 s
tu
dy
 
w
er
e 
us
ed
 to
 d
et
er
m
in
e 
th
e 
fa
m
ily
 
hi
st
or
y 
of
 a
to
pi
c 
di
so
rd
er
s 
in
 p
ar
en
ts
 
or
 s
ib
lin
gs
. I
f a
 p
os
iti
ve
 a
ns
w
er
 o
n 
at
op
y 
qu
es
tio
ns
 w
as
 ra
pp
or
te
d 
a 
S
PT
 o
r b
lo
od
 te
st
 fo
r s
pe
ci
fic
 Ig
E
 
w
as
 c
ar
rie
d 
ou
t o
n 
at
 le
as
t o
ne
 
pa
re
nt
, t
o 
de
te
rm
in
e 
th
ei
r a
lle
rg
ic
 
se
ns
iti
za
tio
n 
(H
D
M
 a
lle
rg
en
s 
(D
er
 
p1
 a
nd
 D
er
 f1
), 
gr
as
s 
m
ix
tu
re
, c
at
 
da
nd
er
); 
If 
su
bj
ec
t d
id
 n
ot
 c
om
pl
y 
to
 th
e 
S
PT
 
th
ey
 h
ad
 th
ei
r b
lo
od
 te
st
ed
 fo
r I
gE
 
to
ta
l a
nd
 s
pe
ci
fic
. 
R
an
do
m
is
at
io
n 
w
as
 in
 2
-w
ee
ks
 
pe
rio
ds
 a
nd
 in
fa
nt
s 
w
er
e 
al
lo
ca
te
d 
ac
co
rd
in
g 
to
 th
e 
ex
pe
ct
ed
 d
at
e 
of
 
de
liv
er
y 
of
 th
e 
ac
tu
al
 d
at
e 
of
 
de
liv
er
y 
if 
re
cr
ui
te
d 
po
st
na
ta
lly
.  
P
ar
tic
ip
an
ts
: 
n=
69
6,
 o
f w
hi
ch
 n
=3
49
 in
 th
e 
in
te
rv
en
tio
n 
gr
ou
p 
an
d 
n=
34
7 
in
 th
e 
co
nt
ro
l g
ro
up
. 
M
on
o-
fa
ce
te
d 
in
te
rv
en
tio
n,
 p
rim
ar
ily
 
ai
m
ed
 a
t H
D
M
 e
xp
os
ur
e 
re
du
ct
io
n:
A
t b
irt
h 
m
ite
 im
pe
rm
ea
bl
e 
m
at
tre
ss
 
en
ca
si
ng
s 
w
er
e 
pr
ov
id
ed
 fo
r t
he
 
in
fa
nt
's
 b
ed
 a
s 
w
el
l a
s 
th
ei
r p
ar
en
t's
 
be
d.
 
In
 a
dd
iti
on
 th
ey
 re
ce
iv
ed
 in
fo
rm
at
io
n 
on
 a
lle
rg
y 
an
d 
al
le
rg
en
 re
du
ci
ng
 
m
ea
su
re
s 
on
 in
cl
ud
in
g 
w
rit
te
n 
en
co
ur
ag
em
en
t t
o 
av
oi
d 
fo
od
 
al
le
rg
en
s;
 
B
re
as
tfe
ed
in
g 
un
til
 3
 m
on
th
s 
of
 a
ge
 
or
 o
th
er
w
is
e 
us
e 
of
 h
yp
oa
lle
rg
en
ic
 
fo
rm
ul
a.
  
C
ow
's
 m
ilk
 fo
rm
ul
a 
w
as
 
re
co
m
m
en
de
d 
to
 b
e 
av
oi
de
d 
un
til
 6
 
m
on
th
s.
  
C
ow
's
 m
ilk
 o
th
er
 th
an
 fo
rm
ul
a 
as
 
w
el
l a
s 
eg
g 
an
d 
fis
h 
w
er
e 
ad
vi
se
d 
to
 
be
 a
vo
id
ed
 u
nt
il 
th
e 
ch
ild
's
 a
ge
 o
f 
12
 m
on
th
s;
 
S
ol
id
 fo
od
s 
sh
ou
ld
 b
e 
de
la
ye
d 
un
til
 
4-
6 
m
on
th
s 
an
d 
w
ea
t s
ho
ul
d 
be
 
av
oi
de
d 
un
til
 6
 m
on
th
s;
 
P
ea
nu
ts
 a
nd
 tr
ee
 n
ut
s 
sh
ou
ld
 n
ot
 b
e 
in
tro
du
ce
d 
un
til
 3
 y
ea
rs
 o
f a
ge
; 
In
fo
rm
at
io
n 
on
 v
en
til
at
io
n 
an
d 
ET
S
 
ex
po
su
re
 re
du
ct
io
n 
an
d 
no
t a
llo
w
in
g 
pe
ts
 in
 th
e 
be
dr
oo
m
 w
as
 p
ro
vi
de
d.
P
la
ce
bo
 in
te
rv
en
tio
n:
 
A
 b
oo
kl
et
 w
as
 p
ro
vi
de
d,
 c
on
ta
in
in
g 
m
or
e 
ba
si
c 
in
fo
rm
at
io
n 
on
 th
e 
m
ea
su
re
s 
th
e 
in
te
rv
en
tio
n 
gr
ou
p 
C
in
ic
al
 o
ut
co
m
es
: 
- A
st
hm
a 
(p
ar
en
ta
l r
ep
or
te
d)
; 
- R
ec
ur
re
nt
 w
he
ez
in
g 
(IS
A
A
C
 
qu
es
tio
nn
ai
re
); 
- N
oc
tu
rn
al
 c
ou
gh
 (I
S
AA
C
 
qu
es
tio
nn
ai
re
); 
- O
th
er
 s
ym
pt
om
s:
 
- R
hi
ni
tis
 (I
S
A
A
C
 q
ue
st
io
nn
ai
re
); 
- S
en
si
tis
at
io
n 
to
 m
ite
s 
(p
os
iti
ve
 
S
PT
 o
r s
pe
ci
fic
 Ig
E
 a
ga
in
st
 D
er
 p
1 
or
 D
er
 f1
 >
1.
43
 k
U
/l)
; 
- A
ny
 a
lle
rg
y 
(d
ef
in
ed
 a
s 
as
th
m
a 
or
 
no
ct
ur
na
l c
ou
gh
 o
r r
ec
ur
re
nt
 
w
he
ez
e 
or
 e
cz
em
a 
or
 rh
in
iti
s 
in
 th
e 
fir
st
 2
4 
m
on
th
s 
of
 li
fe
); 
- A
to
pi
c 
ec
ze
m
a 
(p
ar
en
ta
l r
ep
or
te
d 
do
ct
or
's
 d
ia
gn
os
is
). 
 
A
rti
cl
e 
S
P
A
C
E 
G
 H
al
m
er
ba
ue
r u
se
d 
fo
r a
dd
iti
on
al
 in
fo
rm
at
io
n 
on
 s
tu
dy
 
de
si
gn
 
A
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w
as
 a
dv
is
ed
 o
n.
 
N
o 
pl
ac
eb
o 
m
at
tre
ss
 e
nc
as
in
gs
 
w
er
e 
pr
ov
id
ed
. 
Ze
ig
er
 R
S
 
19
89
24
 
Lo
ng
itu
di
na
l b
irt
h 
co
ho
rt 
in
te
rv
en
tio
n 
st
ud
y 
w
ith
 fo
llo
w
-u
p 
of
 
ch
ild
re
n 
fro
m
 p
re
gn
an
cy
 to
 7
 y
ea
rs
;
P
at
ië
nt
s 
w
er
e 
bl
in
de
d,
 a
s 
w
el
l a
s 
pr
ov
id
er
s 
an
d 
ou
tc
om
e 
as
se
ss
or
s;
N
um
be
r o
f d
ro
p-
ou
ts
 a
t a
ge
2 
ye
ar
s:
 
n=
23
 o
f w
hi
ch
 6
 in
 th
e 
pr
op
hy
la
ct
ic
 
gr
ou
p 
an
d 
17
 in
 th
e 
co
nt
ro
l g
ro
up
. 
R
ec
ru
itm
en
t b
y 
in
fo
rm
in
g 
pr
eg
na
nt
 
w
om
en
 s
ug
ge
st
iv
e 
of
 a
to
py
 
(q
ue
st
io
nn
ai
re
 d
at
a 
fil
le
d 
in
 d
ur
in
g 
a 
ro
ut
in
e 
ob
st
et
ric
al
 v
is
it)
 w
er
e 
in
vi
te
d 
w
ith
 th
ei
r p
ar
tn
er
 to
 a
 s
tu
dy
 
pr
es
en
ta
tio
n.
 
In
cl
us
io
n 
cr
ite
ria
: 
- A
t l
ea
st
 1
 p
ar
en
t h
as
 a
 h
is
to
ry
 o
f 
at
op
ic
 d
is
or
de
r; 
- S
pe
ci
fic
 Ig
E
 b
y 
sk
in
 o
r R
A
S
T 
te
st
in
g.
 S
ki
n 
te
st
ed
 o
f m
ot
he
rs
 to
 
fo
od
s 
an
d 
in
ha
la
nt
s 
4 
m
on
th
s 
po
st
pa
rtu
m
. 
E
xc
lu
si
on
 c
rit
er
ia
: 
- I
nc
lu
si
on
 c
rit
er
ia
 n
ot
 fu
lfi
lle
d.
 
N
um
be
r o
f p
ar
tic
ip
an
ts
: 2
88
 
In
te
rv
en
tio
n 
gr
ou
p 
n=
10
3 
an
d 
co
nt
ro
l g
ro
up
 n
=1
85
 
M
on
o-
fa
ce
te
d 
in
te
rv
en
tio
n 
st
ud
y 
on
 
re
du
ci
ng
 e
xp
os
ur
e 
to
 fo
od
 
al
le
rg
en
s.
 B
ot
h 
gr
ou
ps
 w
er
e 
en
co
ur
ag
ed
 to
 b
re
as
tfe
ed
 th
ei
r c
hi
ld
 
4 
to
 6
 m
on
th
s 
an
d 
pa
re
nt
s 
re
ce
iv
ed
 
in
te
ns
iv
e 
ed
uc
at
io
n 
re
du
ci
ng
 
en
vi
ro
nm
en
ta
l a
lle
rg
en
s 
an
d 
ET
S
. 
P
ro
ph
yl
ac
tic
 g
ro
up
 d
ie
t: 
D
ur
in
g 
la
st
 tr
im
es
te
r o
f p
re
gn
an
cy
 
an
d 
w
hi
le
 b
re
as
tfe
ed
in
g,
 w
om
en
 
w
er
e 
in
st
ru
ct
ed
 to
 a
vo
id
 a
ll 
da
iry
 
m
ilk
, e
gg
 a
nd
 p
ea
nu
t p
ro
du
ct
s,
 
co
nc
en
tra
te
d 
so
y 
fo
od
s 
(to
fu
) a
nd
 
lim
it 
w
he
at
 to
 n
o 
m
or
e 
th
an
 tw
o 
se
rv
in
gs
 d
ai
ly
, w
ith
 o
th
er
 g
ra
in
s 
to
 
fu
lfi
l t
he
 c
er
ea
l a
nd
 s
ta
rc
h 
re
qu
ire
m
en
ts
. D
ie
ta
ry
 in
st
ru
ct
io
ns
 
pr
ov
id
ed
 b
y 
di
et
ic
ia
ns
 b
ef
or
e 
th
e 
th
ird
 tr
im
es
te
r; 
If 
br
ea
st
fe
ed
in
g 
w
as
 s
up
pl
em
en
te
d 
or
 s
to
pp
ed
, a
 c
as
ei
n 
hy
dr
ol
ys
at
e 
fo
rm
ul
a 
w
ith
 lo
w
 s
en
si
tis
at
io
n 
po
te
nt
ia
l w
as
 to
 b
e 
fe
d 
un
til
 1
2 
m
on
th
s 
of
 a
ge
; 
In
tro
du
ci
ng
 s
ol
id
 fo
od
s 
at
 6
 m
on
th
s 
co
nf
or
m
 a
 s
ta
nd
ar
di
ze
d 
st
ep
w
is
e 
in
tro
du
ct
io
n 
pr
ot
oc
ol
 fr
om
 6
 m
on
th
s 
to
 3
 y
ea
rs
.  
C
on
tro
l g
ro
up
 d
ie
t: 
P
re
gn
an
t a
nd
 
la
ct
at
in
g 
w
om
en
 w
er
e 
en
co
ur
ag
ed
 
to
 fo
llo
w
 s
ta
nd
ar
d 
di
et
s 
as
 p
ro
vi
de
d 
by
 th
e 
Ka
is
er
 P
er
m
an
en
te
 O
bs
te
tri
c 
D
ep
ar
tm
en
t. 
A 
co
w
's
 m
ilk
-b
as
e 
w
he
y 
in
fa
nt
 fo
rm
ul
a 
w
as
 p
ro
vi
de
d 
fo
r s
up
pl
em
en
ta
tio
n 
or
 w
ea
ni
ng
 fi
rs
t 
C
lin
ic
al
 o
ut
co
m
es
 a
t 2
 y
ea
rs
: 
- D
ef
in
ite
 A
st
hm
a 
de
fin
ed
 a
s 
3 
ep
is
od
es
 o
f p
hy
si
ci
an
 d
oc
um
en
te
d 
w
he
ez
in
g 
ep
is
od
es
 o
cc
ur
re
d 
un
as
so
ci
at
ed
 w
ith
 fo
re
ig
n 
bo
dy
, 
co
ng
en
ita
l a
bn
or
m
al
ity
, c
ro
up
, 
as
pi
ra
tio
n,
 o
r g
as
tro
-o
es
op
ha
ge
al
 
re
flu
x;
 
- A
lle
rg
ic
 a
st
hm
a 
de
fin
ed
 a
s 
at
 le
as
t 
on
e 
ep
is
od
e 
of
 w
he
ez
in
g 
tri
gg
er
ed
 
by
 fo
od
s 
or
 a
er
oa
lle
rg
en
s 
as
so
ci
at
ed
 w
ith
 c
on
co
m
ita
nt
 
sp
ec
ifi
c 
Ig
E
; 
- P
ro
ba
bl
e 
as
th
m
a,
 d
ef
in
ed
 a
s 
tw
o 
ep
is
od
es
 o
f w
he
ez
in
g 
oc
cu
rre
d 
un
as
so
ci
at
ed
 w
ith
 fo
re
ig
n 
bo
dy
, 
cr
ou
p,
 c
on
ge
ni
ta
l a
bn
or
m
al
ity
, 
as
pi
ra
tio
n 
or
 g
as
tro
-o
es
op
ha
ge
al
 
re
flu
x;
 
- G
as
tro
 In
te
st
in
al
 d
is
ea
se
; 
- A
to
pi
c 
de
rm
at
iti
s;
 
- A
lle
rg
ic
 rh
in
iti
s;
 
- A
ny
 a
to
pi
c 
di
so
rd
er
 (d
ef
in
ite
 a
nd
 
pr
ob
ab
le
). 
D
ef
in
ite
 a
st
hm
a 
ou
tc
om
e 
as
 re
po
rte
d 
in
cl
ud
ed
 in
 c
ur
re
nt
 m
et
a-
an
al
ys
is
. 
A
lth
ou
gh
 c
um
ul
at
iv
e 
as
 w
el
l a
s 
pe
rio
d 
pr
ev
al
en
ce
s 
w
er
e 
re
po
rte
d,
 
on
ly
 p
er
io
d 
pr
ev
al
en
ce
s 
w
er
e 
in
cl
ud
ed
 in
 th
is
 m
et
a-
an
al
ys
is
. 
A
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ye
ar
. S
ol
id
 fo
od
s 
in
tro
du
ce
d 
at
 4
 
m
on
th
s 
(c
er
ea
l) 
fo
llo
w
ed
 b
y 
st
ep
w
is
e 
in
tro
du
ct
io
n 
of
 v
eg
et
ab
le
s,
 
fru
its
 a
nd
 e
gg
 y
ol
ks
, m
ea
t a
nd
 
w
ho
le
 c
ow
's
 m
ilk
 u
nt
il 
12
 m
on
th
s.
 
Ze
ig
er
 R
S
 
19
92
25
 
S
ee
 a
bo
ve
 a
nd
: 
N
um
be
r o
f d
ro
p-
ou
ts
 a
t a
ge
 4
 y
ea
rs
: 
n=
63
 o
f w
hi
ch
 n
=1
8 
in
 th
e 
pr
of
yl
ac
tic
 g
ro
up
 a
nd
 4
5 
in
 th
e 
co
nt
ro
l g
ro
up
 
S
ee
 a
bo
ve
 
S
ee
 a
bo
ve
 
C
lin
ic
al
 o
ut
co
m
es
: 
- A
st
hm
a,
 d
ef
in
ed
 a
s 
ph
ys
ic
ia
n 
do
cu
m
en
te
dl
ow
er
 re
sp
ira
to
ry
 
co
nd
iti
on
 w
ith
 c
ha
ra
ct
er
is
tic
 
re
ve
rs
ib
le
 b
ro
nc
ho
sp
as
m
, o
cc
ur
rin
g 
at
 le
as
t t
w
ic
e 
an
d 
un
as
so
ci
at
ed
 w
ith
 
ot
he
r a
na
to
m
ic
 c
on
ge
ni
ta
l o
r 
im
m
un
ol
og
ic
 c
au
se
s;
 
- A
to
pi
c 
de
rm
at
iti
s,
 d
ef
in
ed
 a
s 
at
 
le
as
t 3
 o
f t
he
 fo
llo
w
in
g 
cr
ite
ria
: 
pr
ur
iti
s,
 ty
pi
ca
l m
or
ph
ol
og
y 
an
d 
di
st
rib
ut
io
n,
 te
nd
en
cy
 to
w
ar
d 
ch
ro
ni
ci
ty
 o
r r
ec
ur
re
nc
e,
 c
on
cu
rre
nt
 
sp
ec
ifi
c 
Ig
E
; 
- U
rti
ca
ria
 /a
nd
gi
oe
de
m
a,
 d
ef
in
ed
 
as
 a
 p
ru
rit
ic
 e
ru
pt
io
n 
w
ith
 ty
pi
ca
l 
m
or
ph
ol
og
ic
 a
pp
ea
ra
nc
e 
re
po
rte
d 
by
 p
hy
si
ci
an
 o
r p
ar
en
t w
ith
 o
r 
w
ith
ou
t i
nc
rim
in
at
in
g 
ag
en
st
 
id
en
tif
ie
d;
 
- A
lle
rg
ic
 rh
in
iti
s,
 d
ef
in
ed
 a
s 
a 
na
sa
l 
co
nd
iti
on
 w
ith
 c
ha
ra
ct
er
is
tic
 
sn
ee
zi
ng
, i
tc
hi
ng
 a
nd
/o
r r
hi
no
rrh
ea
 
w
ith
 c
on
cu
rre
nt
 s
pe
ci
fic
 Ig
E
 a
nd
 
na
sa
l e
os
in
op
hi
lia
; 
- F
oo
d 
al
le
rg
y,
 d
ef
in
ed
 a
s 
fo
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Another 22 studies were excluded for various reasons as described in the table 
'Characteristics of excluded studies' (Table 4.2). 
 
Table 4.2 Characteristics of excluded studies. 
Study Reason for exclusion 
Arshad 199236 Results of the Isle of Wight study on clinical outcome of children at 1 year of age 
described. Inclusion criterion 'description of clinical effectiveness on children aged 
minimally two years' was not fulfilled. 
Boggs 200337 No clinical effectiveness described 
Bottcher 200238 No RCT described 
Brunekreef 200239 Design article of PIAMA study in which results of natural history part of PIAMA on allergen 
exposure are described. No clinical effectiveness described 
Canadian MedAss 
200540 
No RCT described 
Chan-Yeung 200241 Results of intervention Canadian Allergy and Asthma Prevention study on allergen 
reducing outcome. No clinical effectiveness described 
Chandra 199730 Excluded because of investigations by Chandra's university (Memorial University of 
Newfoundland) and the Canadian Broadcasting Corporation strongly suggest that the 
published data may have been fabricated. 
Custovic 2000a42 Only results of intervention nacMAAS study on allergen reducing outcome reported. No 
clinical effectivity described 
Custovic 2000b43 Results described of nacMAAS study on allergen reducing outcome. No clinical effectivity 
described 
Custovic 200144 Results of nacMaas study on clinical outcome of children at 1 year of age described. 
Inclusion criterion 'description of clinical effectiveness on children aged minimally two 
years' was not fulfilled. 
Dunstan 200345 No allergen reducing intervention studied. No clinical effectiveness described 
Johnstone 196629 Study on clinical effectiveness of food allergen reducing intervention (soy formula) that 
seemed to fit all inclusion criteria but was excluded because at least one of the items of 
Delphi-List on quality assessment we based an inclusion criterion on was fulfilled 
(outcome assessor was not blinded and allocation concealment was not clear). 
Kalliomaki 200146 Study on clinical effectiveness of probiotics intervention, no allergen reduction and no 
outcome asthma 
Kjellman 197928 Study on clinical effectiveness of food allergen reducing intervention (soy formula) that 
seemed to fit all inclusion criteria but was excluded because at least one of the items of 
Delphi-List on quality assessment we based an inclusion criterion on was fulfilled 
(outcome assessor was not blinded and allocation concealment was not clear). 
Koopman 20028 Study on clinical effectiveness of mono-faceted house-dust mite reducing intervention that 
fitted all inclusion criteria but was excluded because no point prevalences were described 
nor supplied 
Marini 199647 Multi-faceted intervention study on primary prevention of atopic manifestation but the 
outcomes as selected for current review are not described. 
Marks 200648 CAPS study dietary intervention part in which no allergen reducing manipulation so 
inclusion criteria not fulfilled for this part of the study. House Dust Mite reducing part of 
CAPS intervention as described in this article however is included. 
Mihrshahi 200149 Article on design and research protocol of CAPS study. No clinical effectiveness 
described 
Peat 200450 CAPS study dietary intervention part in which no allergen reducing manipulation so 
inclusion criteria not fulfilled for this part of the study. House Dust Mite reducing part of 
CAPS intervention as described in this article however is included. 
Saarinen 197951 Article does not concern RCT merely natural history study on breastfeeding. 
Simpson 200352 Allergen reducing results of nacMAAS study described. No clinical effectivity described 
Simpson 200453 Review on designs and allergen reducing outcome of RCT's on primary prevention of 
asthma in children. No clinical effectivity described 
van Strien 200254 Allergen exposure outcome in natural history part of PIAMA study reported. No clinical 
effectiveness described 
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Methodological quality of included studies 
The methodological quality of included studies is presented in the additional 
tables 'Quality assessment conform Delphi List', with tabulation of quality for 
year of follow-up (Table 4.3). The ten items in these tables concern 
methodological quality as described in the methods of the current review. 
 
Table 4.3 Quality assessment conform Delphi List. 
Nr. Item Zeiger 
1989-
1995 
Mallet 
1992 
Hide 
1994-
2003 
Becker 
2004, 
2005 
Horak 
2004 
Schönberger 
2005 
Peat, 
HDM 
2004, 
2006 
Corver 
2006 
1 Was a method of 
randomisation 
performed? 
yes yes yes yes yes yes yes yes 
2 Was the allocation 
concealed? 
yes yes yes yes yes yes yes yes 
3 Blinding or naïve 
patient? 
unclear yes yes yes yes no no yes 
4 Blinding or naïve 
health care 
provider? 
yes no yes yes yes no unclear yes 
5 Blinding or naïve 
outcome 
assessor? 
yes yes yes yes yes yes yes yes 
6 Were both 
inclusion and 
exclusion criteria 
specified? 
yes yes yes yes yes yes yes yes 
7 Were the groups 
similar at baseline 
regarding the most 
important 
prognostic 
indicators? 
unclear unclear no unclear unclear yes yes no 
8 Did the analysis 
include an 
intention-to-treat 
analyses? 
no no no no no yes no yes 
9 Were point 
estimates and/or 
measures of 
variability 
presented for 
primary outcome 
measure(s)? 
yes yes yes yes yes yes yes yes 
10 Were the primary 
outcome measures 
specified? 
yes yes yes yes yes yes yes yes 
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Results 
Three multi-faceted allergen reducing intervention trials, some with an additional 
co-intervention (for example, environmental tobacco smoke (ETS) reduction) on 
prevention of asthma in children at high risk of developing asthma (n=1124) and 
six mono-faceted allergen-reducing trials, of which again some with an 
additional intervention like dietary fatty acid modification, (n=2147) were 
included. Data from these studies were pooled separately at several age-
specific time points under the outcomes: 'Current asthma (defined as doctor 
diagnosis) in children aged <5 years'; 'Current asthma (defined as current 
respiratory symptoms (wheezing and/or nocturnal cough and/or dyspnoea) plus 
lung function criteria corresponding with clinical diagnosis asthma (BHR and/or 
reversibility) in children aged ≥5 years'; and 'Current respiratory symptoms' 
(wheezing, nocturnal cough, dyspnoea) as recorded by parents/carers in 
questionnaires. 
Adverse events were not described in any of the included studies.  
Specific results for individual outcomes 
Current Asthma (defined as doctor diagnosis) in children aged <5 years 
Multi-faceted intervention studies scored in favour of treatment at age two years 
(pooled results Canadian study13; Isle of Wight15; PREVASC18: OR 0.72 95% CI 
0.54, 0.97). At four years of age the Isle of Wight study16 was included and 
scored an OR of 0.56 and 95% CI 0.26, 1.23. The overall outcome 'Current 
Asthma in children aged <5 years last reported' resulted in an OR of 0.73 (95% 
CI 0.55, 0.97). The results of multi-faceted trials on outcome current diagnosis 
asthma in children <5years is presented in Figure 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Multi-faceted interventions: outcome current diagnosis asthma <5 years.  
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As presented in Figure 4.2 mono-faceted intervention studies did not show a 
significant difference compared with control when data from children at two 
years of age were combined from Zeiger RS24; SPACE27; Mallet21 (OR 1.01 
95%CI 0.63, 1.63), pooled data at age three years of reported results from 
nacMAAS22, CAPS HDM19 (OR 0.84 95% CI 0.41, 1.71) and the results of the 
pooling of data of studies of Mallet21 and Zeiger25 at the age of four years (OR 
1.41 95% CI 0.52, 2.54). Data analysed at last available assessment in children 
aged between two and five years did not identify a significant difference in the 
likelihood of physician-diagnosed asthma between treatments (OR 1.22 (95% 
CI 0.83, 1.78). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Mono-faceted interventions: outcome current diagnosis asthma <5 years.  
 
 
The Z-test on comparison of multi-faceted and mono-faceted results on 
outcome 'current asthma (defined as doctor diagnosis' in children aged <5 
years) showed a Z-score of -2.115, which indicated a significant difference 
between the two types of interventions. 
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Current Asthma (defined as presence of current respiratory symptoms (wheeze 
and/or nocturnal cough and/or dyspnoea) PLUS lung function criteria 
corresponding with a clinical diagnosis asthma (BHR and/or reversibility), in 
children aged ≥5 years 
As presented in Table 4.3 Multi-faceted intervention studies described results at 
ages seven and eight years using the definition of diagnosis asthma 'presence 
of current wheezing plus BHR' but these could not be age-pooled since there 
was only one study reporting results at age seven and one reporting results at 
age eight years (Canadian study14; Isle of Wight17). Multi-faceted intervention 
showed an OR for a diagnosis of asthma of OR 0.52 (95% CI 0.32, 0.84). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Multi-faceted interventions: outcome current diagnosis asthma ≥5 years.  
 
 
Two mono-faceted intervention studies reported asthma symptoms at five years 
and older (see Figure 4.4). Zeiger26 reported data on diagnosis asthma defined 
as current respiratory symptoms and reversibility at age seven years. CAPS 
HDM20 reported data on current respiratory symptoms and reversibility OR 
asthma diagnosis by health care professional at five years. Both study 
outcomes did not differ significantly (OR 0.86 CI 0.57 1.29 and OR 1.12 CI 0.60 
2.11 respectively).  
Current Asthma in children aged ≥5 years at last assessment was not 
significantly different between treatment and control (OR of 0.93 with 95% CI 
0.66 1.31). 
 
The Z-test on comparison of multi-faceted and mono-faceted results on 
outcome 'current asthma (defined as presence of respiratory symptoms plus 
lung function criteria corresponding with a clinical diagnosis asthma' showed a 
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Z-score of -1.925, which indicates there is no significant difference between the 
two types of interventions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Mono-faceted interventions: outcome current diagnosis asthma ≥5 years.  
Current respiratory symptoms 
Wheezing as described for multi-faceted interventions was reported at ages 
two, seven and eight years and only at age two years data could be pooled age-
specifically (see Figure 4.5). The results of this pooling of data at two years 
were not significantly different between treatment and control (Canadian study 
200413; PREVASC 200518: OR 0.81 95%CI 0.36, 1.85). Wheeze at last reported 
assessment resulted in a significant evidence in favour of treatment (Canadian 
study14; Isle of Wight17; PREVASC18: OR 0.53 95% CI 0.35, 0.81). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Multi-faceted interventions: outcome current wheezing.  
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Outcome of mono-faceted intervention studies was described for children at 
ages three, four and five years (see Figure 4.6). Two studies reported data of 
outcome wheezing at three years of age (CAPS HDM19; nacMAAS22) and 
pooling resulted in an OR of 0.90 (95% CI 0.63, 1.31). Pooling of data 'Current 
wheezing as last reported' showed to be non-significant (nacMAAS22; PIAMA23; 
CAPS HDM20: OR 0.88 95% CI 0.66, 1.19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Mono-faceted interventions: outcome current wheezing.  
 
 
The Z-test on comparison of multi-faceted and mono-faceted results showed a 
Z-score of -1.935 which indicates there is no significant difference between the 
two types of interventions concerning outcome 'current wheezing as last 
reported'. 
 
Nocturnal cough was reported for multi-faceted intervention studies at ages two, 
seven and eight years (PREVASC18; Canadian study14; Isle of Wight17) and 
again could not be age-specifically pooled. Only the outcome 'current nocturnal 
cough as last reported' could be pooled. This pooling of last reported data 
showed an OR of 0.70 (95% CI 0.43, 1.17). The results of the multi-faceted 
intervention studies on outcome current nocturnal cough are presented in 
Figure 4.7. 
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Figure 4.7 Multi-faceted interventions: outcome current nocturnal cough.  
 
Three mono-faceted RCTs described outcome 'current nocturnal cough as 
reported by parents in questionnaires' (SPACE27; nacMAAS22; PIAMA23). 
Pooling of data of these studies at two, three and four years respectively 
resulted in an OR of 0.99 (95% CI 0.74, 1.33). The results of the mono-faceted 
trials on outcome current nocturnal cough are presented in Figure 4.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Mono-faceted interventions: outcome current nocturnal cough.  
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The Z-test on comparison of multi-faceted and mono-faceted results for 
outcome 'current nocturnal cough as last reported' showed a Z-score of 0.149, 
which indicates there is no significant difference between the two types of 
interventions where the outcome 'current nocturnal cough' is concerned.  
 
The only study that reported current dyspnoea as outcome was the multi-
faceted intervention study PREVASC.18 The age at which this outcome was 
reported was two years. The OR found in the PREVASC study was 0.65 with 
95% CI 0.39, 1.08 (see Figure 4.9). 
 
 
 
 
 
 
 
Figure 4.9 Multi-faceted intervention: outcome current dyspnoea.  
 
Sensitivity analyses 
We carried out sensitivity analyses (analyses not included in this paper) in 
which we sought to determine whether removing studies of post-natal 
intervention gave similar results to our primary analyses of all studies. The 
results of these analyses were compared between multi- and mono-faceted 
studies (Z-scores). These analyses revealed that the time of start of the 
intervention did not alter the direction of the results.  
 
Stratification for duration of intervention did not result in any useful information 
for the research question we postulated, as comparisons of mono- and multi-
faceted studies were rarely possible due to large variations in duration of 
intervention. 
Discussion 
We investigated the role of different intervention-strategies (mono- or multi-
faceted interventions) on study outcomes pertaining to current asthma and 
current asthma related respiratory symptoms. We hypothesised that a multi-
factorial disease such as asthma can only be prevented by intervening to 
reduce several, or even all, causal risk factors. Allergen exposure was the 
primary intervention we focused on since this factor has proved to have 
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significant influence on development of asthma in genetically susceptible 
children.55,56,57 Another reason we focused on these types of studies was that 
there have been numerous studies focusing on allergen reduction as primary 
prevention measure in children at high risk of developing asthma with negative 
findings.8,19,22 We hypothesized that the type of interventions assessed in these 
studies might explain these disappointing results since a lot of these studies 
used a mono-faceted approach. Information leading to this assumption is mainly 
based on results of secondary prevention strategies.3,4 To evaluate the validity 
of our assumption we carried out meta-analyses of mono-faceted and multi-
faceted allergen reducing intervention studies separately and performed Z-tests 
on indirect comparisons of these pooled estimates at last assessment for all 
outcomes pooled results of both intervention types were available.  
Mono-faceted intervention versus control 
The effects of mono-faceted intervention compared with control did not indicate 
a significant reduction in diagnosed asthma, or in any of the symptom-related 
endpoints we assessed.  
Multi-faceted intervention versus control 
Nearly all tested outcomes tended to favour treatment of multi-faceted 
intervention studies when pooled at specific age-time points, and when 
combining relevant time points (outcomes as last reported) over control. Based 
on the event rates in the control groups of the two studies reporting data at 
more than five years, 16 children would need to be treated with this form of 
intervention to prevent one child receiving a diagnosis of asthma after five years 
(Visual Rx).  
 
Two of the multi-faceted allergen reducing intervention studies included did not 
only use allergen reducing study interventions but used an intervention on ETS 
exposure reduction as well.13,18 Reducing ETS exposure is associated with a 
reduction in asthma symptoms.58 Considering the low % of parents smoking in 
these study groups and the absence of effect of the ETS reducing intervention, 
it is unlikely that this has distorted the results of the analyses carried out. It is 
feasible that the presence of an additional environmental intervention such as 
this may confound the treatment effect, particularly in families where exposure 
to tobacco smoke is high. Future studies which are concerned primarily with 
exposure to allergens and not toxicants should make provision of such an 
intervention in the control group so as to ensure that the independent variable is 
reduced exposure to allergens alone. 
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Indirect comparison of results 
From the comparison of Z-test scores, multiple intervention strategies were 
more successful than single intervention strategies when diagnosis of asthma in 
children less than five years of age was considered (Z-score -2.118). Z-test 
carried out for the outcome 'diagnosis of asthma as last reported at ages >5 
years' showed that the comparison of mono-faceted and multi-faceted study 
outcome did not reach statistical significance in favour of multi-faceted 
interventions (Z-score -1.925). Z-scores of comparison of respiratory symptoms 
associated with asthma of multi-faceted and mono-faceted results at last 
assessment also did not reach significance either.  
 
The statistical and clinical significance of the pooled data from seems 
convincing of the advantages of multi-faceted interventions over control in 
reducing prevalence of asthma in children. The results of the current meta-
analyses indicate that asthma is likely to be prevented to a greater extent by 
reducing several exposures at the same time, although this observation is from 
an indirect comparison and as such has not been proved. The results of these 
meta-analyses should therefore be interpreted with caution as the method of 
testing the hypothesis by separate pooling of data of mono- and multi-faceted 
RCTs is not a direct randomised comparison. These trials all have differences in 
design, outcome definitions and concomitant differences in types of outcome 
measurements and ages at which outcome measurement was carried out. 
 
Results of sensitivity analyses on starting point and duration of intervention 
showed not to alter the direction of the effect of multi- as well as mono-faceted 
interventions. 
Summary 
The hypothesis that asthma can only be prevented by reduction of exposure to 
multiple allergens simultaneously seems to be correct at least for current 
diagnosis asthma at ages <5 years. The non-significant outcome for the 
comparison of mono- and multi-faceted interventions at ages five years and 
older might have been caused by lack of power, difference in study outcome 
used in the types of studies compared or a true negative result. Multi-faceted 
intervention studies reported data on diagnosis of asthma defined as respiratory 
symptoms and BHR and mono-faceted intervention studies reported data on 
current diagnosis asthma defined as respiratory symptoms plus reversibility as 
measured by the health care professional or as measured by the study 
investigators. 
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This apparent superiority of multiple interventions over mono-faceted 
intervention is sufficient to justify studies which compare differing intensities of 
exposure reduction. This would be an efficient way testing whether the 
hypothesis we have drawn from the indirect comparison formulated, would be 
by designing a study in which both types of interventions are performed and 
directly compared in the same study. Only when tested like this the criteria for 
direct randomised comparison will be fulfilled. To our knowledge studies 
designed like this have never been performed to date. Factors complicating 
performing such a study are the large number of participants needed to secure 
the power of the study, the follow-up duration of minimally six years to secure 
the success rate of lung function measurements and the concomitant costs. 
Such a study however, will be of great importance for shedding new light on 
preventing the development of asthma in genetically susceptible children and 
the current meta-analyses might inspire researchers to undertake this research. 
Reviewers' conclusions 
Implications for practice 
The current meta-analyses provide evidence that multi-faceted interventions, 
characterised by dietary allergen reduction and environmental remediation, 
reduce the odds of a physician diagnosis of asthma later in childhood, in 
children who are at risk of developing childhood asthma by a half. This 
translates to a number needed to treat (NNT) of 16. However, the effect of 
multi-faceted interventions on parent reported wheeze was inconsistent and 
there was no evidence of benefit on nocturnal cough or dyspnoea. Mono-
faceted interventions were no more effective than controls in the reduction of all 
outcomes but there remains uncertainty as to whether multiple interventions are 
more effective than mono-component interventions. Children who grow up in 
low allergen surroundings may be at lower risk of being diagnosed with asthma 
but unlikely to have a lower risk of parental reported symptoms of wheeze, 
nocturnal cough or dyspnoea. 
Implications for research 
There is a pressing need for direct head-to-head comparative trials of mono- 
and multi-faceted allergen reduction strategies. These should be administered 
from birth involving at least six years of follow-up. It will be of crucial importance 
that researchers follow the guidelines for diagnosing asthma for the study 
outcome, and that the diagnosing physician remains blinded to group allocation. 
The cost effectiveness of the intervention strategies and its possible effect on 
family dynamics and mental health status should be formally evaluated. 
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Abstract 
Background 
The distribution of house dust mite allergen (Der p1) in living rooms with smooth floor coverings, as 
measured in the middle compared to the border of the floor was investigated. It was hypothesized 
that activity causes displacement of Der p1, from the middle towards the border. 
 
Methods 
Dust samples from the middle and border of 50 floors with smooth coverings were collected and 
analysed on Der p1 content in a standardized way.  
 
Results 
Der p1 exposure expressed as per unit area (ng/m2) showed that border samples contained 
significantly more Der p1 compared to middle samples (median: 2.57 versus 0.27 respectively, 
p=0.023). Presence of pets and presence of more than two inhabitants both increased the 
difference. When expressed as per unit weight of dust (ng/g) significant differences were only 
detected when comparing Der p1 content of samples collected in households with three or more 
inhabitants (median: 2 (border) versus 53 (middle) respectively, p=0.035). 
 
Conclusions 
Der p1 is unequally distributed on living room floors with smooth coverings, most likely because of 
displacement of dust from the middle towards the border due to activity. Expression as ng/g of dust 
and ng/m2 showed not to be obviously interchangeable. 
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Introduction 
In most survey studies concerning measurement of exposure to house dust 
mite allergen (Der p1) in floor dust, the sampling procedure is standardized.1-2 
For measurement within living rooms the recommendation was made that at 
least two sites should be sampled because of unequal distribution.3 However 
there is no uniformity about the exact sampling locations.4 The aim of the 
present study was to investigate whether Der p1 content of floor dust samples 
collected from sites at the border compared to sites in the middle of living rooms 
with smooth floor coverings are comparable. We hypothesized that activity 
causes displacement of dust and Der p1 mainly from the middle towards the 
border. 
Methods 
Dust samples were collected from 50 living room floors with smooth coverings. 
Participants were asked to make sure that one week prior to sampling, rugs if 
present were removed and their living room floor was not cleaned. Presence of 
pets in the living room and number of inhabitants were assessed. On each floor 
two dust samples were collected of which one at the border (3 m2 adjacent to 
the wall, one meter wide) and one as much as possible in the middle of the 
room (3 m2). It was made sure that the sampling sites were as far as possible 
from frequently used doors. Sampling sites were vacuumed for 2 min/m2 each 
(vacuum cleaner 1300 W). Dust was collected onto glass micro fibre filters and 
stored at -12°C until analysis. After weighing the un-sieved dust, a 10% (w/v) 
extract in borate-buffered saline with 0.1% Tween-20, pH=8.0, was obtained by 
overhead rotation for two hours at room temperature. After centrifuging (ten 
minutes 4250 RPM), Der p1 content was determined by means of two-site 
monoclonal ELISA with an assay sensitivity of 2 ng/g of dust. Allergen standard 
93/03 (2500 ng/ml Derp1) was used for calculation of results. Data were 
expressed as ng/g of dust and Der p1 content expressed as ng/m2 was 
computed.  
Untransformed Der p1 levels were used for statistical analysis, as logarithmic 
transformation failed to normalize the distribution. By means of the non-
parametric Wilcoxon Signed Ranks Test (α=0.05) comparison was made 
between Der p1 levels of the two sampling sites.  
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Results 
In Table 5.1 and 5.2 median, range and level of significance of Der p1 content 
of middle versus border samples are presented. Table 5.1 contains data 
expressed as ng/m2 and data expressed as ng/g of dust are shown in Table 5.2. 
Data on overall allergen content as well as on the comparison of samples 
collected in homes with versus those without pets and with less than three 
versus those with three or more inhabitants are presented.  
 
Table 5.1 Comparison of Der p1 content of dust samples collected from sites in the middle and at 
the border of living room floors with smooth coverings expressed as per unit area 
(ng/m2). 
 n Median (range) p(α=0.05) 
  Middle Border  
Overall data 50 0.27 (0.0067-84.89) 2.57 (0.0067-161.60) 0.023 
More than two inhabitants 
Yes 
No 
 
23 
27 
 
0.29 (0.053-84.84) 
0.25 (0.0067-84.89) 
 
4.58 (0.053-83.50) 
0.39 (0.0067-161.60) 
 
0.018 
0.501 
Presence of pets 
Yes 
No 
 
19 
31 
 
0.29 (0.053-84.89) 
0.25 (0.0067-84.84) 
 
5.76 (0.093-161.60) 
0.37 (0.0067-83.50) 
 
0.009 
0.465 
 
 
Table 5.2 Comparison of Der p1 content of dust samples collected from sites in the middle and at 
the border of living room floors with smooth coverings expressed as per unit weight of 
dust (ng/g). 
 n Median (range) p(α=0.05) 
  Middle Border  
Overall data 50 2 (2-749) 21 (2-835) 0.136 
More than two inhabitants 
Yes 
No 
 
23 
27 
 
2 (2-471) 
2 (2-749) 
 
53 (2-835) 
2 (2-606) 
 
0.035 
0.955 
Presence of pets 
Yes 
No 
 
19 
31 
 
2 (2-749) 
2 (2-471) 
 
53 (2-606) 
2 (2-835) 
 
0.124 
0.687 
 
 
Overall more Der p1 was found in samples collected at the border compared to 
levels in the middle of the room irrespective of the way of expression (ng/g or 
ng/m2). However, when expressed as ng/g of dust, the difference appeared not 
to be significant (p=0.136) in contrast with expression as ng/m2. 
The median overall Der p1 content, expressed as ng/m2, in middle samples 
versus samples at the border was 0.27 and 2.57 respectively (p=0.023).  
In households where pets were allowed to stay in the living room (n=19) and in 
those that were occupied by more than two inhabitants (n=23) the difference of 
Der p1 content showed to be larger than the difference in overall Der p1 
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content, again irrespective of the way of expression. A significant difference 
between the median Der p1 content in samples collected at the border as 
compared to the middle of the room in households with three or more 
inhabitants was demonstrated when expressed as ng/m2 as well as ng/g dust 
(p=0.018 and p=0.035 respectively). As was the case when comparing middle 
and border samples on overall Der p1 content, presence of pets showed to 
differ significantly only when data were expressed as ng/m2 (ng/m2 p=0.009, 
ng/g p=0.124). 
Discussion 
The results of the present study show that on smooth floor coverings there 
actually does seem to be a clear pattern of distribution of Der p1, for we found 
significantly greater amounts of Der p1 at the border compared to areas in the 
middle of the living room floor. Earlier research on the distribution of Der p1 
within carpeted living rooms did not show a consistent pattern of distribution of 
Der p1, although a great variation of Der p1 levels between areas on the floor 
was found.5  
Although there’s still much unclear about factors affecting the distribution of 
house dust mites,6 our findings suggest that on floors with smooth coverings 
activity favours displacement of Der p1 towards the border. As was 
hypothesized Der p1 levels in the middle of the room showed to be less than at 
the border and distribution is increased when more inhabitants or pets are 
present. 
It is of further interest whether allergen content of dust should be expressed as 
ng/m2 or as ng/g of dust. In epidemiological studies expression as ng/g of dust 
is considered to be suitable, however in intervention studies expression as 
ng/m2 is recommended.2 In addition, the suggestion has been made that these 
methods for expression can be interchanged.7 In the present study however this 
was not the case, as variation of the amount of dust (g) between different 
sampling areas on the living room floor lead to different results when Der p1 
content was expressed as ng/g of dust. Where a statistically significant 
difference was detected between middle and border samples when expressed 
as ng/m2, no significant difference was detected when overall data were 
expressed as ng/g of dust. Possibly the lack of significance can be explained by 
the smaller range of Der p1 results when expressed as ng/g of dust. However, 
the expression as ng/m2 does reflect the actual amount of Der p1 present at the 
sampled area whereas the expression as ng/g of dust merely reflects the 
concentration of Der p1 in floor dust.  
We conclude that Der p1 content of dust samples taken from middle and border 
sites on the living room floor differ significantly when expressed as ng/m2, most 
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likely because of displacement of dust from the middle towards the border due 
to activity by inhabitants and pets. When expressed as ng/g of dust, a 
statistically significant difference was determined only when comparing data on 
Der p1 content in samples collected in households with three or more 
inhabitants. We suggest that Der p1 content expressed as ng/g of dust and 
ng/m2 cannot obviously be interchanged. Given this knowledge and the 
plausibility that Der p1 expressed as ng/m2 does reflect the actual allergen 
exposure our study results do underline the use of the expression as ng/m2 in 
studies in which Der p1 exposure is a possible determining factor. 
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Abstract 
Background 
The hygiene hypothesis assumes that infections in early childhood keep the developing immune 
system from becoming unbalanced and therefore from developing allergic diseases. 
 
Objective 
To assess the relationship between the occurrence of upper respiratory tract (URT) and 
gastrointestinal (GI) infections, and the development of asthma in the first four to six years of life. 
 
Methods 
The relationship between infections and the occurrence of asthma was studied in 443 high risk 
children of the PREVASC cohort. The number of episodes of common cold and diarrhoea were the 
independent variables. Dependent variables were a general practitioners’ diagnosis of asthma, 
asthmatic symptoms at age four to six and total and specific IgE at age six. 
 
Results 
Regression analyses showed no significant relationship between asthma diagnosis and common 
cold nor diarrhoea. The number of episodes of diarrhoea however was found to be related to the 
occurrence of asthma symptoms at age four to six (OR=1.240, CI 1.085 to 1.417). The number of 
episodes of common cold showed to be inversely related to total IgE at age six (B=-0.080, CI -0.134 
to -0.027). Diarrhoea showed to be related to the level of specific IgE against HDM allergens 
(OR=0.690, CI 0.483 to 0.984). 
 
Conclusion 
This study does not provide evidence for the assumption that the development of asthma is 
prevented by URT or GI infections in children at high risk of developing asthma. The infections 
although seemed to influence atopy. 
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Introduction 
Asthma is a multi-factorial disease that is thought to be caused by genetic 
factors as well as by environmental influences. In the past decade the hygiene 
hypothesis1, describing the effects of infections on allergy and asthma 
development, gained popularity. This hypothesis states that infections might 
keep the developing immune system from becoming unbalanced and so from 
developing a predisposition to allergic diseases like asthma. 
After the hygiene hypothesis was launched, several studies were carried out to 
try to confirm this immunological theory, as well as to come up with the clinical 
evidence to underpin this hypothesis. The immune deviation theory, explaining 
the immunological background of the hygiene hypothesis, was first described 
for humans by Holt and colleagues.2-4 Whereas children usually are born with a 
T-helper cell type 2 (Th2) polarised immune system, exposure to viral 
infections, known for their T-helper cell type 1 (Th1) stimulating effect, was 
hypothesized to cause the immune system to deviate towards the non-allergic 
mode within the first 2 years of life.2-4 Recent evidence suggests that this 
protective effect might be mediated by regulatory T lymphocytes (Treg). The 
Treg reaction results in inhibition of both Th1 and Th2 response.5,6  
Previous studies investigating the hygiene hypothesis in children were 
retrospective studies concerning the influences of proxy variables for infection 
load such as day-care attendance and older siblings.7-13 The link between these 
variables and the hygiene hypothesis is that those children that come in contact 
with older children on a regular basis are more exposed to different pathogens 
at a younger age and are likely to develop more common infections. Golding 
and Peters first described the sibling, or birth-order, effect in 1986.14 They found 
a significant negative effect on the occurrence of eczema and hay fever in 
relation to the number of older siblings. They concluded that more older siblings 
might protect a child against the development of asthma.  
Based on multiple prospective studies on the clinical effect of specific viruses on 
allergic disease, published opinions on the influence of infectious disease in 
childhood have taken on a more cautious tone in recent years.15 Although 
positive as well as negative results have been published, a summary of these 
results does not support any firm conclusion that infections do have a clear 
effect on the development of atopic diseases.16,17  
We had access to prospectively collected data for episodes of common cold 
and diarrhoea from children at high risk of developing asthma, who had been 
followed up from prenatal age to the age of six years in the PREVASC study, a 
randomised controlled multi-faceted trial on the primary PREVention of ASthma 
in Children at high risk of developing asthma.18,19 These data might contribute to 
our knowledge of the effects infectious diseases may have on allergy and 
asthma development. 
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The current research question is a post-hoc research question within the scope 
of the PREVASC study.18 The question posed in this manuscript is: What is the 
relationship between the proxy parameters of URT infections (common cold) 
and gastrointestinal infections (diarrhoea associated with fever), and the 
development of asthma (at age four to six) and allergy (at age six, based on IgE 
level) in children at high risk of developing asthma? 
Methods 
The PREVASC database, which contains data for 443 participating children 
followed up from birth until six years of age, was used to answer the current 
research question.18 This RCT was designed to answer the research question if 
asthma can be prevented in children at risk of developing asthma by making 
use of an educational intervention aimed at reducing the exposure to 
environmental factors like allergens and tobacco smoke. The PREVASC study 
recruited children with a high risk of developing asthma during the prenatal 
period and randomised them to either 1) a control group (n=221), receiving 
usual care; or 2) an intervention group (n=222) in which families received 
instructions from nurses on how to reduce the exposure of newborns to mite, 
pet and food allergens, as well as to passive smoking. ‘High risk’ was defined 
as ‘at least one first-degree family member (i.e., the pregnant woman, the 
biological father of the unborn child or a full sibling) suffering from GP-registered 
asthma’.18 Randomisation and blinding was done in zip-code clusters at the 
general practitioners’ (GP) practice level in order to minimise the probability of 
exchange of information between participants.  
The primary outcome variable evaluated in the present post-hoc research 
question was the diagnosis of asthma in the first four to six years of life as 
prospectively reported by GPs. The PREVASC study collected GP diagnoses, 
as well as symptoms. For the measurement of symptoms suggestive of asthma 
as reported by parents questionnaires based on the International Study of 
Asthma and Allergies in Childhood were used.20 Parents were asked to 
complete these questionnaires.  
Total and specific Immunoglobulin E (IgE) serum levels were measured to be 
used as additional information on the development of allergy. The specific IgE 
levels measured in the PREVASC study were aimed at house dust mite, cat 
and dog allergens. The samples the serum was derived from were obtained by 
finger prick tests (capillary blood) in children at age six. The samples were 
absorbed on filter paper. These analyses were performed by Sanquin, The 
Netherlands.21 IgE levels above the threshold value 25IU/ml for total IgE and 
above 0.35 IU/ml for specific IgE were analysed. 
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A complete review of the methods of the PREVASC study is given in the articles 
by Schönberger et al. and Kuiper et al.18,19  
The independent variables used to answer our research question were: the 
number of episodes of common cold and of diarrhoea associated with fever in 
the first two years of the child’s life as prospectively registered by parents in 
weekly reports. 
The primary outcome variable was the diagnosis of asthma (GP diagnosis at 
age four to six). The other outcome variables were symptoms associated with 
asthma (wheezing, nocturnal coughing and dyspnoea) in the first four to six 
years as prospectively registered by the parents in questionnaires and/or the 
GP (0/1) and total and specific (house dust mite) IgE serum level at age six.  
The confounding proxy variables for infection load that were included were 
based on earlier studies,  proxy variables for infection load: older sibling(s) (0/1) 
and day-care attendance ever (0/1).7-12,22,23 Other confounding variables 
included were gender (boy 0/1) and the mother’s history of asthma (GP 
reported 0/1), any siblings with a history of asthma (GP reported 0/1), group 
allocation in the PREVASC-study (intervention group 0/1) as well as the 
possible confounding exposure factors: the number of weeks the children were 
breastfed (exclusive or in combination with artificial formula and/or solid foods), 
the smoking status of mothers during pregnancy (0/1), the smoking status of 
parents during the first year of the child’s life (0/1), HDM (Der p1), cat (Fel d1) 
and dog (Can f1) allergen exposure level as measured in dust samples 
collected from the mattresses of parents and children at age six months, 
expressed as µg/ m2, and the presence of a cat or dog in the household (0/1). 
Statistics 
Regression analyses were carried out using the Statistical Package for the 
Social Sciences (SPSS) for Windows version 15.0.  
The development of asthma was registered by the GP (diagnosis and 
symptoms, 0/1) and parents (symptoms, 0/1); these data were tested in logistic 
regression analyses. The total IgE serum level was log normal transformed to 
obtain a normal distribution for linear multiple regression analyses. The specific 
IgE levels (HDM, cat and dog) were dichotomised above or below the level 
associated with allergic disease: 0.35 IU/ml. Logistic regression analyses were 
carried out for the outcomes on the specific IgE levels.  
Infection load, number of episodes of common cold and diarrhoea remained 
mandatory in the logistic model even if they had no statistically significant 
relationship with the outcome variables. The number of episodes of diarrhoea 
associated with fever the children experienced during the first two years of life 
was included in a single variable. To protect the analyses from loosing too many 
cases in the analyses two variables on the number of episodes of common cold 
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were included. The variable with the least influence was removed from the 
model.  
Using a backward procedure we excluded step-by-step those variables that 
were shown not to influence the outcome variable (p<0.100).  
Due to missing values and the deletion of several variables in the regression 
analyses, outcomes may not be given for the entire cohort. The number of 
participants still eligible for analysis will be mentioned in the title of every table. 
Results 
A total of 476 families were included in the study; 242 families in the 
intervention group and 234 families in the control group. Loss to follow-up until 
age six was 23 in the intervention group and 14 in the control group. Text Box 
6.1 contains information on the participants flow of the PREVASC trial as used 
for answering the ad hoc research question described in the current article. 
Prevalence data 
Prevalence data of variables included in the analyses are presented in Table 
6.1. 
Diagnosis of asthma 
No significant relationship between the number of infections and the diagnosis 
of asthma was found (Table 6.2).  
The presence of older siblings and day-care attendance showed not to be 
related to the diagnosis of asthma. 
Asthmatic symptoms 
The number of episodes of diarrhoea associated with fever showed to be 
positively related to the development of asthmatic symptoms (Table 6.3). 
Common cold however, was not related to the development of asthmatic 
symptoms. Day care attendance and the exposure to Der p1 on the child’s 
mattress showed a positive trend with the development of symptoms associated 
with asthma, whereas none of the other variables included in the analysis 
showed to be of influence.  
The influence of common cold and diarrhoea on the total IgE level is presented 
in Table 6.4. The number of episodes of common cold during the first 12 
months of life was inversely related to total IgE at age six, as was the presence 
of a dog in the household. None of the other variables included in the analysis 
did influence the total IgE level at age six.  
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Table 6.1 Prevalence of variables included in the analyses. 
Variable (n) n/N % median minimum maximum 
Common cold during 1st year of child’s 
life (episodes) 
 431 / 443  97.3 15  0  49 
Common cold during 2nd year of child’s 
life (episodes) 
 326 / 443  73.6 12  0  44 
Diarrhoea plus fever during 1st two 
years of child’s life (episodes) 
 373 / 443  84.2 1  0  12 
Diagnosis asthma age 4 to 6 (0/1)  30 / 383  7.8 0  0  1 
Asthma symptoms age 4 to 6 (0/1)  146 / 418  34.9 0  0  1 
Total IgE serum level IU/ml  367 / 443  82.8  0.01  0.01  8604.15 
House dust mite allergen specific IgE 
above 0.25 IU/ml (0/1) 
 55 / 302  18.2 0  0  1 
Any older siblings (0/1)  272 / 443  61.4 1  0  1 
Day-care attendance (0/1)  163 / 407  40.0 0  0  1 
Presence of a cat (0/1)  52 / 443  11.7 0  0  1 
Presence of a dog (0/1)  84 / 443  19.0 0  0  1 
Derp1 exposure level µg/m2   414 / 443  93.5  0.0104  0.00  142.33 
Fel d1 exposure level µg/m2  414 / 443  93.5  0.0314  0.00  47.48 
Can f1 exposure level µg/m2  414 / 443  93.5  0.0125  0.00  32.56 
Gender (boy 0/1)  230 / 443  51.9 1  0  1 
Mother’s history of asthma (0/1)  229 / 443  52.0 1  0  1 
Any sibling with a history of asthma 
(0/1) 
 178 / 277  64.3 1  0  1 
Number of weeks breastfed  350 / 443  79.0  13.5  0  52 
Smoking status of mother during 
pregnancy (0/1) 
 40 / 440  9.0 0  0  1 
Smoking status of parents during 1st 
year of child’s life (0/1) 
 118 / 404  29.2 0  0  1 
Study group allocation (intervention 0/1)  222 / 443  50.1 x  0  1 
 
 
Table 6.2 GP-diagnosed asthma at age four to six: contribution of episodes of infections (logistic 
regression) (n=289). 
Variable Coefficient (B) Odds ratio 95% CI for OR P value 
Common cold during 2nd year 
(episodes) 
 0.014 1.014 0.964 / 1.067 0.588 
Diarrhoea plus fever (episodes) -0.040 0.960 0.722 / 1.278 0.781 
 
 
Table 6.3 Asthma symptoms at age four to six (n=337): possible determinants (logistic 
regression). 
Variable Coefficient (B) Odds ratio 95% CI for OR P value 
Common cold during 1st year 
(episodes) 
-0.011 0.989 0.965 / 1.013 0.989 
Diarrhoea plus fever (episodes)  0.215 1.240 1.085 / 1.417 0.002 
Day-care attendance (0/1)  0.446 1.562 0.973 / 2.508 0.065 
Der p1 level mattress child µg/m2  0.141 1.151 0.977 / 1.356 0.092 
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Table 6.4 Total IgE at age six years (n=317): relationship with exposure (multiple linear 
regression). 
Variable Coefficient (B) 95% CI for B P value 
Common cold during 1st year (episodes) -0.080 -0.134 / -0.027 0.003 
Diarrhoea (episodes) -0.134 -0.422 / 0.155 0.353 
Dog in the household (0/1) -1.729 -3.077 / -0.381 0.012 
 
Specific IgE levels 
The influence of infections on the outcome variables cat and dog specific IgE 
were not analysed as these variables did show to be above the reference value 
in only 9 and 6.5% of cases. Results of the analyses on the influence of 
infection on the HDM specific IgE levels are presented in Table 6.5. The 
number of episodes of diarrhoea was associated with a reduction of HDM 
specific IgE level. The number of episodes of common cold showed a positive 
trend with HDM specific IgE level. The presence of a sibling diagnosed with 
asthma was inversely related to HDM specific IgE. 
 
Table 6.5 Specific IgE HDM (above or below 0.35 IU/ml) at age six (n=126): possible 
determinants (logistic regression). 
Variable Coefficient (B) Odds ratio 95% CI for OR P value 
Common cold during 2nd year 
(episodes) 
 0.050 1.051 0.991 / 1.115 0.095 
Diarrhoea plus fever (episodes) -0.372 0.690 0.483 / 0.984 0.041 
Breastfeeding (weeks)  0.026 1.026 0.997 / 1.055 0.075 
Sibling(s) diagnosed with asthma (0/1) -1.740 0.175 0.062 / 0.497 0.001 
Dog in the household (0/1) -1.907 0.149 0.017 / 1.293 0.084 
 
Discussion 
Our findings do not support the hypothesis that URT infections (common cold) 
or GI infections (diarrhoea) would teach the developing immune system to arm 
itself against the development of asthma and asthma-like symptoms. We 
observed no significant relationship between the number of episodes of URT or 
GI infections, and the diagnosis of asthma at the age of four to six years.  
Although often described to influence the development of atopy, siblings and 
day-care attendance did not show to influence the development of atopy in our 
analyses. We separately included the sibling variables ‘any sibling 0/1’ as well 
as a variable ‘number of siblings categorised as 0, 1 or ≥2’ in the multiple 
regression analyses to be sure we did not miss any information. Only when a 
sibling was diagnosed with asthma there was an inverse relationship with the 
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outcome HDM specific IgE. This variable does not represent a proxy measure 
for infection load but might be correlated with the genetic susceptibility of the 
child. The commonly held assumption that day-care attendance and the number 
of siblings are proxy variables for infection load may not apply to the subgroup 
of children at high risk of developing asthma.  
It might be possible that we found no relationship between asthma diagnosis 
and URT infection (common cold) or GI infection (diarrhoea) because the 
symptoms of these common infections as reported by the parents were not 
suitable proxy measures for infection load. Although the results we presented 
might be true, they could have been the result of a lack of power. However, our 
results seem to be in line with the results of Harris et al.24 They found no 
relationship between early-life infections and subsequent respiratory disease in 
later life. 
Our results show that more infections with common cold in early life are 
associated with a lower level of total IgE. Atopic diseases are characterised by 
Th2, and IgE responses to common environmental and food allergens. IgE 
levels are extremely low in non-atopic individuals, suggesting that IgE 
production is under the regulation of the immune system. One of the reasons 
behind the lack of atopy in healthy individuals is the activity of regulatory T cells, 
which prevent naïve T helper cell precursors from acquiring a differentiated Th2 
phenotype.25 Our results could suggest that, although we did not find a 
relationship with asthma diagnosis or symptoms, URT infections might well 
influence atopy. Common cold did show a negative relationship with total IgE 
and diarrhoea did show an inverse relationship with HDM specific IgE.  
These results seem to be in line with part of the recently launched hypothesis of 
Holt et al.26 They assume that respiratory tract infection can have dualistic 
effects, in particular via promoting resistance to atopy (lowering IgE 
development). At the same time they describe URT infections might stimulate 
the development of asthma through a pathway extrinsic to the immune system. 
This last mentioned part of their hypothesis was not confirmed in the current 
study. 
Conclusions 
The present data do not support the hypothesis that infections teach the 
developing immune system to arm itself either against the diagnosis of asthma, 
or against the development of asthma-like symptoms.  
Common cold had an inverse relationship with the total IgE level. The number 
of episodes of diarrhoea associated with fever was inversely related to specific 
IgE for house dust mite allergens. These results suggest that URT infections 
might influence atopy development (total IgE). 
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Abstract 
Aim 
To show the effectiveness of the PREVASC intervention on primary PREVention of ASthma in 
genetically predisposed Children through the reduction of multiple environmental exposures. In this 
paper we will describe the outcome of the exposure-reducing interventions, as well as the clinical 
effectiveness as measured at ages four and six.  
 
Methods 
Children susceptible to developing asthma on grounds of genetic predisposition were included 
during prenatal life. These children were randomly assigned to an intervention group (IG) or a 
control group (CG) and followed from prenatal life until the age of six. The results at age two were 
published earlier. The number of children we followed up until age six was n=219 in the IG and 
n=213 in the CG. We offered an intervention focused on a simultaneous reduction of multiple 
environmental exposures such as food allergens, inhalant allergens and environmental tobacco 
smoke (ETS), suitable for implementation in daily general practice.  
At age four the clinical outcomes evaluated were asthma, asthma symptoms (wheezing, nocturnal 
coughing, dyspnoea) and atopic dermatitis as registered by general practitioners and parents 
(questionnaire data). At age six the main outcome asthma status was categorized by a predefined 
algorithm (no asthma, possible asthma, current asthma). The categorization of this asthma status 
was based on spirometry and symptoms as prospectively reported by parents and general 
practitioners.  
A multiple logistic regression analysis, not based on study group comparisons, were carried out for 
assessment of the influence of individual intervention elements on the development of asthma at 
age six. 
 
Results 
The exposure to both food allergens and inhalant allergens was significantly lower in the IG as 
compared to the CG. The food intervention was very successful in reducing exposure to cow’s milk 
and solid foods. In 84/205 children in the IG (41.0%) versus 25/217 in the CG (11.5%), p<0.001) the 
exposure to cow’s milk and solid food was successfully reduced. No differences for breastfeeding 
practices have been observed between groups. Inhalant allergen exposure was significantly 
reduced in the IG as compared to the CG (house dust mite [HDM] allergen level IG 82.62 ng/m2 
versus CG 124.36 ng/m2 [p=0.043], cat allergen level IG 13.48 ng/m2 versus CG 21.68 ng/m2 
[p=0.037], dog allergen level IG 48.83 ng/m2 versus CG 88.88 ng/m2 [p=0.012]. There were no 
differences in ETS exposure between groups. 
Although the exposure outcome showed to be significantly reduced in the IG, the clinical outcome 
was not shown to be statistically different between groups. In the CG 25.9% of children were 
diagnosed with current asthma as opposed to 29.7% of children in the IG, 50.6% of children in the 
CG versus 46.5% in the IG were categorized as having possible asthma, and 23.5% versus 23.8% 
were shown to have no current asthma at all (p=0.491). The logistic multiple regression analysis 
showed that breastfeeding and an HDM allergen level below the group median (0.6606 µg/g) have a 
statistically significant reducing effect on the development of asthma. 
 
Conclusion 
The PREVASC multi-faceted intervention was not clinically effective. Only minimal room for 
improvement for the ETS- and HDM-reducing interventions was shown. Besides this lack of room 
for improvement, compliance might have played a part in the lack of effectiveness, especially for the 
breastfeeding promoting intervention and the HDM allergen reducing intervention. 
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Introduction 
Over the past decades the prevalence of asthma in children has increased 
substantially.1,2 This increase in asthma prevalence has led researchers to turn 
their interest towards elucidating the cause of this increase and the possibilities 
for preventing the development of asthma in susceptible children.  
It is unlikely that the increase in prevalence of asthma in this relatively short 
period of time has been caused by genetic factors. The development of asthma 
seems to be a result of gene-environment interaction.3 Allergen exposure is one 
of the environmental factors seemingly associated with the development of 
asthma. 
Several randomised controlled trials (RCTs) are currently studying reduction in 
food and/or inhalant allergen exposure. The types of interventions studied are 
either mono-faceted, focused on one (allergen) exposure, or multi-faceted, 
focused on multiple exposures. Since asthma is a multi-factorial disease, it 
seems likely that asthma might be prevented to a greater extent if multiple 
exposures were simultaneously reduced.4 The majority of RCTs investigating 
allergen exposure reduction, in terms of a preventive intervention for asthma 
development in children, are using a mono-faceted approach.5-14 The only three 
multi-faceted intervention studies are the Isle of Wight study, the Canadian 
Childhood Asthma Primary Prevention Study and the PREVention of ASthma in 
Children (PREVASC) study.15-17 These multi-faceted RCTs all reported 
significant results in favour of treatment on allergen exposure data and clinical 
observations.15,18-25 These results showed that changing multiple environmental 
factors may, to some extent, prevent asthma (or asthma symptoms) from 
developing in genetically susceptible children. Differences between the three 
multi-faceted studies lay in the different baseline house dust mite (HDM) 
exposure levels, and the focus of the three multi-faceted RCTs. The Isle of 
Wight study and the Canadian Childhood Asthma Primary Prevention Study 
focused less on feasibility and implementation than did the PREVASC study. In 
addition to the general intervention recommendations supplied, both the 
Canadian and Isle of Wight study had regular contact with parents concerning 
performance of the intervention measures so as to improve compliance. This is 
a different approach from that followed in the PREVASC study. In the 
PREVASC study the intervention was aimed at educating parents on how to 
lower the allergen exposure of their child by a method easy to implement in 
daily general practice, taking into account the busy schedules of general 
practitioners (GPs) and practical nurses.  
An initial report on the clinical effectiveness of the PREVASC intervention was 
already published when the children reached age two.25 In the present paper we 
will be reporting the outcome of the PREVASC study as measured at ages four 
and six. 
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The research questions of the current study are: 
1. What is the clinical effectiveness of a combination of prenatally started 
measures, aimed at reducing exposure to inhalant and food allergens as 
well as Environmental Tobacco Smoke (ETS) on primary prevention of 
asthma in genetically susceptible children? 
2. Does the intervention’s duration (extended or short) have any effect on the 
development of asthma in genetically susceptible children? 
3. What is the effect of the environmental factors included in the PREVASC 
multi-faceted intervention on the outcome asthma as measured at age six? 
Methods 
Design 
The PREVASC study on PREVention of Asthma in Children at high risk of 
developing asthma is a randomised controlled trial using a multi-faceted 
intervention for reduction of environmental exposures: inhalant and food 
allergens, as well as ETS. The design of the PREVASC programme, including 
the present study, plus the rationale behind the study, was described by 
Schönberger et al. 199826, 200525 and Kuiper et al. 2005.17 In the present paper 
we will specifically describe the parts relevant to outcome at ages four and six. 
Study population 
Children at high risk of developing asthma were included during prenatal life. 
Families were randomly assigned to an IG or a CG. The CG was not offered 
any specific intervention, but received the usual care in accordance with the 
standards of the Dutch Society of General Practitioners (NHG). 
During home visits the IG was offered an educational intervention in which 
parents were coached to reduce their child’s exposure to inhalant allergens, 
food allergens and ETS. The IG received HDM-impermeable encasings for the 
beds of the parents and participating child (mattress plus pillow and duvet, or 
infant’s sleeping bag) and received advice on measures for reducing their 
child’s inhalant allergen exposure (HDM and pet allergens). Recommendations 
on food allergen reducing measures were based on the promotion of exclusive 
breastfeeding during the first six months of life without any other milk feeding or 
introduction of solids. If mothers were not able to act upon the breastfeeding 
recommendations, they were offered the opportunity to buy hypoallergenic 
artificial formula (HAF, nutrilon pepti, Nutricia, The Netherlands) at the price of 
regular formula so there would not be a financial barrier to compliance. For the 
ETS-exposure part of the intervention, parents were coached to quit smoking 
using the Minimal Intervention Strategy (MIS) developed by the Dutch 
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organization STIVORO.27,28 In addition, parents were also advised to keep their 
child away from smoking areas. 
To obtain information on the optimal intervention duration we compared the 
effects of two different periods of intervention. For this purpose the children in 
the IG were randomly assigned to one of two groups at the age of two. The two 
groups that resulted from this second randomisation were the extended-IG 
(n=111), in which the intervention was continued until age six, and the short-IG 
(n=108), in which the intervention stopped at age two. The extended IG 
received the intervention treatment concerning the diminishing of inhalant 
allergen exposure including advice on how to reduce exposure to ETS and HDM
Measurement of outcome during the whole study period 
Every year around their child’s birthday, parents were asked to complete 
questionnaires on their child’s health (based on the ISAAC questionnaire29) as 
well as exposure to inhalant allergens and ETS. GPs prospectively recorded 
symptoms, medication and diagnoses related to allergy and asthma for the 
participating children throughout the study period. At the age of two and four, 
research assistants made home visits during which exposure measures were 
assessed. During the home visit at age two, the research assistant put new 
encasings on the child’s mattress, duvet and pillow (either HDM-impermeable or 
placebo). In the extended-IG recommendations on reducing exposure to ETS 
and inhalant allergens were reiterated. A finger prick blood sample was 
collected within the first ten days after birth and at ages one, two, four and six to 
determine total and specific Immune globuline E (IgE) concentrations in the 
child’s blood.30  
Primary outcome measured at age six 
At age six, the child’s lung function was measured to assess the primary study 
outcome current asthma-status, including forced expiratory volume in one 
second (FEV1) before and after bronchodilatation, forced vital capacity (FVC), 
tiffeneau index (FEV1/FVC) and bronchial hyper reactivity (PC20). All children 
were invited to visit the lung-function laboratory of the Maastricht University 
Hospital (azM) when they reached the age of six.  
allergen. For reduction of HDM allergen exposure MiteCare special soft HDM- 
Impermeable bedding encasings for the child's bed were supplied (Sanalife, The
Netherlands). The families were kept uninformed as to the group they were allo- 
receive placebo bedding encasings for their child after the second randomisation.
The families were not aware of the exact differences between the groups as
this would have un-blinded the intervention.  
cated to. Both intervention subgroups were aware of the possibility that they might 
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We used a predefined automated algorithm for determining the asthma status of 
participating children in which they were assigned to one of the three following 
groups (see Text Box 7.1): 
1. No current asthma, 2. Possible asthma, 3. Current asthma.  
The information used for this categorization was based on both lung-function 
results and symptoms reported by GPs and parents. If participants were unable 
to visit the lung-function laboratory, they were offered the opportunity to have 
the spirometry performed by a research assistant at home. The equipment used 
for home determination of lung function was technically the same as the 
spirometer used in the hospital (Flowscreen II, VIASYS Healthcare The 
Netherlands BV). Histamine-provocation testing (bronchial hyperreactivity test) 
and Nitric Oxide (NO) measurement could not be performed during the home 
visits.  
After the algorithm program was finished, data for two specific groups of 
children were separately and independently evaluated by two experts 
([paediatric] pulmonologists): 
− Children that inhaled corticosteroids and were not assigned to the current 
asthma group were evaluated by pulmonologists because of the greater 
chance of lung-function deviations not being measurable when the asthma 
was medication-regulated; 
− Children that had their lung function measured in the home situation when 
being assigned to the ‘possible asthma’ group were discussed by 
pulmonologists, since no PC20 measurement was possible outside the 
laboratory. The lack of PC20 outcome resulted in incomplete information on 
lung-function status. 
The pulmonologists were supplied with all the data collected during the study 
period. In those cases where the pulmonologists did not reach a consensus on 
the group in which a child should be categorized, a GP experienced in 
paediatric pulmonology made the final categorization. 
Secondary study outcomes 
− FEV1 and FVC, both expressed as percentages, predicted PC20, 
reversibility and fractional exhaled nitric oxide ((fe)NO); 
− Doctor’s diagnosis of asthma and the asthma symptoms of wheezing, 
nocturnal coughing and dyspnoea, as reported by the GP at ages 3-4 and 
5–6; 
− Asthma symptoms of wheezing, nocturnal coughing and dyspnoea, as 
reported by parents in questionnaires at ages 3-4 and 5-6; 
− Asthma medication (overall), inhaled corticosteroids, beta2sympatico-
mimetics, anticholinergics, antihistamines prescribed by the GP at ages 3-4 
and 5-6; 
− Total IgE and specific IgE IU/ml at ages four and six. 
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Text Box 7.1 Criteria used for determining asthma status by algorithm PREVASC. 
 
 A) No Current Asthma  
Lung function results: 
FEV1/FVC > % predicted-2 SD  
AND reversibility <9% difference between pre and post bronchodilator FEV1 % predicted  
AND PC20 >8 mg/ml histamine. 
 
Symptoms questionnaire 
None  of the following symptoms is registered:  
Question: Has your child ever experienced an episode of wheezing at the age of 4 to 6 years? 
NO. 
Question: Did your child ever experience an episode of dyspnoea at the age of 4 to 6 years? NO . 
Question: Did your child ever experience an episode of nocturnal cough not associated with 
common cold or airways infection at the age of 4 to 6 years? NO. 
 
General Practitioners registration  4-6 years 
All of the following conditions are fulfilled: 
Expiratory wheezing is never reported; 
Wheezing not associated with exertion is never reported; 
Night time cough is reported maximally once; 
Dyspnoea not associated with exertion never reported. 
 
B) Possible Asthma 
 
No current asthma but either: 
Current asthma symptoms reported (see current asthma) but no lung function deviations 
measured (see no asthma); 
Or: 
Lung function deviations measured (see current asthma) but no current asthma symptoms 
reported (see no asthma).  
 
C) Current Asthma 
 
Lung function results: 
FEV1/FVC (ml) ≤ % predicted-2 SD  
AND reversibility ≤9% difference FEV1 %predicted pre and post bronchodilator AND/OR PC20 
<8 mg/ml histamine. 
 
Symptoms questionnaire 5 and 6 years 
Minimally 1 of the following symptoms is registered: 
Question: Has your child ever experienced an episode of wheezing as of the age of 4 to 6 years? 
YES. 
Question: How often did your child wheeze during this period in total? 1-3,  
4-12 or >12. 
Question: How often did wheezing cause your child to wake up? 0 to 1 night/ week or 1 or more 
nights/week. 
1. Question: Did your child ever experience an episode of dyspnoea at the age of 4 to 6 years? 
YES 
2. Question: How often did your child experience an episode of dyspnoea during this period in 
total? 1-3, 4-12 or >12. 
3. Question: How often did your child wake up because of dyspnoea? 0 to 1 night/ week or 1 or 
more nights/week. 
4. Question: Did your child ever experience an episode of nocturnal cough not associated with 
common cold or airways infection at the age of 4 to 6 years? YES. 
5. Question: How often did your child experience an episode of nocturnal cough not associated 
with common cold or airways infection? 1 or more nights/week. 
 
General Practitioners (GPs) registration 4-6 years 
Minimally one of the following conditions is fulfilled: 
Expiratory wheezing is registered minimally once; 
Wheezing not associated with exertion is registered minimally once; 
Night time cough is registered several times (minimum 2); 
Dyspnoea not associated with exertion is registered minimally once. 
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Statistical aspects 
Power calculation 
Based on the longitudinal study results of Saarinen et al. 1995,30 a minimum 
amount of 194 infants in both the intervention and the CG was required to be 
able to detect a reduction of the asthma incidence by at least 30% (taking into 
account a type I error of 0.05 and a power of 0.80). SPSS for Windows version 
15 was used to perform the statistical analyses. 
Analysis of differences between the total IG and CG, as well as separate 
analyses on differences between the extended-IG and the short-IG as 
compared to controls, were carried out for all outcomes tested. 
Kruskal-Wallis tests were used for evaluating differences between groups in 
terms of the primary outcome. Pearson Chi2 tests were performed to test if there 
were any differences between groups for nominal exposure outcome, 
questionnaire data and data on symptoms and diagnoses as reported by GPs. 
The ordinal data on inhalant allergen exposure, breastfeeding practice, use of 
HDM-impermeable mattress encasings and separate lung-function parameters 
was evaluated for group differences by carrying out Mann-Whitney U tests. 
To determine the effect of all the environmental factors included in the 
intervention (research question 3), we carried out a multiple logistic regression 
analysis independent of group allocation. With this analysis we tested the 
influence of the separate environmental factors on the combined outcome of 
‘current asthma’ or ‘possible asthma’, as compared to the group of children 
categorized as having ‘no asthma’. 
The independent variables included in the logistic regression analysis were 
those that showed to be related to the tested asthma outcome (chi-square tests, 
p<0.100). A backward procedure was followed. 
Results 
Participants 
A total of 443 children, all at high risk of developing asthma on grounds of a 
genetic predisposition in first-degree relatives (mother and/or father and/or 
sibling[s] diagnosed as asthmatics) were included in the PREVASC study. The 
children were included between January 1, 1997, and January 1, 2000, during 
pregnancy with the help of GPs and midwives, and were followed up until age 
six. They were randomly assigned to an IG (n=222) or a CG (n=221). The 
extended-IG comprised of n=111 children, whereas the short IG consisted of 
n=108 children. 
A flow chart of participants in the PREVASC study presented in Text Box 7.2 
shows that the number of children lost to follow-up has been less than 10% 
since the start of the study (45/476). 
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Exposure outcome 
Table 7.1 presents the differences in results of exposure outcome in the IG(s) 
versus the CG. The number of cases offered feeding in accordance with 
research intervention recommendations (breastfeeding and/or HAF without 
introduction of solids during the first six months of life) differed significantly in 
favour of the IG. The percentage of children exclusively breastfed and/or fed 
with hypo-allergenic formula during the first six months of life was higher in the 
IG as compared to the CG. Another finding was that children in the IG were 
significantly more often introduced to solids after they had reached the age of 
six months as compared to children in the CG.  
 
Table 7.1 Environmental exposures at age four and six years: Comparison of intervention group 
as a whole, and short intervention group as well as extended intervention group 
separately, versus the control group. 
 Control group  
n/N  
(%) 
Intervention group 
n/N (%)  
Asymp. Sig. 
2-sided 
Extended Intervention 
n/N (%) 
Asymp. Sig.  
2-sided 
Short Intervention  
n/N (%) 
Asymp. Sig.  
2-sided 
Exclusively breastfed and/or hypo-
allergenic bottle fed 26 wks plus 
introduction solids >6 months^ 
25/217 (12.0) 84/203 (41.4) 
<0.001 
48/103 (46.6) 
<0.001 
36/100 (36.0) 
<0.001 
Exclusively breastfed and/or hypo-
allergenic bottle fed 26 wks^ 
49/219 (22.4) 115/208 (55.3) 
<0.001 
61/108 (56.5) 
<0.001 
54/100 (54.0) 
<0.001 
Exclusively breastfed 26 wks^ 25/217 (12.0) 21/217 (9.7) 
0.450 
14/110(12.7) 
0.857 
7/107 (6.5) 
0.125 
Initially breastfed^ 162/207 (79.7) 175/215 (81.4) 
0.662 
89/110 (81.7) 
0.636 
85/105 (81.0) 
0.749 
Exclusively breastfed, median 
number of weeks* 
7 7 
0.738 
7.5 
0.746 
7.5 
0.427 
Breastfed overall, median number  
of weeks* 
13 12 
0.635 
14 
0.932 
10 
0.318 
Introduction solids >6 months^ 58/208 (27.9) 142/204 (69.6) 
<0.001 
76/102 (74.5) 
<0.001 
66/102 (64.7) 
<0.001 
Mother smoked inside age 4 yrs^ 16/201 (8.0) 24/206 (11.7) 
0.211 
8/107 (7.5) 
0.880 
16/99 (16.2) 
0.030 
Father smoked inside age 4 yrs^ 24/200 (12.0) 30/206 (14.6) 
0.447 
12/107 (11.2) 
0.839 
18/99 (18.2) 
0.084 
Mother smoked inside age 6 yrs^ 14/152 (9.2) 13/158 (8.2) 
0.786 
6/82 (7.3) 
0.621 
7/76 (9.2) 
1.000 
Father smoked inside age 6 yrs^ 21/152 (13.8) 16/158 (10.1) 
0.338 
8/82 (9.8) 
0.369 
8/76 (10.5) 
0.482 
Furry pets kept inside age 4 yrs^ 61/200 (30.5) 44/204 (21.6) 
0.041 
21/107(19.6) 
0.040 
23/97 (23.7) 
0.223 
Furry pets kept inside age 6 yrs^ 65/198 (32.8) 47/185 (25.4) 
0.111 
21/95 (22.1) 
0.053 
26/90 (28.9) 
0.471 
^Pearson Chi2 test carried out; *Mann-Whitney U test carried out 
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However, IG mothers started breastfeeding their child as often as CG mothers 
did, and no statistical significance was reached for exclusive breastfeeding 
during the first six months of life.  
Environmental tobacco smoke exposure, defined as ‘number of smoking 
mothers’ and ‘number of smoking fathers’, did not differ between the total IG 
and the CG. The number of smoking mothers in the short IG, however, was 
shown to be significantly higher than that in the CG. The results of ETS 
exposure are presented in Table 7.1. 
Furry pets were more often kept indoors in control-group families as compared 
to intervention-group families at age four (as was the case at age two), but not 
at age six (Table 7.1). A similar result was found in the separate comparison of 
the extended-IG and the CG. 
Inhalant allergen exposure  
HDM allergen Der p1, as well as cat allergen Fel d1 and dog allergen Can f1, 
were tested for differences in levels between groups. Statistical significance 
was reached for all inhalant allergen exposure data in favour of the total IG and 
the extended-IG as compared to controls (Table 7.2). No differences were 
detected for allergen levels in terms of the comparison of the short-IG versus 
the CG. 
 
Table 7.2 Inhalant allergen exposure levels at age four years: Comparison of intervention group 
as a whole, as well as the short intervention group and extended intervention group 
separately versus the control group  
 Control 
group  
Median 
Intervention 
group 
Median 
Asymp. Sig. 
2-sided 
Extended 
Intervention  
Median 
Asymp. Sig. 
2-sided 
Short 
Intervention  
Median 
Asymp. Sig. 
2-sided 
Der p1 ng/m2 124.36 82.62 
0.043 
65.79 
0.007 
119.98 
0.558 
Fel d1 ng/m2 21.66 13.48 
0.037 
6.21 
<0.001 
21.53 
0.692 
Can f1 ng/m2 88.88 48.83 
0.012 
37.65 
0.002 
87.19 
0.307 
Use of HDM impermeable mattress 
covers, number of years 
0.6 2.9 
<0.001 
3.5 
<0.001 
2.2 
<0.001 
Mann-Whitney U tests carried out for all outcomes presented in this table 
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Clinical outcome 
Primary outcome asthma resulting from the PREVASC algorithm 
No differences in the occurrence of current asthma were shown between 
groups. Also, no differences were observed between groups on separate lung-
function parameters (Tables 7.3 and 7.4).  
 
Table 7.3 Asthma at age six years: Comparing cases in the separate intervention groups versus 
controls. 
 Control group 
 
n/N (%) 
Intervention group 
 
n/N (%) 
Extended 
intervention group 
n/N (%) 
Short intervention 
group 
n/N (%) 
Current asthma  
 
Possible asthma  
 
No current asthma  
 
Asymp. Sig. 2-sided 
44/170 (25.9) 
 
86/170 (50.6) 
 
40/170 (23.5) 
 
 
51/172 (29.7) 
 
80/172 (46.5) 
 
41/172 (23.8) 
 
0.645 
23/86 (26.7) 
 
43/86 (50.0) 
 
20/86 (23.3) 
 
0.853 
28/86 (32.6) 
 
37/86 (43.0) 
 
21/86 (24.4) 
 
0.491 
Only those cases that could be categorized on grounds of the algorithm asthma were included in 
these Kruskal-Wallis analyses (for algorithm asthma PREVASC project see Text Box 7.1). 
 
Table 7.4 Lung function parameters: Comparing cases in the separate intervention groups versus 
controls. 
 Control group  
median 
Intervention group 
Median 
Asymp. Sig. 
2-sided 
Extended Intervention  
Median 
Asymp. Sig. 
2-sided 
Short Intervention  
Median 
Asymp. Sig. 
2-sided 
(FE)NO 11.80 10.80 
p=0.491 
10.80 
p=0.956 
10.80 
p=0.272 
FEV1 % predicted 107.05 109.0 
p=0.280 
109.0 
p=0.484 
109.30 
p=0.345 
FVC % predicted 99.80 100.80 
p=0.456 
100.70 
p=0.678 
102.0 
p=0.506 
Tiffeneau index 93.26 93.29 
p=0.766 
93.18 
p=0.443 
93.54 
p=0.763 
PC20 4.56 4.11 
p=0.310 
4.07 
p=0.141 
4.42 
p=0.733 
Reversibility (%) 3.62 4.57 
p=0.936 
5.71 
p=0.765 
3.54 
p=0.737 
Mann-Whitney U tests carried out for all outcomes presented in this table 
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Questionnaire data  
Equal numbers of children in the IG and CG were shown to be diagnosed with 
asthma and asthma symptoms at both ages four and six (Table 7.5). 
Comparable results were shown for the separate analyses of the intervention 
subgroups versus the CG.  
 
Table 7.5 Questionnaire data on asthma and asthma symptoms at age four and six years: 
Comparing intervention group as a whole, and extended intervention group as well as 
short intervention group separately, versus control group  
 Control group 
n/N (%) 
Intervention group
n/N (%) 
Asymp. Sign.  
2-sided 
Extended 
intervention group 
n/N (%) 
Asymp. Sign.  
2-sided 
Short intervention 
group n/N (%) 
Asymp. Sign.  
2-sided 
Asthma mentioned by 
GP at age 4yrs  
18/201 (9.0) 16/206 (7.8) 
0.665 
10/107 (9.3) 
0.910 
6/99 (6.1) 
0.385 
Wheezing 
age 4yrs 
43/201 (21.4) 39/206 (18.9) 
0.536 
18/107 (16.8) 
0.338 
21/99 (21.2) 
0.971 
Nocturnal cough 
age 4yrs 
49/201 (24.4) 62/206 (30.1) 
0.195 
31/107 (29.0) 
0.381 
31/99 (31.3) 
0.202 
Dyspnoea 
age 4yrs 
43/201 (21.4) 42/206 (20.4) 
0.803 
25/107 (23.4) 
0.691 
17/99 (17.2) 
0.390 
Asthma mentioned by 
GP at age 6yrs 
32/184 (17.4) 36/185 (19.5) 
0.608 
18/95 (18.9) 
0.795 
18/90 (20.0) 
0.643 
Wheezing 
at age 6yrs 
27/185 (14.6) 27/183 (14.8) 
0.966 
12/93 (12.9) 
0.664 
15/90 (16.7) 
0.694 
Nocturnal cough 
age 6yrs 
48/185 (25.9) 43/185 (23.2) 
0.546 
48/182 (26.4) 
0.240 
24/90 (26.7) 
0.959 
Dyspnoea 
age 6yrs 
35/185 (18.9) 32/185 (17.3) 
0.685 
14/95 (14.7) 
0.410 
18/90 (20.0) 
0.795 
Chi2 tests carried out for all outcomes presented in this table 
Data prospectively registered by GPs 
Most comparisons of data prospectively registered by GPs did not reach 
statistical significance (Table 7.6). However, statistically significant results were 
observed for wheezing and dyspnoea at age six. Children in the short-IG visited 
their GP more often for wheezing symptoms (p=0.022) and symptoms of 
dyspnoea (p=0.007) as compared to controls.  
Inhaled corticosteroids, beta2 sympaticomimetics, anticholinergics and 
antihistamines were as often prescribed to children in the IG as compared to 
controls at ages four and six (ever prescribed: yes or no). At age six, however, 
GPs were shown to have prescribed inhaled corticosteroids more often for 
cases in the short-IG than for children in the CG (13.2% versus 5.3% p=0.022).  
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Table 7.6 General practitioners registration of asthma and asthma symptoms at age four and six 
years: Comparing intervention group as a whole, extended intervention group and short 
intervention group separately versus control group  
 Control group 
n/N (%) 
Intervention group
n/N (%) 
Asymp. Sign.  
2-sided 
Extended 
intervention group 
n/N (%) 
Asymp. Sign.  
2-sided 
Short intervention 
group n/N (%) 
Asymp. Sign.  
2-sided 
Asthma diagnosis 
age 4yrs 
11/194 (5.9)  9/201 (4.5) 
0.589 
5/106 (4.7) 
0.725 
4/95 (4.2) 
0.599 
Wheezing 
age 4yrs 
7/192 (3.6) 7/199 (3.5) 
0.946 
2/106 (1.9) 
0.396 
5/93 (5.4) 
0.495 
Nocturnal cough 
age 4yrs 
25/195 (12.8) 21/201 (10.4) 
0.461 
8/106 (7.5) 
0.196 
13/95 (13.7) 
0.754 
Dyspnoea 
age 4yrs 
3/193 (1.6) 7/201 (3.5) 
0.224 
3/106 (2.8) 
0.452 
4/95 (4.2) 
0.169 
Asthma diagnosis  
age 6yrs 
7/188 (3.7) 7/196 (3.6) 
0.937 
6/106 (5.7) 
0.438 
1/90 (1.1) 
0.223 
Wheezing 
at age 6yrs 
1/188 (0.5) 6/196 (3.1) 
0.064 
2/106 (1.9) 
0.267  
4/90 (4.4) 
0.022 
Nocturnal cough 
at age 6yrs 
10/189 (5.3) 12/196 (6.1) 
0.725 
6/106 (5.7) 
0.893 
6/90 (6.7) 
0.644 
Dyspnoea 
at age 6yrs 
1/188 (0.5) 8/196 (4.1) 
0.022 
3/106 (2.8) 
0.102 
5/90 (5.6) 
0.007 
Chi2 tests carried out for all outcomes presented in this table 
 
 
Total and specific IgE levels were similar between groups at ages four and six, 
except for the comparison of the extended-IG with the CG, for the total IgE level 
at age four. Children in the extended-IG were shown to have a lower total IgE 
level as compared to controls (p=0.035).  
Logistic regression analysis 
The variables that were most suitable for inclusion in the logistic regression 
analysis were the variables Der p1 level above or below the group median 
expressed as ng/g dust (1/0), number of weeks exclusively breastfed expressed 
in quartiles, and having a mother that ever had asthma (1/0)  
The number of children included in the logistic regression analysis showed to be 
269. Since not all participants agreed with carrying out lung-function tests 
(n=43), some lung-function measurements could not be performed for all 
children due to child-specific circumstances (for instance behavioural problems 
or non-asthma related disease); and some independent data were lacking, the 
number of subjects in the multiple-regression analyses was reduced to 269 out 
of 387 children followed up until age six (69.5%). As participating children did 
not differ from non-participants no selection bias occurred. The results showed 
that those children who had been exclusively breastfed were protected from 
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developing current or possible asthma (when compared to never exclusively 
breastfed) as measured at age six (p=0.017). Those children that were 
exclusively breastfed for 8-17 weeks were protected from developing asthma, 
p=0.003, OR=0.271 (CI 0.113 0.645). When exclusively breastfed for 18-26 
weeks a protective trend was shown: p=0.076, OR 0.443 (CI 0.180 1.088)). 
Children that were exclusively breastfed for 1 to 7 weeks on the other hand, 
showed not to have any benefit from breastfeeding as compared to the 
reference group (p=0.409, CI 0.261 1.731). A HDM exposure level, (Der p1) 
below the group median 0.6606 µg/g, showed to protect children from 
developing asthma (p=0.026, above median: OR=1.962 (1.082; 3.555)). Having 
a mother that ever had been diagnosed with asthma did not show to have a 
statistically significant influence on the development of asthma in children at 
high risk. 
Discussion 
The results of the first part of the PREVASC study described in 2005 showed 
that the PREVASC research intervention was effective in reducing the 
development of asthma symptoms to some extent. Wheezing, nocturnal 
coughing and dyspnoea were shown to be less frequently reported for children 
in the IG as opposed to the CG.25  
However, the results shown after four and six years in this paper do not confirm 
the hypothesis that asthma and asthma symptoms can be prevented by 
reducing multiple exposures (ETS, HDM allergen, cow’s milk). Although the 
intervention was shown to be reasonably effective in reducing exposure to both 
inhalant and food allergens, these measures were not clinically effective as 
measured at ages four and six.  
In a recent meta-analysis we tested whether single-intervention strategies or 
multi-faceted interventions for reduction of allergen exposure in children at high 
risk of developing asthma would be more effective for the primary prevention of 
asthma.4 We found that multi-faceted interventions were significantly more 
effective than mono-faceted interventions, although this result was not 
applicable for current asthma symptoms (wheezing, nocturnal coughing and 
dyspnoea).  
Comparable studies carried out in Canada and the United Kingdom (Isle of 
Wight study) seemed to support the hypothesis that multi-faceted allergen 
reduction might prevent the development of asthma in susceptible children. 
What could explain the discrepancy between these studies and the present 
study is the low number of families complying with our recommendation. 
Families we supplied with HDM-impermeable covers during the whole study 
period of six years were shown not to have used them consistently (median 3.5 
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years). The reason for this low compliance might have been that we informed 
the parents that they had a 50% chance of having received placebo mattress 
encasings for their child’s bed as of age two. During the first part of the 
PREVASC study, when all IG families were told they had received mite-
impermeable bedding encasings, the compliance was nearly 100%. If the 
families had used the HDM-impermeable encasings during the whole study 
period as expected, the median exposure level in the IG(s) would probably have 
been lower. The HDM allergen exposure level in the Netherlands as measured 
in the present study is shown to be low. The HDM-exposure levels in the 
Canadian, but even more so in the Isle of Wight study, were shown to be much 
higher than the levels we measured in the PREVASC study. In the Isle of Wight 
study the exposure levels were reduced from approximately 25 µg/g of dust 
during pregnancy to 6 µg/g of dust after birth,19 while in the Canadian Childhood 
Asthma Primary Prevention Study a reduction from 1.5 µg/g of dust to 0.8 µg/g 
of dust was established.16 The PREVASC study intervention realized a median 
reduction of Der p1 level from 0.7 µg/g of dust to approximately 0.2 µg/g of dust 
after one year of intervention (back to 0.7 µg/g after four years). 
The cow’s milk avoidance measure of the PREVASC intervention was partly 
successful. However, the most important part of the intervention (the 
recommendation to exclusively breastfeed the infants during the first six months 
of life) did not result in significant differences between groups. The cow’s milk 
avoidance properties of HAF are known to be as good as those of human milk. 
In the PREVASC study HAF was used as replacement for human milk by a 
significantly greater number of families in the IG. It is plausible that the most 
important benefit for breastfeeding infants instead of using artificial formula is 
that breastfeeding not only reduces exposure of infants to cow’s milk, but also 
provides the child with important components that might strengthen their 
immune and digestive systems, such as secretory IgA, cytokines, poly-
unsaturated fatty acids, prebiotics and lysosyme.31-34 So this part of the 
intervention was not as successful as could have been possible.  
Little room for improvement for ETS-exposure reduction might have caused the 
ETS-reducing intervention part to fail. In the IG 10.8% of mothers smoked 
during pregnancy. The ETS-exposure in the IG was not significantly reduced 
compared to the CG. We did not offer parents the use of aids like nicotine 
chewing gum to make their quitting efforts more successful. Advising parents to 
quit smoking, of course, is a sensible way of intervening for ETS-exposure 
reduction. In households where a minimum of one member is diagnosed as 
having asthma, however, these recommendations are likely to have been given 
quite often already, possibly leaving less room for improvement. 
The Canadian Childhood Asthma Primary Prevention Study appeared to have 
the same problem of little room for improvement and lack of success for the 
ETS-reducing intervention part.16 The failing ETS-reducing intervention 
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therefore is unlikely to be the cause of the huge difference in effectiveness 
between the Canadian and the PREVASC study. 
HDM allergen avoidance and breastfeeding: Results of the logistic 
regression analyses 
In spite of the extremely low median levels of HDM allergen at baseline, the 
results of the logistic regression analysis showed that inhalant allergen 
reduction had a preventive effect on the development of asthma. Possibly the 
results of our intervention would have been more successful when we would 
have put more effort in stimulating compliance with the use of the HDM-
impermeable encasings. 
Another profound result of the logistic regression analysis was the preventive 
influence of breastfeeding. The lack of compliance with the breastfeeding part of 
the intervention might have been another reason why we were not able to 
confirm the hypothesis. In the Canadian Childhood Asthma Primary Prevention 
Study the parents were more compliant with the breastfeeding 
recommendations than was the case in the PREVASC study. In the Canadian 
study more children in the IG were breastfed at eight months of age as 
compared to children in the CG (61% versus 50%, p=0.02).  
The breastfeeding-recommendation study of Gijsbers et al. tailored the 
breastfeeding intervention part, as used in the present study, more intensively; 
our own intervention failed to strengthen the women to stand up to the 
difficulties they encountered.35 In the present study, a large number of women in 
both groups started breastfeeding their child but, for whatever reason, did not 
continue to do so through the age of six months. By the time women start 
working − in the Netherlands usually by the time their child is three months old − 
most mothers in our study had stopped breastfeeding their child. Although 
breastfeeding is encouraged in the Netherlands, (employers are obliged to 
make sure breastfeeding mothers have sufficient time and a private room to 
express milk), breastfeeding is shown to be very difficult for mothers to combine 
with their work.36 Another reason why mothers who start breastfeeding stop 
before the child is six months old is that they often do not get the social support 
they need.35, 36  
In the study of Gijsbers et al., the breastfeeding brochure of the PREVASC 
study was evaluated and improved. A total of 48% of children in the IG was 
exclusively breastfed for six months as opposed to 27% of children in the CG 
(p=0.03).37 By using the tailored version of the PREVASC breastfeeding 
intervention the number of children exclusively breastfed in the study of Gijsbers 
et al., raised the number of children exclusively breastfed by 21% as opposed to 
the CG. 
128⏐Chapter 7 
The feeding-intervention part of the PREVASC study differed from the 
interventions of the Canadian Childhood Asthma Primary Prevention Study and 
the Isle of Wight study to some extent. Apart from advising parents to 
exclusively breastfeed their child for six or nine months, their feeding 
intervention consisted of more recommendations. During (pregnancy and) 
lactation, participating mothers were advised to follow a strict dietary regimen 
that excluded dairy products and nuts.15,16 Parents also received specific advice 
on how to start introducing solid food. They were dissuaded from feeding their 
child food that was known to be highly allergenic, such as dairy products, fish, 
other seafood, eggs, nuts, soy, peanuts and oranges, during at least the first 12 
months, and they were advised when to introduce these foods (dairy products 
and soy from the age of nine months, wheat at ten months and eggs at eleven 
months). This extensive advice on how to reduce food allergens might have 
been of crucial importance for the prevention of asthmatic complaints. 
Does the intervention’s duration have any effect on the prevention 
of asthma in susceptible children? 
The inhalant allergen exposure levels were significantly lower in the extended-
IG. However, this did not result in differences in clinical outcome. The present 
study is the only study ever carried out in which two multi-faceted interventions 
of different duration were compared. Since our intervention was shown not to 
have led to sufficient compliance in all aspects, the intervention-duration issue 
remains undecided. 
Intervention strategy aimed at implementation in daily general 
practice 
With our intervention we aimed at educating parents on how to lower their 
child’s environmental exposure by a method suitable for implementation in daily 
general practice.  
The results of the logistic regression analysis have shown that parts of our 
intervention (aimed at breastfeeding promotion and HDM allergen reduction) did 
have reducing effects on the development of asthma. These effects were not 
shown when comparing the randomised study groups. Possibly this was due to 
the intervention strategy chosen, which was aimed at a feasible implementation 
in general practice taking into account the busy schedules of GPs and practice 
nurses.  
One related effect of the presumed consequences of the intervention strategy 
was the disappointing compliance with the intervention recommendations. Both 
the Isle of Wight study and the Canadian Childhood Asthma Primary Prevention 
Study supplied parents with additional advice on how to reduce exposure to 
HDM (encasings plus repeated mite-killing treatment) and food allergens 
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(breastfeeding promotion, HAF use, plus diet instructions for mothers and 
children) and thus asked for more effort from the part of the parents. This might 
have caused parents to comply more extensively with the recommendations 
supplied. Besides these additional recommendations, the Isle of Wight study 
group contacted parents regularly to support compliance with the intervention.  
Conclusions 
In the present study no differences in asthma outcome were shown between 
groups, nor were any differences observed between groups on the separate 
lung-function parameters used in the algorithm. The exposure to inhalant and 
food allergens (with the exception of breastfeeding), however, was shown to 
have been significantly lowered by the intervention coeffias compared to 
controls. 
The lack of effect from the ETS-reducing intervention, the low compliance with 
the breastfeeding intervention and the disappointing compliance with the HDM 
allergen reducing intervention may explain the absence of clinical efficacy. 
So far the hypothesis does seem to have been confirmed by other multi-faceted 
intervention studies. Country-specific circumstances, as well as the fact that our 
intervention was not sufficiently aimed at enhancing compliance, might have 
played a role in the lack of clinical effectiveness. 
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Introduction 
In this chapter the results of the PREVASC-study, the methodological 
considerations, added value of the current thesis, conclusions and 
recommendations for clinical practice and further research are described. 
The PREVASC trial: The Present thesis 
The primary aim of this thesis (PREVention of Asthma in Children) was to 
investigate whether asthma could be prevented in children with a familial 
predisposition for asthma where at least one of their first-degree family 
members has been diagnosed with asthma.  
Four hundred and seventy-six pregnant women were initially included with the 
help of general practitioners (GPs), midwives and gynaecologists. The number 
of children followed up resulting from these pregnancies until the age of two 
was 443. Randomisation allocated 222 children to the intervention group (IG) 
and 221 to the control group (CG). Ninety-eight percent of participants (n=432) 
decided to extend their participation in the PREVASC study when their child 
was two years of age (IG n=219 and CG n=213). Four hundred twenty nine of 
were followed up until the age of six (96.8% of 443) and of 342 lung function 
was objectively measured (77.2% of 443). The results at two years of age have 
been published previously.1  
The intervention offered from pregnancy onward was focused on educating 
parents about the multiple measures for optimising their child’s exposure to 
environmental circumstances associated with asthma. The measures focused 
on were lowering exposure to inhalant allergens and food allergens, 
breastfeeding promotion and reduction of exposure to environmental tobacco 
smoke (ETS). 
Two secondary research questions were included, focusing on 1) the difference 
in effect when two different intervention periods are compared and 2) the effect 
of environmental factors on the outcome asthma at age six independent of 
group allocation. To gather information on the optimal intervention duration, the 
effects of an extended intervention in which the intervention was continued until 
the age of six (n=111) was compared with a short intervention in which that 
intervention stopped at two years of age (n=108). To ensure group blinding, 
these latter received placebo bedding encasings. The extended-intervention 
group received intervention treatment for decreasing inhalant allergen 
exposure, including recommendations and House Dust Mite (HDM) allergen 
impermeable bedding encasings for the child’s bed. They also received 
recommendations on how to reduce exposure to ETS. The families were kept 
uninformed about the group they were allocated to. The families were unaware 
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of the exact differences between the groups, as this would have un-blinded the 
intervention.  
The main outcome was asthma status at age six as categorized by a predefined 
algorithm (no asthma, possible asthma, current asthma). The categorization of 
the asthma status was based on spirometry and symptoms, as prospectively 
reported by parents and GPs. In cases the algorithm was not able to classify 
subjects an expert panel gave the final diagnosis.  
PREVASC programme 
Two randomised clinical trials (RCTs) and one cohort study were part of the 
PREVASC programme on PREVention of ASthma in Children. The study 
described in this thesis was the first project carried out in this research 
programme. In addition to this RCT, another trial, carried out by Gijsbers et al., 
was part of the programme, and focused on whether optimizing the PREVASC 
intervention would lead to increased adherence. The cohort study included in 
the PREVASC programme is the study carried out by Kuiper et al. In this part of 
the programme, data on the PREVASC trial control group (children with a 
familial predisposition for asthma in first-degree family members) and a cohort 
of children with no genetic predisposition was evaluated. Based on these data, 
an estimate would then be made of the predictive value of a positive family 
history of asthma (as assessed in the prenatal period by the GP) on the 
development of childhood asthma. The health-economic benefits of high-risk 
identification and primary prevention of asthma were also studied in that part of 
the study. 
Research on asthma development in children at high risk  
In recent years, several birth cohort studies and intervention studies on asthma 
development in children at high risk of developing asthma have been carried 
out. The majority of these studies focused on exposures such as HDM 
allergens, pet allergens, food allergens and ETS. Designs vary from cohort 
studies to RCTs. Cohort studies are of particular importance as explorative 
studies on the role played by specific exposures. Knowledge resulting from 
these studies has been used in RCTs that are primarily focused on the 
effectiveness of specific interventions. Proof of the effectiveness of interventions 
based on results of cohort studies thereby is provided by RCTs. The ongoing 
RCTs are comparable to a certain extend, and so it is important to compare the 
effect of the intervention(s) on development of asthma in susceptible children 
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and to pool the data from these studies, thereby increasing the strength of the 
results. 
Intervention strategies used in RCTs on allergen reduction are either focused 
on exposure to one single allergen, referred to as mono-faceted interventions, 
or focused on reduction of multiple allergens simultaneously, so-called multi-
faceted interventions. As asthma is a multi-factorial disease, we assumed that 
simultaneous decrease of exposure to allergens of inhalant and food origin, 
might lead to a reduction in children developing asthma. Mono-faceted 
interventions could therefore be less successful. We separately pooled data of 
mono-faceted intervention studies and multi-faceted intervention studies. 
Indirect comparison between these treatments indeed suggested that multiple 
interventions were more successful in reducing the development of asthma in 
children than mono-interventions. However, the effect of multi-faceted 
interventions on parent-reported wheezing was inconsistent, and there was no 
beneficial effect on nocturnal coughing. Mono-faceted interventions were no 
more effective than controls in the reduction of all outcomes. 
Since the results of the meta-analyses showed that multi-faceted interventions 
were more effective than mono-faceted intervention strategies, we assume that 
the hypothesis that asthma could best be prevented by reducing exposure to 
multiple allergens might be correct. However, as the meta-analyses performed 
were not randomised comparisons and the effects on respiratory symptoms 
were not consistent, we suggest designing a new study in which both types of 
interventions are performed simultaneously. To our knowledge, no other studies 
are ongoing in which both intervention strategies are randomly compared. Such 
a study would be of great importance in shedding new light on preventing the 
development of asthma in children susceptible to developing asthma. 
Results of the present multi-faceted intervention study 
PREVASC 
In the present study no differences in asthma outcome were shown between 
groups. There were also no differences observed between groups as far as the 
separate lung function parameters were concerned. The exposure to inhalant 
allergens as well as food allergens however, was significantly lowered by the 
intervention supplied by the study. The absence of clinical efficacy may be 
explained by the lack of effect from the ETS-reducing intervention, the low 
compliance with the breastfeeding intervention, the low room for improvement in 
the HDM allergen exposure level, and the disappointing compliance with the 
HDM allergen-reducing intervention. 
So far, the hypothesis seems to be supported by other multi-faceted 
intervention studies. Country specific circumstances as well as the fact that our 
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intervention was aimed at implementation in real life and thereby less focused 
on enhancing compliance might have played a part in the lack of clinical 
effectiveness. 
Compliance with the PREVASC intervention 
− For the HDM allergen-reducing intervention, the second randomisation 
implied a change of design. We informed both intervention subgroups about 
the possibility that they might be receiving placebo bedding encasings for 
their child as of age two. This seems to have resulted in a decrease in the use 
of HDM-impermeable bedding encasings. In the first part of the PREVASC 
study, all participants of the intervention group were informed that they had 
received HDM-impermeable bedding encasings until their child turned two. In 
this first part of the study, nearly a hundred percent of the families in the 
intervention group used the covers constantly. As of age two, when they were 
randomly assigned to the differing intervention duration groups, the use of the 
encasings was shown to have drastically decreased. The total use of the 
encasings reached a median number of 3.5 years in the extended-
intervention group and 2.2 years in the short intervention group.  
− The breastfeeding promoting intervention showed to have failed to strengthen 
the women to stand up against the difficulties they encountered with 
prolonged breastfeeding.2 Emotional support, the support offered by partners, 
family and friends, as well as the practical and theoretical skills of 
breastfeeding lacked in the PREVASC participants as was shown in the study 
of Gijsbers et al. 
− The ETS exposure part of the intervention was not convincing or effective 
enough for parents to quit smoking. We did not offer parents the use of aids 
like for instance nicotine chewing gum to make their quitting efforts more 
successful. Advising parents to quit smoking, is a sensible way of intervening 
for ETS exposure reduction. In households where at least one member is 
diagnosed with asthma, however, these recommendations are likely to have 
already been given quite often, possibly leaving little room for improvement. 
 
It was shown that breastfeeding and a HDM allergen exposure equal to or lower 
than the group median (0.6606 µg/g) reduced the chances of developing 
asthma. These results were the outcome of a multiple logistic regression 
analysis on the effect of the environmental exposures intervened on in the 
PREVASC study, when both study groups were combined,. No effectiveness for 
low exposure to ETS was shown, possibly due to the low percentage of children 
being raised in a household with parents who smoked. 
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House dust mite allergen reduction 
In the studies on reducing inhalant allergens, the interventions focused primarily 
on allergens originating from house dust mite (Dermatophagoides 
Pteronyssinus [Der p1] and Dermatophagoides Farinae [Der f1], also referred to 
as European dust mite allergen and American dust mite allergen, respectively).  
On the basis of the results of a pilot study we performed,3 we concluded that 
Der p1 is unequally distributed on living room floors with smooth coverings, 
most likely because of displacement of dust from the middle to the edge due to 
activity. Expression as ng/g of dust and ng/m2 showed that they were not 
interchangeable. 
The hygiene hypothesis 
A very popular hypothesis is the hygiene hypothesis that assumes that 
infections might help the developing immune system from becoming 
unbalanced and from developing a predisposition towards allergic diseases 
such as asthma.  
Conflicting results have been published thus far and a summary of these results 
does not support any firm conclusion that infections do have a clear effect on 
the development of atopic diseases and asthma.4,5  
To find out whether the results of the PREVASC study did or did not support the 
hygiene hypothesis, we evaluated data on the relationship of respiratory and 
gastrointestinal infections (common cold and diarrhoea associated with fever), 
in relation to the development of asthma in the first four to six years of life.  
The results of our linear and logistic regression analyses on the influence of 
infections on the development of asthma and asthma symptoms showed no 
concordance with the hygiene hypothesis. The PREVASC-data therefore do not 
supply evidence for the assumption that infections in susceptible children can 
protect against the development of asthma. Our results suggest however that 
common cold and diarrhoea might well influence atopy. Common cold did show 
a negative relationship with total IgE and diarrhoea did show an inverse 
relationship with HDM specific IgE.  
A limitation of our study is the lack of information concerning  the type of 
pathogen the child was infected with. As we had to make use of the facilities 
and logistics of a community based trial with another primary research question, 
no microbiological essays could be performed. In future studies further 
determination of specific pathogens is recommended.  
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Methodological considerations 
In the current thesis some issues are addressed as these might have had its 
influence on the outcome at ages four and six years. Some of these issues 
were already reported in the thesis of Dr Schönberger, the researcher of the 
first part of the PREVASC study (pregnancy to two years of age).6   
Inclusion of pregnant women carrying a child at high risk of 
developing asthma 
Pregnant women were included in the PREVASC-study when the child they 
were carrying was supposed to be genetically predisposed. As genetic 
predisposition is not possible to define during prenatal life, positive family 
history of asthma was chosen as proxy measure of genetic predisposition. 
Allocation of families to the intervention group or control group was carried out 
by means of pre-randomisation in clusters based on ZIP-code of domicile of the 
participants in combination with the location of the general practice attended. 
The GPs did inform their eligible patients about the study and supplied them 
with study information. Pre-randomisation in clusters was chosen to prevent 
contamination to occur when GPs would be treating patients from both groups. 
It was assumed that cluster randomisation would also prevent spontaneous 
intervention behaviour in the control group because of unwanted exchange of 
information on the preventive measures between groups in the waiting room of 
the GP, or in the neighbourhood. Intervention group families did show to have 
higher inhalant allergen exposure levels as opposed to the control group at 
baseline (IG 148 ng/m2, CG 79 ng/m2, p<0.001). After one year of intervention 
the difference in Der p1 exposure level between groups showed to be inverted 
(IG 17 ng/m2 and CG 79 ng/m2, p<0.001). The difference in baseline levels of 
Der p1 exposure between groups might have been caused by the seasonal 
influence on the mite exposure level as more intervention group families were 
enrolled during autumn and winter as compared to control group families. Apart 
from this control group mothers showed to be of higher educational level. There 
were no other differences at baseline on family history of asthma, smoking 
behaviour of parents, furry pets in the household, type of house lived in (its age) 
and number of first pregnancies.  
The number of smoking parents was under-represented in the PREVASC-
study. The reason for under-representation of smoking mothers could be that 
they chose not to participate because they did not want anyone to be informed 
about their smoking habits as this is known to be harmful for the health of their 
unborn child. However it is well possible that women in genetically predisposed 
families smoked less than other pregnant women in The Netherlands as they 
might already have been aware of the health risks of (passive) smoking. 
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Collection of health outcomes  
Children’s lung function at age six was measured to assess the primary study 
outcome of their current asthma, including forced expiratory volume in one 
second (FEV1) before and after bronchodilatation, forced expiratory vital 
capacity (FVC), tiffeneau index (FEV1/FVC ratio) and bronchial hyper 
responsiveness (PC20 histamine). All children were invited to visit the lung-
function laboratory of the Maastricht University Hospital (azM) when they 
reached the age of six.  
A predefined automated algorithm was used for determining the asthma status 
of participating children, in which they were assigned to one of three following 
groups: 
1  no asthma 
2  possible asthma 
3  current asthma 
 
The information used for this categorization was based on both lung-function 
results and symptoms reported by GPs and parents. If participants were unable 
to visit the lung-function laboratory, they were given the opportunity of having 
the spirometry performed during a home visit by a research assistant. There 
were no differences between the groups whose lung function was measured in 
the home situation compared with the laboratory. The equipment used for home 
determination of lung function was technically the same as the spirometer used 
in the hospital (Flow screen, Viasys healthcare The Netherlands, Bilthoven). 
Histamine provocation testing and NO measurement, however, could not be 
included in the home visits.  
 
Symptom outcomes as prospectively reported by GPs was collected. The GPs 
completed standardized (computerized) registration forms during or immediately 
after the participating children visited their offices. This form of health-outcome 
collection is a valid method, since GPs are trained to recognize asthma 
symptoms. Bias might have occurred, as parents and GPs were not blinded for 
the intervention. This could have influenced their symptom reporting, diagnostic 
labelling and treatment to the participants of both groups. 
Another way of collecting health outcomes was by parents’ completing weekly 
reports during the first two years of their child’s life, and yearly questionnaires 
(based on validated ISAAC questionnaires7) from birth onwards. The health 
outcome as reported by parents, of course, might be liable to some subjectivity, 
but since only a maximum of twenty percent of all illnesses experienced by 
children reaches the GP or other doctors, this was considered to be a method 
necessary for the collection of a total package of health outcomes.8  
In the Isle of Wight study and the Canadian Childhood Asthma Primary 
Prevention Study, data prospectively reported by GPs was not available. In 
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these studies the symptom outcome was dependent on the symptoms as 
reported by parents in questionnaires. 
Collection of exposure outcomes 
Inhalant allergen exposure in the present study was assessed by sampling 
settled dust during pregnancy one year after the first measurement at ages two 
and four. Only for the first two measurements were dust samples collected in 
the living room (two open play sites were sampled and, if a carpet was present 
on a floor with smooth coverings, both floor coverings were sampled), as well as 
on the parental mattress. When the children had the age of two and four, a dust 
sample was collected from the child’s mattress. Mattresses were sampled 
without the bedding, with the exception of HDM-impermeable bedding, if this 
was in use. Sampling sites were vacuumed for 2 min/m2 each (using a 1300 W 
vacuum cleaner). Dust was collected onto glass micro fibre filters and stored at 
-12°C until analysis. The samples were analysed for Der p1, Fel d1 and Can f1 
content by the Laboratory for Biological Agentia at the Technical University 
Eindhoven in the Netherlands. There is some discussion as to the best way of 
sampling mattresses,  the bedding or the bare mattress. However this is not a 
relevant discussion point within a trial, as long as the method of sampling used 
is not dependent on group allocation. In international research the sampling 
methods are not always described extensively. For comparability of study 
outcome a thorough description of the sampling method is crucial. Different 
methods are available for measuring the exposure level of inhalant allergens. 
Airborne allergen samples or allergen levels in settled dust are the methods 
used in research.9,10 In fact, for mite and cat allergens, the relationship between 
airborne levels and dust samples is extremely variable.9,10 Although each 
circumstance might pose specific requirements for the preferred sampling 
method used, measurement of allergen exposure from collected dust samples 
is considered the best method available.11  
For measurements in living rooms it is recommended that at least two sites are 
sampled because of unequal distribution.12 However, there is no uniformity 
about the exact sampling locations.13 It is important in studies that the sampling 
procedure is be standardized so study comparisons can be made.14,15  
The expression of inhalant allergen exposure most used is ng/g of dust. 
However, the expression ng/m2 reflects the actual amount of Der p1 present at 
the sampled area, whereas the expression ng/g of dust merely reflects the 
concentration of allergen in floor dust. One probable cause that Der p1 ng/g is 
more commonly used is that the exposure levels above 2 µg/g of dust and 10 
µg/g of dust are described as being associated with an increased risk of 
sensitisation and asthma,16 while no reference exposure levels are known for 
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Der p1 expressed as ng/m2. As the expression of Der p1 as ng/m2 reflects the 
actual exposure level, this might be a better exposure expression than ng/g. 
It is arguable whether settled dust as collected from mattresses does in fact 
reflect the actual allergen exposure. We decided therefore to only measure 
allergen exposure at ages two and four sampled from mattresses as described, 
since the bed is the location where one-third of the time is spent within a 24-
hour period. Babies and toddlers are more likely to come in contact with 
inhalant allergens from the living room floor, since they are usually crawling. 
We considered that the objective measurement of inhalant allergen exposure in 
settled dust was the most valid way of collecting exposure data. We used 
questionnaires for collecting data on washing, airing, ventilating and other 
behavioural information associated with allergen exposure.  
Another issue that we encountered is the influence of uncertainty on the 
compliance with an intervention. This was shown for the inhalant allergen 
exposure reducing intervention from age two onwards. As parents were 
informed to have a 50% chance of having received placebo mattress encasings 
they showed to be less compliant than when told they had received HDM 
impermeable encasings. Honesty and ethical correctness in this case did result 
in a reduction of compliance by a half (100% until age two as opposed to 48.3% 
from age two to age six).  
 
Food allergen exposure was measured in weekly reports completed by the 
parents for children aged 0–2. In addition to this method of data gathering, 
questionnaires were used when the child was aged six months. In our opinion 
the weekly reports were the most valid method to collect exposure to food 
allergen, because it is associated with a very low recall bias, as long as parents 
filled out the reports weekly as we asked them to. However, some participants 
tended to forget to complete the weekly reports in this period of the child’s life, 
which is a relatively busy and intensive time for young parents. Parents who did 
not send us the reports in time (every three months) received a telephone call 
reminding them to do so. Data collected after calling parents to remind them to 
completed the weekly reports, is are assumed to have been subject to more 
recall bias as compared to the reports that were completed weekly. 
 
Exposure to ETS was measured by yearly questionnaires. Although results of a 
validation study have shown that exposure classification based on 
questionnaire data is likely to be reasonably valid, it is arguable whether 
questioning parents on the ETS exposure of their child is a valid method of 
information extraction on smoking exposure of a child. We could have chosen to 
measure cotinine levels in urine of children as a measure for actual ETS 
exposure. Since collecting urine samples of children that are not potty-trained is 
such a nuisance and we had already asked parents to do so much, we did not 
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want to burden them with collecting urine samples regularly from their child by 
supplying them with an adhesive plastic pouch. Another important reason we 
chose not to include this measurement was because of the relatively high 
additional costs associated with cotinine measurements. 
What this research adds 
The current trial will not change the guidelines on primary prevention of asthma 
in susceptible children. The results are not in concordance with outcome of 
comparable studies although post-hoc analyses showed breastfeeding and 
reduction of HDM allergen exposure both seem to have an effect on asthma 
development in susceptible children. 
What the PREVASC trial has taught us is that the trial intervention cannot be 
recommended for use in general practice in the Netherlands. Country specific 
circumstances (e.g. low HDM allergen exposure levels in the Netherlands) as 
well as the fact that our intervention was aimed at implementation in real life 
and thereby less focused on enhancing compliance might have played a role in 
the lack of clinical effectiveness. This resulted an insufficient reduction of 
exposure to environmental factors.  
If the multi-faceted intervention is optimised with improved compliance, the 
outcome will give more decisive answers on the question if asthma can be 
prevented in susceptible children by reducing environmental exposures. The 
study of Gijsbers et al. already showed how optimising an intervention results in 
increased compliance. 
We therefore do advise to perform a study aimed at prevention of asthma in 
susceptible children by using an optimised intervention on reduction of 
environmental exposures preferably in multiple countries with differing room for 
improvement. This type of research is necessary for the generalization of 
results. 
Conclusions 
1. The PREVASC trial did not result in reduction of asthma in susceptible 
children. Aside from the possibility that reducing environmental allergen 
exposure truly does not prevent asthma development, other explanations 
might be: 
a. Low levels of HDM allergen and ETS exposure (low room for 
improvement); 
b. The fact that the PREVASC intervention was aimed at implementation in 
real life and thereby was less focused on enhancing compliance. 
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2. Although the current trial did not support the results of the meta-analyses 
carried out in this thesis, asthma seems to be best prevented in high-risk 
children by intervening on multiple allergen exposures simultaneously.  
3. Post-hoc analysis of PREVASC data has indicated that asthma might be 
prevented when a child is exposed to low levels of HDM allergen exposure. 
Also breastfeeding seemed to have a preventive effect. Other exposures did 
not indicate to play any role in the development of asthma in susceptible 
children. 
4. PREVASC-data do not supply evidence for the assumption that infections in 
susceptible children can protect against the development of asthma and 
atopy. 
Recommendations 
Clinical practice 
Although the current trial did not support the results of the meta-analyses, 
asthma seems to be best prevented in high-risk children by intervening on 
multiple allergen exposures simultaneously. This would imply that health care 
professionals during pregnancy and just after birth of children at high risk of 
developing asthma need to advise parents on measures for reducing their 
child’s contact with multiple environmental exposures simultaneously in order to 
reduce the likelihood of developing asthma later in childhood. Children who 
grow up in low-allergen surroundings may be at lower risk of developing 
asthma. 
Future research 
We would call for a multi-faceted intervention study on the reduction of 
environmental exposures in which several countries with different baseline 
exposure levels co-operate. Stimulating compliance to the intervention would 
have to receive sufficient attention.  
 
Another recommendation resulting from the present thesis is to perform a study 
in which multi-faceted and mono-faceted interventions on the reduction of 
allergen exposure are randomly compared. Only when such a study has been 
carried out a more definite conclusion might be drawn concerning the 
preference of intervention types (mono-faceted or multi-faceted) in the primary 
prevention of asthma in children at risk.  
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We would propose that these research recommendations are combined in one 
and the same (large) longitudinal trial. We are aware that the factors 
complicating the performance of such a study are the large number of 
participants needed to ensure the power of the study, the follow-up duration of a 
minimum of six years to ensure the success rate of lung-function measurements 
and the concomitant costs. Because of its presumed impact on asthma care, 
however the importance of such a study is expected to counterbalance these 
complicating factors. 
 
146⏐Chapter 8 
References 
1. Schönberger HJ, Dompeling E, Knottnerus JA, Maas T, Muris JW, van Weel C, van Schayck 
CP. The PREVASC study: the clinical effect of a multifaceted educational intervention to 
prevent childhood asthma. Eur Respir J 2005;25:660-70. 
2.  Gijsbers B, Mesters I, Knottnerus JA, Legtenberg AHG, Schayck van CP. Factors influencing 
breastfeeding practices and postponement of solid food to prevent allergic disease in high-risk 
children: results from an explorative study. Patient Education and Counseling 2004. 
3.  Maas T, Rovers JJ, Schönberger HJ, Schayck CP. Distribution of house dust mite allergen: 
comparing house dust mite allergen levels in dust samples collected from different sites on 
living room floors with smooth coverings. Allergy 2003;58:500-2. 
4.  Borchers AT, Keen CL, Gershwin ME. Hope for the hygiene hypothesis: when the dirt hits the 
fan. J Asthma 2005;42:225-47. 
5. Platts-Mills TA, Erwin E, Heymann P, Woodfolk J. Is the hygiene hypothesis still a viable 
explanation for the increased prevalence of asthma? Allergy 2005;60 Suppl 79:25-31. 
6.  Schönberger H. Towards (primary) prevention of childhood asthma in primary care: Maastricht 
University, 2003. 
7.  Jenkins MA, Clarke JR, Carlin JB, Robertson CF, Hopper JL, Dalton MF, Holst DP, Choi K, 
Giles GG. Validation of questionnaire and bronchial hyper responsiveness against respiratory 
physician assessment in the diagnosis of asthma. Int J Epidemiol 1996;25:609-16. 
8.  Bruijnzeels MA, Foets M, van der Wouden JC, van den Heuvel WJ, Prins A. Everyday 
symptoms in childhood: occurrence and general practitioner consultation rates. British journal 
of general practice the journal of the Royal College of General Practitioners 1998;48:880-4. 
9.  Swanson MC, Campbell AR, Klauck MJ, Reed CE. Correlations between levels of mite and 
cat allergens in settled and airborne dust. J Allergy Clin Immunol 1989;83:776-83. 
10.  Custovic A, Simpson B, Simpson A, Hallam C, Craven M, Woodcock A. Relationship between 
mite, cat, and dog allergens in reservoir dust and ambient air. Allergy 1999;54:612-6. 
11.  Tovey ER, Mitakakis TZ, Sercombe JK, Vanlaar CH, Marks GB. Four methods of sampling for 
dust mite allergen: differences in 'dust'. Allergy 2003;58:790-4. 
12.  Marks GB, Tovey ER, Peat JK, Salome CM, Woolcock AJ. Variability and repeatability of 
house dust mite allergen measurement: implications for study design and interpretation. Clin 
Exp Allergy 1995;25:1190-7. 
13.  Hill MR. Quantification of house-dust-mite populations. Allergy 1998;53(48 Suppl):18-23. 
14.  Platts-Mills TA, Thomas WR, Aalberse RC, Vervloet D, Champman MD. Dust mite allergens 
and asthma: report of a second international workshop. J Allergy Clin Immunol 1992;89: 
1046-60. 
15.  Luczynska CM. Identification and quantification of mite allergens. Allergy 1998;53(S48):54-7. 
16.  Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der 
pI) and the development of asthma in childhood. A prospective study. N Engl J Med 
1990;323:502-7. 
 
 
  
 
 
 
 
 
Chapter 8 
 
 
 
 
Summary 
 
 
 
 
 
 
 
 
 
148⏐ 
 Summary⏐149 
Summary 
Asthma is the most common chronic disease in childhood and although it often 
can be treated successfully, asthma can have major consequences for 
children’s well-being.1-4 In developed countries a five-fold increase in the 
prevalence of asthma has been observed between 1980 and 2000. This 
tendency seems to have reversed thereafter.5 The most recently observed 
(2006) prevalence of asthma in children aged five to eight years was 
approximately 5.7 to 10.5%.6,7  
 
In the current thesis the PREVASC study on the primary prevention of asthma 
in children susceptible to the development of asthma is described. Being a 
disease that is associated with both genetic and environmental factors8, 
children, however genetically predisposed, may not develop asthma when 
environmental exposures are adequately reduced. The hypothesis studied in 
the current research is that asthma might be prevented in children with a 
genetic predisposition by educating parents about multiple measures for 
optimising their child’s exposure to environmental factors associated with 
asthma (multi-faceted intervention). The intervention used in the PREVASC 
study was based on a simultaneous reduction of exposure to environmental 
factors such as inhalant and food allergens, stimulating breastfeeding, and 
decreasing the exposure to environmental tobacco smoke. Secondary research 
questions the PREVASC study focused on were the optimal duration of the 
intervention offered (short versus extended intervention duration) and the effect 
of the environmental factors included in the PREVASC intervention on the 
outcome asthma as measured at age six. Details on the design are described in 
chapter 3. 
 
Chapter 2 describes the lack of explanation for what could have caused the rise 
in prevalence. Assuming that the prevalence may be decreased by reducing 
exposure to environmental factors, several birth cohort studies are being (or 
have been) carried out all over the world. Thirteen cohort studies and six 
randomised controlled trials focusing on the relationship between allergen 
exposure (solely or in combination with other environmental exposures) and 
asthma development in children were identified. 
Similarities and differences between designs and variable sets are described as 
basis for carrying out a meta-analysis.9 
It was concluded that randomised controlled trials are best candidates for 
inclusion in a meta-analysis. Four trials were evaluated to be particularly 
suitable because of similarities in their study designs: The Isle of Wight study, 
the Canadian Allergy and Asthma Project, the CAPS-study and the PREVASC-
project. These four all recommend multi-faceted interventions.  
150⏐ 
In chapter 3 it is described that the PREVASC study was the first study in the 
research program on prevention of asthma in children of the Maastricht 
University. The PREVASC study was also the first (and up until now the only) 
multi-faceted intervention study carried out in The Netherlands that focused on 
the primary prevention of asthma in children by intervening on allergen 
exposure.  
A total of 888 Infants were prenatally included in the research program for 
answering several research questions.10 By the time of inclusion the mothers 
were 3-7 months pregnant. Twenty-seven Infants were excluded from the study 
and 21 dropped out. Of the remaining 840 infants 532 had a first-degree familial 
predisposition of asthma (high-risk group), whereas a reference group of 308 
infants was not predisposed for asthma in the first degree (low-risk group).  
The PREVASC study was set up to evaluate the effectiveness of a prenatally 
started multi-faceted intervention on prevention of asthma. A high-risk group of 
children was included during pregnancy and they were allocated to either an 
intervention group (n=222) or a control group (n=221). The infants were 
followed from the prenatal stage until they reached the age of six years. At this 
age lung function measurements were carried out. Children were categorised in 
one of 3 lung function groups (no asthma, possible asthma, current asthma). 
This categorisation was based on lung function outcome as well as 
prospectively reported symptoms by parents and general practitioners. The 
exposure outcome the research focussed upon was determined by 
standardised measurements and questionnaires completed by parents. 
The results of this study are described in chapter 7.  
 
A meta-analysis comparing mono-faceted and multi-faceted interventions is 
presented in chapter 4. The research question posed was whether a 
simultaneous reduction of multiple exposures will lead to better asthma 
outcome than single allergen reduction in genetically predisposed children. 
Some evidence is leading to the assumption that asthma is associated with 
exposure to allergens.11, 12 Based on the theoretical consideration that asthma is 
a multi-factorial disease, it is hypothesised that prevention might only prove 
effective if most or all relevant environmental factors are simultaneously 
avoided (multi-faceted intervention).  
The effect(s) of mono-faceted and multi-faceted interventions, focussing on 
preventing asthma and asthma symptoms in children by optimising allergen 
exposure, were assessed when compared with control interventions.13 
Eligible studies were screened on relevant results for the current meta-analysis. 
Studies were included in the analyses when the primary outcome 'current 
diagnosis asthma' and/or one of the secondary outcomes 'current respiratory 
symptoms: wheezing, nocturnal cough and dyspnoea' were described. Three 
multi-faceted and six mono-faceted intervention studies that described their 
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results at various intervals met the entry criteria. These studies together 
randomised 3271 children.  
Multi-faceted and mono-faceted intervention studies were pooled separately 
and an indirect comparison of their effects was performed. 
The available evidence suggests that multi-faceted interventions characterised 
by dietary allergen reduction and environmental remediation reduce the 
likelihood of a current diagnosis of asthma at ages <5 years, whereas the 
evidence of mono-intervention studies does not indicate a statistically significant 
difference with control. The results of statistical comparison of outcome of multi-
faceted and mono-faceted interventions favoured multi-faceted intervention 
strategies (diagnosis asthma in children <5 years: Z-score -2.118). Z-test 
comparison in diagnosis of asthma in children five years and older was not 
significant between multiple and single interventions (Z-score -1.925).  
The effect of multi-faceted interventions on parent reported wheeze was 
inconsistent and no beneficial effect on nocturnal cough or dyspnoea was 
found. Mono-faceted interventions were no more effective than controls in the 
reduction of all outcomes.  
Uncertainty remains as to whether multiple interventions are more effective than 
mono-component interventions. The lack of difference between mono- and 
multi-faceted interventions on outcome diagnosis asthma at ages five years and 
older might be real, but on the other hand might have been caused by lack of 
power (too small number of studies / participants included) or by the difference 
in study outcome used in the studies compared.  
The findings warrant further direct comparison between multiple- and mono-
faceted interventions at reducing the prevalence of asthma in children. Since 
the current meta analyses are not randomised comparisons, we recommend 
that a new study which assesses both types of interventions is undertaken. 
There are no studies ongoing to our knowledge in which both intervention 
strategies are randomly compared. Such a study will be of great importance for 
shedding new light on preventing the development of asthma in genetically 
susceptible children. 
 
In chapter 5 a pilot study on the distribution of the house dust mite allergen on 
living room floors with smooth coverings is described.  
In most studies concerning measurement of exposure to house dust mite 
allergen in floor dust, the sampling procedure is standardised.12, 14 For 
measurement within living rooms at least two sites should be sampled because 
of unequal distribution.15 However, there is no consensus about the exact 
sampling locations.16 
In this study it is assumed that standardisation of sampling sites surely does 
matter as daily life activity causes displacement of dust and house dust mite 
allergen mainly from the middle towards the border of the floor.  
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As was hypothesised, house dust mite allergen levels sampled in the middle of 
the room showed to be lower than at the border and the difference was larger 
when more inhabitants or pets were present (more activity). 
It is of further interest whether allergen content of dust should be expressed as 
ng/m2 or as ng/g of dust. In research the expression of the level of house dust 
mite allergen as ng/g of dust is used most often. Although it is generally 
assumed that both types of expression can be interchanged17, our research did 
not underline this assumption. Where a statistically significant difference was 
detected between middle and border samples when expressed as ng/m2, no 
significant difference was detected when overall data were expressed as ng/g of 
dust. The lack of significance can possibly be explained by the smaller range of 
house dust mite allergen levels when expressed as ng/g of dust. We concluded 
that house dust mite allergen content expressed as ng/g of dust and ng/m2 
therefore cannot obviously be interchanged. In households where small 
amounts of dust are present, but in these small amounts the concentration of 
allergen is high (high exposure when expressed as ng/g of dust), the actual 
exposure will be low on the contrary. We therefore state that expression of 
exposure to house dust mite allergen will be better estimated when presentation 
as ng/m2 is used. This will be especially important in studies in which house 
dust mite allergen exposure is a possible determining factor. 
 
The hygiene hypothesis assumes infections in early childhood keep the 
developing immune system from becoming unbalanced and therefore from 
developing allergic diseases.18 In chapter 6 this popular hypothesis is 
evaluated by making use of data collected by parents and general practitioners 
of the 443 children included in the PREVASC-cohort.  
The number of episodes of common cold and diarrhoea associated with fever 
were the parental reported infection variables used as independent predictors. 
Outcome variables were a general practitioners’ diagnosis of asthma, asthmatic 
symptoms at age four to six and total and specific immune globulin E (IgE) at 
age six.  
The results showed that the more episodes of common cold were reported, the 
lower the total IgE level measured. Episodes of diarrhoea associated with fever 
showed to be related to a decrease of the specific IgE level for house dust mite 
allergens. As IgE is an important diagnostic factor for allergy19, the results of the 
current analyses suggest that infections might play a preventive role in the 
development of allergy. 
The analyses however showed NOT to support the hypothesis that infections 
teach the developing immune system to arm itself either against the 
development of asthma or asthma-like symptoms in children at high risk of 
developing asthma. 
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It might be possible that no relationship between asthma diagnosis or asthma 
symptoms, common cold and diarrhoea was found because the symptoms of 
these common infections as reported by the parents were not suitable 
measures for infection load. 
 
The results of the PREVASC study-intervention are described in chapter 7. The 
children that could be followed up until the age of six were invited to participate 
in lung function measurements. This accounted for 219 children in the 
intervention group (IG) and 215 children in the control group (CG). 
The intervention offered was focussed on a simultaneous optimisation of 
multiple environmental exposures such as breast feeding, food allergens, 
inhalant allergens and environmental tobacco smoke. The intervention used 
was suitable for direct implementation in general practice. 
The IG was divided into two subgroups: a short IG in which children received 
the intervention from pregnancy to 2 years of age (n=108), and an extended IG 
(n=111) in which children received the intervention up until six years of age. 
Primary outcome of the study was asthma diagnosis at age six categorised by a 
predefined algorithm (no asthma, possible asthma or current asthma). The 
categorisation was based on lung function outcome as well as health reports of 
general practitioners and parents. 
For answering the primary research question the IG as a whole was compared 
with the CG. Comparisons of the separate IG subgroups with the CG were 
carried out for answering the secondary research question on the intervention 
duration. 
A multiple logistic regression analysis was carried out to assess the influence of 
individual intervention elements on the development of asthma. 
The PREVASC study intervention resulted in a statistically significant reduction 
of exposure of the IG to food allergens at six months (p<0.001) and inhalant 
allergens at age four (Der p1 p=0.012, Fel d1 p=0.037, Can f1 p=0.043) but no 
differences were observed where the exposure to pet (p=0.111) and 
environmental tobacco smoke (p=0.786) were evaluated at six years of age. 
Although the exposure outcome showed to be significantly reduced in the IG, 
the clinical outcome was not shown to be statistically different between groups. 
Neither the IG as a whole (0.645), nor the separate IGs (p=0.491, p=0.853) 
showed to have different clinical outcome as compared to the CG.  
Therefore it was concluded that the PREVASC intervention was not effective in 
reducing the development of asthma in children at risk and it was not possible 
to define optimal intervention duration. The room for improvement for reducing 
the exposure to house dust mite allergen and exposure to environmental 
tobacco smoke was limited, as the baseline exposure to these factors showed 
to be very low. Aside from these observations lack of compliance might have 
played a part in the absence of clinical effectiveness, especially for the 
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breastfeeding promoting intervention and the house dust mite allergen reducing 
intervention.  
The analysis on the influence of the individual intervention elements (secondary 
research question 2) revealed that breastfeeding and house dust mite allergen 
exposure were of particular importance in the PREVASC intervention. These 
particular parts of the intervention however showed not to have resulted in a 
desirable exposure outcome. 
The only two comparable studies were carried out in Canada and the United 
Kingdom and seemed to support the hypothesis that multi-faceted allergen 
reduction might prevent the development of asthma in susceptible children. The 
discrepancy between these studies and the present study might be explained 
by the low number of families complying with our recommendations. Possibly 
the results of our intervention would have been more successful when we would 
have put more effort in stimulating compliance with the use of the house dust 
mite impermeable encasings and the promotion of breastfeeding. 
 
A general discussion of the present thesis is provided in chapter 8. In this 
chapter the results of the PREVASC-study, the methodological considerations, 
added value of the current thesis, conclusions and recommendations for clinical 
practice and further research are described.  
What could be concluded from the current thesis? 
1. The PREVASC trial did not result in reduction of asthma in susceptible 
children. Aside from the possibility that reducing environmental allergen 
exposure truly does not prevent asthma development, other explanations 
might be: 
a. Low levels of house dust mite allergen and environmental tobacco 
smoke exposure (low room for improvement); 
b. The fact that the PREVASC intervention was aimed at implementation 
in real life and thereby was less focused on enhancing compliance. 
2. Although the current trial did not support the results of the meta-analyses 
carried out in this thesis, asthma seems to be best prevented in high-risk 
children by intervening on multiple allergen exposures simultaneously.  
3. Post-hoc analysis of PREVASC data has indicated that asthma might be 
prevented when a child is exposed to low levels of house dust mite 
allergen exposure. Also breastfeeding seemed to have a preventive effect. 
Other exposures did not indicate to play any role in the development of 
asthma in susceptible children. 
4. PREVASC-data do not supply evidence for the assumption that infections 
in susceptible children can protect against the development of asthma and 
atopy.  
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What this research adds? 
The current trial will not change the guidelines on primary prevention of asthma 
in susceptible children. What the PREVASC trial has taught us is that the trial 
intervention cannot be recommended for use in general practice in the 
Netherlands. Country specific circumstances (e.g. low house dust mite allergen 
exposure levels in the Netherlands) as well as the fact that our intervention was 
aimed at implementation in real life and thereby less focused on enhancing 
compliance might have played a role in the lack of clinical effectiveness. This 
resulted in insufficient reduction of exposure to environmental factors.  
If the multi-faceted intervention is optimised with improved compliance, the 
outcome will give more decisive answers on the question if asthma can be 
prevented in susceptible children by reducing environmental exposures. The 
study of Gijsbers et al. already showed how optimising an intervention results in 
increased compliance. 
We therefore do advise to perform a study aimed at prevention of asthma in 
susceptible children by using an optimised intervention on reduction of 
environmental exposures preferably in multiple countries with differing room for 
improvement. This type of research is necessary for the generalisation of 
results. 
Recommendations for clinical practice 
Although the current trial did not support the results of the meta-analyses, 
asthma seems to be best prevented in high-risk children by intervening on 
multiple allergen exposures simultaneously. We therefore recommend for 
primary care providers to advice parents of children susceptible to develop 
asthma to create an overall low allergen environment for their children. 
 
Recommendations for future research 
A large longitudinal study might be set up in which the following research 
question will be answered: 
9 Is a multi-faceted allergen reducing intervention on primary prevention of 
asthma in susceptible children more effective than its mono-faceted 
counterpart? 
Performing a multi-faceted intervention as well as several mono-faceted 
interventions on the reduction of (food and inhalant) allergen exposures  in 
which several countries with different baseline exposure levels co-operate is 
recommended. Stimulating compliance to the interventions used would have to 
receive enough attention. 
In a study like this, multi-faceted and mono-faceted interventions on the 
reduction of allergen exposure should be randomly compared. Only when such 
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a study has been carried out more definite conclusions can be drawn 
concerning the possibility and/or preference of intervention types (mono-faceted 
or multi-faceted) in the primary prevention of asthma in children at risk.  
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Samenvatting 
Algemene inleiding 
Astma is de meest voorkomende chronische ziekte bij kinderen en hoewel 
astma over het algemeen succesvol behandeld kan worden, is er met name bij 
kinderen voldoende reden om er alles aan te doen astma te voorkomen. Het 
belang van preventie van astma is groot aangezien de gevolgen van astma 
voor een kind vaak erg beangstigend zijn.1-3 Astma heeft bij kinderen dan ook 
grote consequenties voor de ervaren kwaliteit van leven.4  
Het voorkomen van astma in westerse landen is enorm gestegen in de periode 
van 1980 tot 2000 maar lijkt te zijn gedaald in de periode na 2000.5 De laatste 
metingen van de gegevens betreffende het voorkomen van astma in 
ontwikkelde landen werden in 2006 gedaan in Scandinavië. In deze 
onderzoeken werd aangetoond dat het aantal patiënten met astma in de leeftijd 
van vijf tot acht jaar rond de 5.7 tot 10.5% lag.6, 7 
 
In dit proefschrift wordt de PREVASK studie beschreven, een onderzoek naar 
de preventie van astma bij kinderen met een verhoogde kans deze ziekte te 
ontwikkelen. Het ontstaan van astma wordt geassocieerd met zowel erfelijke 
factoren als omgevingsfactoren8, en aangenomen wordt dat kinderen met een 
erfelijke aanleg astma te ontwikkelen mogelijk geen astma zullen krijgen als 
omgevingsfactoren worden geoptimaliseerd. Dit laatste heeft geleid tot de 
hypothese van het PREVASK onderzoek: Astma kan voorkomen worden bij 
familiaal belaste kinderen door de ouders voor te lichten over manieren waarop 
ze de blootstelling van hun kind aan meerdere omgevingsfactoren simultaan 
kunnen optimaliseren. De interventie die gehanteerd werd in het PREVASK 
onderzoek is gebaseerd op de vermindering van de blootstelling aan 
omgevingsfactoren als inhalatieallergenen, voedingsallergenen en 
sigarettenrook evenals het stimuleren van het geven van borstvoeding 
(meervoudige interventie). Secundaire onderzoeksvragen van het PREVASK 
onderzoek waren gericht op de optimale duur van de interventie (kortdurende of 
uitgebreide interventie) en de mate van invloed van elk van de 
omgevingsfactoren waarop geïntervenieerd werd, op de uitkomstmaat astma. 
Details van het design van het PREVASK onderzoek zijn beschreven in 
hoofdstuk 3. 
Geboortecohort studies naar de preventie van astma bij kinderen 
In hoofdstuk 2 wordt beschreven dat de oorzaak van de stijging van de 
prevalentie van het aantal astma gevallen niet duidelijk is. Er vanuit gaande dat 
de blootstelling aan allergenen een belangrijke rol spelen zijn verschillende 
geboortecohort studies opgezet (of zijn reeds afgerond) over de hele wereld. 
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Dertien cohort studies en zes gerandomiseerd gecontroleerde trials gericht op 
de relatie tussen de blootstelling aan allergenen (enkelvoudig of in combinatie 
met andere blootstellingen) en de ontwikkeling van astma werden 
geïdentificeerd. 
Overeenkomsten en verschillen tussen de designs en sets van variabelen 
werden beschreven als voorbereiding op het uitvoeren van een zogenoemde 
meta-analyse.9 In een meta-analyse worden de resultaten van verschillende 
onderzoeken samengevoegd waardoor de onderzoekspopulatie groter wordt en 
de uitkomsten meer kracht krijgen. 
Conclusie was dat gerandomiseerd gecontroleerde onderzoeken (Isle of Wight 
studie, Canadese allergie en astma bij kinderen studie, CAPS studie en de 
PREVASK studie) de beste kandidaten zijn voor opname in een meta-analyse. 
Deze onderzoeken maken namelijk alle drie gebruik van een meervoudige 
interventie.  
Onderzoeksprogramma naar preventie van astma bij kinderen 
In hoofdstuk 3 is beschreven dat de PREVASK studie de eerste studie is 
binnen het onderzoeksprogramma naar de preventie van astma bij kinderen, 
dat wordt uitgevoerd door onderzoekers van de Universiteit Maastricht. Deze 
studie is tevens de eerste (en tot nu toe de enige) Nederlandse meervoudige 
interventie studie gericht op de primaire preventie van astma bij kinderen 
waarbij wordt ingegrepen in de blootstelling aan omgevingsfactoren. 
In het volledige onderzoeksprogramma werden in totaal 888 kinderen prenataal 
ingesloten om de verschillende onderzoeksvragen te beantwoorden.10 Op het 
moment van insluiting waren de moeders 3-7 maanden zwanger. 
Zevenentwintig kinderen werden uitgesloten en 21 vielen uit op enig moment na 
insluiting. De gegevens van 840 kinderen konden worden gebruikt voor 
beantwoording van de onderzoeksvragen. Van deze kinderen was de grootste 
groep erfelijk belast voor het ontwikkelen van astma op enig moment in hun 
leven (532 kinderen, hoogrisico groep). Een groep van 308 kinderen had een 
laag risico om astma te ontwikkelen. 
De PREVASK studie is opgezet voor de evaluatie van de effectiviteit van een 
prenataal gestarte meervoudige interventie. Kinderen met een verhoogd risico 
om astma te ontwikkelen op grond van voorkomen van astma in het gezin 
werden gevolgd vanaf de zwangerschap. Deze kinderen werden op grond van 
toeval ingedeeld in een interventiegroep (IG 222 kinderen) waaraan een 
meervoudige interventie werd aangeboden, of een controlegroep (CG 221 
kinderen) waarin de reguliere zorg tijdens zwangerschap en kinderleeftijd werd 
gehanteerd. Deelnemende kinderen werden gevolgd totdat zij de leeftijd van 
zes jaar bereikten. Op deze leeftijd kregen ze een longfunctiemeting en werden 
ze ingedeeld in een van de drie astmagroepen (geen astma, mogelijk astma, 
zeker astma). Deze categorisering werd gebaseerd op de uitkomst van de 
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longfunctiemeting en symptomen die prospectief longitudinaal gerapporteerd 
werden door ouders en huisartsen. De uitkomsten van de blootstelling aan de 
omgevingsfactoren waarop het onderzoek zich richtte werden met behulp van 
gestandaardiseerde metingen geobjectiveerd en gerelateerde factoren (gedrag) 
werden gerapporteerd door de ouders in vragenlijsten. 
De resultaten van deze studie zijn beschreven in hoofdstuk 7. 
 
Meta-analyse 
Hoofdstuk 4 beschrijft een meta-analyse uitgevoerd met als doel te 
verduidelijken of astma, een ziekte die wordt veroorzaakt door zowel erfelijke- 
als omgevingsfactoren8, voorkomen kan worden door een enkelvoudige 
allergeen reducerende interventie aan te bieden aan kinderen met een hoog 
risico op het ontwikkelen van astma. Er zijn duidelijke aanwijzingen dat 
prikkelende stoffen (allergenen) geassocieerd zijn met het ontstaan van 
astma.11,12 Onderzocht is in de huidige studie of meervoudige interventies, 
interventies gericht op simultane optimalisering van meerdere prikkelende 
factoren, vaker leiden tot een preventief effect. 
Om deze aanname te toetsen werden de samengevoegde resultaten van 
enkelvoudige interventiestudies en meervoudige interventiestudies statistisch 
getoetst.13 De studies waren allen gericht op optimalisering van blootstelling 
aan allergenen ter voorkoming van astma en astmasymptomen bij kinderen met 
een verhoogd risico op het ontwikkelen van astma.  
Om in aanmerking te komen voor opname in deze meta-analyse moesten 
studies minimaal het eindpunt astma getoetst hebben bij kinderen met een 
verhoogd risico op het ontstaan van astma. Indien gerapporteerd, werden ook 
gegevens met betrekking tot astma symptomen geëvalueerd (piepen, nachtelijk 
hoesten, kortademigheid). Drie meervoudige interventie studies, gericht op 
optimalisering van blootstelling aan meerdere factoren (voedings- en 
inhalatieallergenen), en zes enkelvoudige interventiestudies (reductie van 
blootstelling aan een enkel allergeen), voldeden aan de criteria. Deze studies 
hadden gezamenlijk 3271 deelnemers.  
Studies van de beide interventietypen werden groepsgewijs geanalyseerd. 
Vervolgens werd een statistische vergelijking gemaakt van de gepoolde 
resultaten van primaire preventie studies die gebruik maakten van een 
meervoudige of een enkelvoudige interventie. 
Meervoudige interventies verminderden de kans op het ontstaan van astma bij 
kinderen in de leeftijd van twee tot vijf jaar significant succesvoller. Effecten van 
meervoudige interventies op de diagnose astma in de leeftijd van vijf jaar en 
ouder bleken echter niet significant te verschillen van de effecten van 
enkelvoudige interventies. Deze uitkomst zou correct kunnen zijn maar het is 
niet onwaarschijnlijk dat de afwezigheid van significantie veroorzaakt is doordat 
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er te weinig studies (n=2 per interventietype) en/of een te klein aantal 
proefpersonen konden worden vergeleken. Daarnaast werden er in de beide 
typen interventiestudies verschillende manieren van diagnosestelling 
gehanteerd die de vergelijking bemoeilijkten. 
De effecten van meervoudige interventiestudies op de preventie van piepen 
waren niet consistent en deze interventies bleken niet effectief in het 
voorkomen van nachtelijk hoesten of kortademigheid. Enkelvoudige interventies 
bleken in geen geval effectiever dan usual care. Geconcludeerd werd dat er 
geen statistisch significant verschil kon worden aangetoond tussen de 
resultaten van beide groepen interventies met betrekking tot het voorkomen van 
astma symptomen.  
Hoewel meervoudige interventies effectiever leken dan enkelvoudige 
interventies bij de preventie van astma blijft er onzekerheid over deze uitkomst. 
De analyses die gedaan zijn in het huidige proefschrift waren indirect van aard, 
wat betekent dat beide interventietypen niet in één en hetzelfde onderzoek 
werden uitgevoerd. Gevolg hiervan zijn mogelijke verschillen in 
basisblootstelling, insluitcriteria en uitkomstparameters. De resultaten van de 
uitgevoerde meta-analyse zijn echter een duidelijke indicatie dat meervoudige 
interventies bij astmapreventie mogelijk effectiever zijn dan enkelvoudige 
interventies. Een krachtiger uitspraak zou gedaan kunnen worden wanneer een 
nieuw onderzoek opgezet wordt waarin beide interventietypen worden 
opgenomen. Een onderzoek waarin de effecten van een meervoudige 
interventie én enkelvoudige interventies gericht op allergeenreductie 
gerandomiseerd worden vergeleken, is tot op heden niet uitgevoerd. Dergelijk 
onderzoek zou naar ons inzicht van groot belang zijn om duidelijkheid te krijgen 
over de beste manier om astma en astmasymptomen te voorkómen door de 
blootstelling aan allergenen te optimaliseren bij kinderen met een verhoogd 
risico.  
Verspreiding van huisstofmijt allergeen over gladde vloeren 
Eén van de omgevingsfactoren die verband lijkt te houden met het ontstaan van 
astma is de blootstelling aan huisstofmijtallergeen. Hoofdstuk 5 behandelt de 
studie waarin de verspreiding van huisstofmijtallergeen in woonkamers met 
gladde vloeren onderzocht werd. Bij de meeste studies waarin de blootstelling 
aan huisstofmijtallergeen in vloerstof wordt gemeten, is de methode van meting 
gestandaardiseerd.14, 15 Daarbij valt echter op dat er geen uniformiteit is in de 
plaatsen waar de metingen verricht worden.16 Wel is bekend dat de spreiding 
van huisstofmijtallergeen niet gelijkmatig verdeeld is over de vloer en dat 
daarom minimaal twee plekken op de vloer gemonsterd zouden moeten 
worden.17 
Aangenomen werd dat de huisstofmijtallergenen voornamelijk van het midden 
naar de rand van de kamer worden verplaatst door activiteit in de woonkamer. 
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Om deze aanname te toetsen werden er stofmonsters genomen in woonkamers 
met gladde vloeren op locaties in het midden en de zijkant van de kamer. Uit de 
stofmonsters die afgenomen werden bleek inderdaad dat de hoeveelheden 
huisstofmijtallergeen lager waren in het midden van de woonkamer ten opzichte 
van de hoeveelheden aanwezig aan de randen. Daarnaast bleek dat 
verplaatsing van de hoeveelheden huisstofmijtallergeen meer voorkwam in 
huishoudens waarin meerdere huisgenoten of huisdieren aanwezig waren 
(meer activiteit). 
Naast deze waarneming is het interessant te bediscussiëren of de 
hoeveelheden huisstofmijtallergeen beter uitgedrukt zouden kunnen worden in 
ng/m2 of als ng/g stof. Over het algemeen wordt bepleit dat beide manieren van 
uitdrukken vergelijkbaar zouden zijn.18 Echter, in dit onderzoek werd wel een 
statistisch significant verschil gevonden tussen stofmonsters genomen in het 
midden en monsters genomen aan de rand van de woonkamer wanneer de 
uitslagen werden uitgedrukt in ng/m2. Er bleek geen verschil te zijn tussen de 
verschillende locaties van meting wanneer de uitkomsten uitgedrukt werden in 
ng/g stof.  
Een mogelijke verklaring voor deze waarneming kan zijn dat de variatie in 
huisstofmijtallergeen hoeveelheden kleiner is wanneer deze zijn uitgedrukt als 
ng/g stof. Hoewel in wetenschappelijk onderzoek meestal de uitdrukking als 
ng/g stof wordt gehanteerd zijn wij van mening dat deze allergeen 
hoeveelheden - in onderzoek waarin dit allergeen een belangrijke voorspellende 
waarde wordt toegedicht - beter uitgedrukt kunnen worden als ng/m2. In 
woonkamers waarin weinig stof ligt, kan per gram stof namelijk wel een hoge 
concentratie allergeen aanwezig zijn, terwijl in dit geval de blootstelling in 
werkelijkheid laag blijft. Wanneer uitgedrukt in ng/g stof zou kunnen worden 
gesuggereerd dat er een hoge concentratie werd gemeten. 
Preventief effect van infecties op jonge leeftijd 
De hygiëne hypothese is een zeer populaire theorie dat infecties die voorkomen 
tijdens het jonge leven van kinderen het nog in ontwikkeling zijnde 
immuunsysteem beschermen tegen het ontstaan van allergie en astma.19 In 
hoofdstuk 6 wordt deze hypothese geëvalueerd door gebruik te maken van data 
die verzameld zijn door de ouders en huisartsen van de kinderen die 
deelnamen aan het PREVASK onderzoek. 
Het aantal episodes van verkoudheid en diarree geassocieerd met koorts, 
waren de infectievariabelen die gebruikt werden. De uitkomstvariabelen waren 
de door de huisartsen gerapporteerde diagnose astma en astma symptomen in 
de leeftijd van vier tot zes jaar en het totaal en specifiek Immuunglobuline E 
(IgE) op zes jarige leeftijd. IgE is een belangrijke factor die gebruikt wordt bij de 
diagnostiek van allergie.20  
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Uit de analyses bleek dat hoe meer episodes van verkoudheid werden 
gerapporteerd door de ouders, hoe lager het IgE niveau was dat werd gemeten 
in het bloed van de kinderen. Episodes van diarree met koorts bleken ditzelfde 
effect te hebben op het specifiek IgE gericht op huisstofmijt allergenen. 
Conclusies die we konden trekken uit de uitgevoerde analyses zijn dat infecties 
het ontstaan van allergie mogelijk voorkomen maar dat een dergelijk preventief 
effect NIET geobserveerd werd als het gaat om het ontstaan van astma of 
astma symptomen bij kinderen met een hoog risico hierop. 
Mogelijk is het uitblijven van een preventief effect van infecties op astma en 
astma symptomen in dit onderzoek er het gevolg van dat we de gerapporteerde 
en niet de objectief vastgestelde infecties hebben gebruikt in de analyses. Het 
is daarnaast ook mogelijk dat er te weinig waarnemingen waren waarop de 
conclusies gebaseerd konden worden (power probleem). 
Resultaten van de PREVASK interventie 
De resultaten van de PREVASK interventie zijn beschreven in hoofdstuk 7. De 
aanname dat astma voorkomen zou kunnen worden bij familiaal belaste 
kinderen door meerdere omgevingsfactoren simultaan te optimaliseren werd 
getoetst. 
Naast de effectiviteit van de interventie op de mate van blootstelling aan de 
omgevingsfactoren waarop de interventie zich richtte, werd de klinische 
effectiviteit zoals gemeten op vier en zesjarige leeftijd beschreven 
(hoofdvraagstelling). 
Resultaten van de secundaire onderzoeksvraagstellingen gericht op 1) de 
optimale interventieduur en 2) de invloed van de individuele omgevingsfactoren 
waarop de interventie was gericht (borstvoeding, voedingsallergenen, 
inhalatieallergenen, sigarettenrook) werden eveneens vermeld. 
De interventie die aangeboden werd was gericht op de simultane optimalisering 
van de blootstelling aan de omgevingsfactoren borstvoeding, 
voedselallergenen, inhalatieallergenen en passief roken. De interventie was zo 
opgezet dat deze direct geïmplementeerd zou kunnen worden in de 
huisartspraktijk. 
Tot hun tweede levensjaar kregen alle kinderen in de interventiegroep (IG) 
dezelfde interventie aangeboden en vanaf dat moment werd een splitsing 
gemaakt, wederom op grond van het lot, in een lange IG en een korte IG. Aan 
gezinnen in de korte IG (n=108) werden vanaf twee jaar geen maatregelen 
meer geadviseerd die de blootstelling aan de omgevingsfactoren zouden 
optimaliseren. De gezinnen in de lange IG (n=111) daarentegen kregen nog 
steeds adviezen over de optimalisering van de blootstellingen waarop het 
onderzoek zich richtte. Aan gezinnen in de controlegroep (CG) werd de 
reguliere zorg aangeboden. 
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Die kinderen die bleven deelnemen tot hun zesde levensjaar werden 
uitgenodigd om longfunctiemetingen te laten verrichten (mede) op grond 
waarvan kon worden vastgesteld of ze astma hadden ontwikkeld of niet. Het 
aantal kinderen, dat deelnam tot hun zesde levensjaar was 219 in de IG and 
215 in de CG (>90% van de initieel ingesloten kinderen). 
De primaire uitkomstmaat was de diagnose astma zoals gemeten op zes jarige 
leeftijd. Nadat de longfunctiemetingen uitgevoerd waren, werden de kinderen 
gecategoriseerd in een van de drie astmagroepen (geen astma, mogelijk astma, 
zeker astma) door een vooraf opgesteld algoritme. De categorisering vond 
plaats op grond van de longfunctie-uitslagen, prospectief geregistreerde 
gezondheidsgegevens gerapporteerd door de huisartsen en door de ouders 
(gezondheidsvragenlijsten). 
De groepen die op grond van hun astmastatus werden vergeleken voor 
beantwoording van de hoofdvraagstelling waren de IG in zijn totaliteit en de CG. 
Daarnaast werd de CG vergeleken met de beide afzonderlijke 
interventiegroepen voor beantwoording van de secundaire vraagstelling over de 
optimale interventieduur. 
Een logistische regressie analyse werd uitgevoerd voor beantwoording van de 
secundaire vraagstelling over de invloed van de afzonderlijke 
omgevingsfactoren die onderdeel waren van de inteventie, op de ontwikkeling 
van astma zoals gemeten op zes jarige leeftijd. 
De resultaten van het PREVASK onderzoek toonden aan dat de interventie, in 
vergelijking tot de CG gegevens, succesvol was in het reduceren van de 
blootstelling aan voedselallergenen en inhalatieallergenen. De interventie 
gericht op vermindering van de blootstelling aan huisdieren en sigarettenrook 
was niet effectief.  
Hoewel de blootstelling voor een belangrijk deel effectief was gebleken, werden 
er geen statistisch significante verschillen waargenomen op grond van de 
uitkomstmaat astma bij vergelijking van de studiegroepen (IGtotaal versus CG, 
IGkort versus CG, IGlang versus CG). 
We hebben dan ook moeten concluderen dat de interventie niet effectief was in 
het reduceren van de ontwikkeling van astma bij kinderen die hierop vanwege 
hun familiale achtergrond een hoger risico hadden. De interventie werd niet in 
voldoende mate gevolgd door de ouders waardoor de vraagstelling betreffende 
de optimale interventieduur niet beantwoord kon worden. 
De blootstelling aan huisstofmijtallergeen en sigarettenrook bleken reeds bij 
start van het onderzoek erg laag te zijn. Hierdoor was de ruimte voor 
verbetering voor deze interventie onderdelen klein / onvoldoende. Behalve deze 
waarneming bleek er ook sprake te zijn van onvoldoende therapietrouw bij het 
uitvoeren van de borstvoedingstimulerende interventie en de huisstofmijt 
allergeen reducerende interventie.  
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De resultaten van de vraagstelling gericht op de effectiviteit van de individuele 
interventie elementen (secundaire vraagstelling 2) lieten zien dat juist deze 
factoren van belang waren in de preventie van astma bij kinderen met een 
verhoogd risico om astma te ontwikkelen.  
In Engeland en Canada zijn vergelijkbare studies uitgevoerd die de hypothese 
dat meervoudige interventies gericht op optimalisering van omgevingsfactoren 
de ontwikkeling van astma zou voorkomen WEL onderschrijven. Mogelijk heeft 
het gebrek aan voldoende ruimte voor verbetering van de huisstofmijt allergeen 
blootstelling en de afwezigheid van voldoende therapietrouw met de 
borstvoedings- en hoezenadviezen geleid tot het verschil in uitslag tussen de 
PREVASK studie en de overige meervoudige interventiestudies. Mogelijk 
zouden de resultaten van de PREVASK interventie de hypothese wél hebben 
kunnen bewijzen als er meer aandacht was gegeven aan het stimuleren van de 
interventietrouw / therapietrouw. 
Slotbeschouwing 
Een slotbeschouwing betreffende de onderwerpen opgenomen in het huidige 
proefschrift is beschreven in hoofdstuk 8. In dit hoofdstuk worden de resultaten 
van de PREVASK-studie beschreven. Er wordt een kritische blik geworpen op 
de methodologie en de toegevoegde waarde van het huidige proefschrift en ook 
de conclusies en aanbevelingen voor de huisartspraktijk en verder onderzoek 
krijgen aandacht. 
Wat kan er geconcludeerd worden uit het onderzoek gepresenteerd in het 
huidige proefschrift? 
1. Het PREVASK onderzoek heeft niet geresulteerd in de preventie van astma 
bij familiaal belaste kinderen. Dit resultaat zou kunnen betekenen dat astma 
niet voorkomen kan worden door het optimaliseren van omgevingsfactoren. 
Gezien de positieve resultaten van vergelijkbare onderzoeken bestaat ook de 
mogelijkheid dat onderstaande factoren een belangrijke rol hebben gespeeld 
bij het uitblijven van een preventief effect: 
a. Gebrek aan voldoende ruimte voor verbetering van de niveaus van 
blootstelling aan huisstofmijtallergeen en sigarettenrook; 
b. Het feit dat de PREVASK-interventie vooral gericht was op implementatie in 
de dagelijkse huisartspraktijk en niet voldoende gericht was op bevordering 
van trouw aan de interventiemaatregelen. 
2. Hoewel het PREVASK onderzoek de resultaten van de uitgevoerde meta-
analyse die wordt beschreven in het huidige proefschrift niet bevestigt, lijkt 
astma het beste voorkomen te kunnen worden bij hoogrisico kinderen door de 
blootstelling aan verschillende allergenen gelijktijdig te reduceren. 
3. Posthoc analyses van de PREVASK gegevens hebben duidelijk gemaakt dat 
astma voorkomen kan worden door de blootstelling aan huisstofmijtallergeen 
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te reduceren en ook borstvoeding bleek een preventief effect te hebben op de 
ontwikkeling van astma bij familiaal belaste kinderen. 
4. PREVASK gegevens leiden niet tot bewijs voor de aanname dat infecties bij 
familiaal belaste kinderen het ontstaan van astma zouden kunnen 
voorkomen. 
Wat voegt dit onderzoek toe? 
Het PREVASK onderzoek draagt niet bij aan enige verandering van richtlijnen 
aangaande de primaire preventie van astma bij hoogrisico kinderen. Wat de 
PREVASK studie ons heeft geleerd is dat de gebruikte onderzoeksinterventie 
niet kan worden aanbevolen voor gebruik in de huisartspraktijk in Nederland ter 
voorkoming van astma bij kinderen. 
Het is aannemelijk dat omstandigheden specifiek voor de Nederlandse situatie 
(met name de lage blootstelling aan huisstofmijt allergeen) een rol hebben 
gespeeld in het gebrek aan effectiviteit van de interventie. De 
onderzoeksinterventie was gericht op implementatie in de reguliere 
huisartspraktijk en daardoor minder gericht op het bevorderen van de 
therapietrouw. Dit kan een rol hebben gespeeld in het gebrek aan klinische 
effectiviteit. Dit alles heeft mogelijk geleid tot een te lage reductie van 
blootstelling aan omgevingsfactoren. 
De studie uitgevoerd door Gijsbers en collega’s heeft reeds aangetoond hoe 
een geoptimaliseerde interventie resulteert in een verhoogde therapietrouw. Om 
deze reden adviseren wij om de PREVASK studie-interventie te optimaliseren 
ter bevordering van de therapietrouw waarin bij voorkeur meerdere landen met 
een verschillende blootstelling, en dus verschillende ruimte voor verbetering 
aan de te onderzoeken omgevingsfactoren, samenwerken. Dit type onderzoek 
is van groot belang voor de generaliseerbaarheid van de resultaten van het 
preventieve astmaonderzoek. 
Aanbevelingen voor de klinische praktijk 
Hoewel de PREVASK studie de resultaten van de in dit proefschrift uitgevoerde 
meta-analyse niet onderschrijft, lijkt het aannemelijk dat astma het beste 
voorkomen kan worden door gebruik te maken van een meervoudige interventie 
waarbij allergeenblootstellingen simultaan gereduceerd worden. Kinderen die 
opgroeien in een omgeving waarin zij blootgesteld worden aan lage 
allergeenwaarden lijken een kleiner risico te lopen astma te ontwikkelen. 
Aanbevelingen voor toekomstig onderzoek 
Een grote langlopende studie waarin de onderstaande onderzoeksvraag wordt 
beantwoord wordt aanbevolen: 
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9 Heeft een meervoudige allergeenreducerende interventie inderdaad, zoals 
de meta-analyse impliceert, de voorkeur boven een enkelvoudige 
allergeenreducerende interventie ter voorkoming van astma bij kinderen 
met een verhoogd risico astma te ontwikkelen? 
Aanbevolen wordt een onderzoek uit te voeren waarin zowel een meervoudige 
interventie als ook verschillende enkelvoudige interventies gericht op 
vermindering van blootstelling aan allergenen worden uitgevoerd. Van groot 
belang is dat aan een dergelijke studie meerdere landen met verschillende 
allergeen basisniveaus bijdragen zodat er voldoende ruimte voor verbetering is. 
Het stimuleren van de therapietrouw dient bij beide interventietypen evenveel 
aandacht te krijgen. Alleen op deze manier zullen de verschillende 
interventietypen gerandomiseerd vergeleken kunnen worden en zal een 
duidelijke uitspraak gedaan kunnen worden over de mogelijkheid en/of een 
eventuele voorkeur voor een meervoudige- of enkelvoudige allergeen-
reducerende interventie ter voorkoming van astma bij familiaal belaste kinderen.  
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Dankwoord 
Waar het begon 
Mijn loopbaan bij PREVASC startte doordat ik Ilse van Beerendonk, een 
bekende uit mijn jeugd, tegenkwam in de universiteit waar ik op dat moment 
studeerde. Ze werkte bij PREVASC als onderzoeksassistente en tipte me dat 
ze op zoek waren naar een verpleegkundige met consultatiebureau ervaring. Ik 
solliciteerde en werd aangenomen als preventieverpleegkundige. De 
aanstellingen bij het onderzoek volgden elkaar vervolgens naadloos op via 
onderzoeksassistente tot onderzoeker. En nu sta ik hier! Ilse bedankt voor je 
bijdrage aan die eerste stap. We hebben een leuke tijd gehad samen, toch een 
beetje dat gevoel van oude jongens (ahum meisjes) krentenbrood……………… 
Kring van wijzen 
Het PREVASC onderzoek werd geleid door Professor Onno van Schayck en 
Professor André Knottnerus. Huub Schönberger was de onderzoeker van het 
eerste deel van het project (zwangerschap tot twee jarige leeftijd).  
Onno, ik heb je positivistische instelling en geloof in mogelijkheden zeer 
gewaardeerd. Jou wil ik bedanken omdat ik zonder jou waarschijnlijk niet zou 
zijn gekomen waar ik nu sta. André, ik heb je als een hele prettige, uitermate 
slimme en menselijke begeleider ervaren. Mijn grote dank hiervoor. Huub, je 
was samen met de bovengenoemde professoren de grondlegger van 
PREVASC. Bedankt voor het leggen van de bodem voor het onderzoek. 
Leden van de projectgroep van het onderzoek waren mijn co-promotoren 
kinderlongarts Edward Dompeling en longarts Geertjan Wesseling en daarnaast 
maakte huisarts Jean Muris deel uit van de groep van begeleiders. Edward, jou 
heb ik ervaren als een zeer menselijke begeleider. Dank je voor je 
deskundigheid, betrokkenheid en oog voor de mens achter de promovendus. 
Geertjan, jij werd pas in een laat stadium opgenomen in de projectgroep. Met 
name bij de eindmeting heb je een belangrijke rol gespeeld. Dank je dat je deze 
cruciale fase samen met Edward en Jean zo goed hebt begeleid. Jean, alleen 
een huisarts was voldoende toegerust om het eerstelijns karakter van het 
onderzoek te waarborgen. 
Het onderzoek werd op afstand begeleid door de begeleidingscommissie. 
Tijdens onze vergaderingen in Utrecht werden waardevolle en vooral ook 
bruikbare opmerkingen gemaakt. Zeer veel dank hiervoor. 
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De hoofdrolspelers binnen het onderzoek 
Uiteraard wil ik de deelnemers van het PREVASC onderzoek bedanken. Ruim 
400 gezinnen hebben met veel inzet meegewerkt aan deze studie vanaf de 
zwangerschap totdat hun kind zes jaar was. Er zijn weinig langlopende 
onderzoeken die zo’n betrokken deelnemersgroep hebben als de PREVASC-
deelnemers voor ons zijn geweest. Een uitvalspercentage van minder dan 5% 
van start tot einde (6,5 jaar per gezin) is uniek! 
De deelnemers werden veelal met de hulp van hun huisarts geïncludeerd in het 
onderzoek (ruim 250 huisartspraktijken werkten mee!). Bedankt voor de hulp bij 
de inclusie en het aanleveren van de prospectief gestandaardiseerde gegevens 
die van grote waarde waren bij zowel secundaire als primaire outcome. De 
academische huisartsengroepen verbonden aan de universiteiten van 
Maastricht (RNH) en Nijmegen (NMP) wil ik hierbij speciaal noemen. 
PREVASC meer dan een onderzoek alleen 
PREVASC was niet alleen de naam van het onderzoek dat ik uitvoerde. 
PREVASC is tevens de naam van de onderzoekslijn naar preventie van astma 
bij kinderen waarin naast het in dit proefschrift beschreven onderzoek ook een 
aantal gelieerde projecten zijn opgenomen. De onderzoekers Lisette van den 
Bemt en Annemiek Nijholt van het at Risk onderzoek, Barbara Gijsbers van 
FOCUS en Sandra Kuiper van het RAKKER project met hun assistentes Mayke 
Jilderda, Anita Legtenberg en Kitty van der Meer waren mijn collega’s binnen de 
PREVASC onderzoekslijn. We hebben indien van toepassing de onderzoeken 
op elkaar afgestemd wat onze samenwerking tot een zeer vruchtbare heeft 
gemaakt! Karin Manders was mijn eerste ‘maatje’ binnen PREVASC. Karin, met 
jou heb ik ook ontzettend graag samengewerkt. Je legde eenzelfde traject 
binnen PREVASC af als ik van verpleegkundige naar onderzoeker. Ook jou wil 
ik bedanken voor je gezelschap, collegialiteit en vooral ook vriendschappelijke 
contact.  
Omdat (uitkomstmaat) astma pas op 6-jarige leeftijd objectief gemeten kan 
worden zijn we verder gegaan met het vervolgtraject van PREVASC (twee tot 
zes jaar). Het onderzoek werd gekenmerkt door vooral veel veldwerk door 
onderzoeksmedewerkers (al dan niet met een verpleegkundige achtergrond) 
die de gezinnen regelmatig thuis bezochten. Inke Schaap, Cindy Brink, Twanny 
Rouwhorst, Ellie de Vree, Marjan Terhaar, Marjori Rovers (jij hebt hele 
bijzondere rol gespeeld als deelnemer én onderzoeksverpleegkundige!), Gerti 
van Driel en Kitty van der Meer. Kitty, aan jou ook een speciaal woordje omdat 
wij niet altijd op dezelfde golflengte zaten. Ik wil je bij deze nogmaals zeggen 
dat ik je inzet voor het onderzoek zeer zeker heb gewaardeerd. Heel fijn dat jij 
een van de PREVASC-Kitties wilde zijn! De andere Kittie was uiteraard Kittie 
Coolen. We hebben samen de doorstart van twee naar zes jaar gemaakt. Kittie, 
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ik kon er altijd van op aan dat alles dat jij aanpakte goed gebeurde. We waren 
echt een team dus ik vond het ook erg jammer dat je ons team moest verlaten. 
Gelukkig heb je een hele leuke baan gevonden bij het MEMIC waar je nu ook 
weer een spilfunctie vervult. 
Gelukkig kwam er na het afscheid van Kittie, weer een fantastische 
onderzoeksassistente het team versterken. Waar Kittie de begin- en 
middenfase van het onderzoek heeft ondersteund, heeft Karen Groot de 
eindfase voor haar rekening genomen. Karen je hebt binnen PREVASC de 
kinderen begeleid bij de longfunctiemetingen. Je hebt heel vakkundig je rol 
vervuld. Ik had het alleen nooit kunnen redden allemaal. Heel erg bedankt voor 
je waardevolle bijdrage aan het onderzoek! Een onderzoeksassistente die 
Karen heeft opgevolgd was Susanne Hanssen. Jij hielp naast PREVASC ook 
andere projecten tot een succesvol einde brengen. Bedankt dat je er was. 
Renske Bottema kwam ons team versterken toen we gevraagd werden mee te 
werken aan een groot genetica-onderzoek op het gebied van astma 
(Allergenic). Naast werk voor Allergenic, waar je zelf op zal gaan promoveren, 
hielp je ook bij de begeleiding van gezinnen bij de longfunctie meting van 
PREVASC. Je was een plezierige collega en deed belangrijk werk voor ons 
beider projecten! 
Secretaresses zijn managers 
Buiten de mensen die ik al noemde zijn er nog veel meer die hun bijdrage 
hebben geleverd aan PREVASC: De secretaresses Anne-Marie Korsten en 
Annemarie Spaninks wil ik hierbij speciaal benoemen. Annemarie Spaninks, 
goud ben je waard geweest voor het onderzoek! Jammer dat ons afscheid zo 
abrupt moest zijn en zo definitief…………. Ik had graag nog veel langer met je 
samengewerkt.  
Anne-Marie Korsten was er vanaf het eerste uur. Je hebt de beginfase van het 
PREVASC onderzoek secretarieel begeleid en wij zijn sinds die tijd, met 
wisselende intensiteit, ook als vrienden verder gegaan. Je ligt me persoonlijk na 
aan het hart maar je hebt ook veel voor het onderzoek betekent. Deze 
combinatie was voor mij het perfecte excuus om je te vragen naast mij te 
komen ‘staan’ als een van mijn paranimfen. Naast secretariële werkzaamheden 
in de eerste fase van PREVASC heb je ook regelmatig hand en span diensten 
gedaan voor de tweede fase van PREVASC. Bedankt dat je mijn vriendin wil 
zijn. Kim Luyten is ook een secretaresse die haar licht heeft laten schijnen over 
PREVASC. Kim je had tijdens je periode bij PREVASC een bezige baan als 
persoonlijk secretaresse van André en drijvende kracht van het Journal of 
Clinical Epidemiology. Je hebt voor PREVASC je taken uitgebreid door te 
helpen bij de dataverzameling in de breedste zin van het woord. Je bent een 
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grote en vooral ook plezierige kracht en vakkundige assistente geweest voor 
het onderzoek. Dank je wel! 
 
Data-invoer en -beheer door MEMIC voor het PREVASC onderzoek werd door 
Jacqueline Pisters vakkundig aangestuurd. Naast Jacqueline zijn ook de dames 
van de data-invoer, Jildou Sijbrandij en Alfons Schroten, aangestuurd door 
Annemie Mordant van grote waarde geweest. Dank je! 
Eindmeting van longfunctie op zes jarige leeftijd 
De longfunctiemetingen werden uitgevoerd in het academisch ziekenhuis 
Maastricht. De medewerkers van het longfunctielaboratorium die hierbij een 
hoofdrol hebben gespeeld wil ik speciaal bedanken: Marie-José Jaspers, Judith 
Baars  Manon Broekhuizen, Hedwich Wildeveld en secretaresses Monique 
Ramaekers en Esther Warnier. Jullie hebben alles rondom de 
longfunctiemetingen bij de kindjes van PREVASC in het azM op jullie kundige 
schouders genomen. Bedankt daarvoor! Marie-José, jou wil ik speciaal 
bedanken. Dankzij jou kon ik leren zelfstanding longfunctiemetingen uit te 
voeren bij de kindjes die niet naar Maastricht konden komen. Ik heb veel van je 
geleerd. 
 
Er zijn naast de hierboven genoemden vele andere medewerkers geweest die 
hebben bijgedragen aan het PREVASC onderzoek. Vaak waren het 
onderzoeksassistentes die naast hun eigen werkzaamheden incidenteel bij het 
project hebben geholpen. Hoewel ik jullie niet met naam benoem in dit 
dankwoord kan ik jullie zeker zeggen dat deze hulp er zeker toe heeft 
bijgedragen dat het project succesvol is afgerond. Nogmaals bedankt! 
Deze dank wil ik ook uitbrengen aan de uitzendkrachten Peter van Schayck, 
Anja Crounse en Rick Hoen. Ook jullie waren van grote waarde voor het 
project,  bedankt! 
Ook Jeroen Rovers, Jacqueline Vaes, Janneke Peeters, Marcos Gallegos, 
Yolanda Dennert, Marjolein Hutten en Esther Verduin hebben een waardevolle 
bijdrage geleverd aan het onderzoek tijdens hun stage. Ook mijn dank aan 
jullie. 
Collega’s huisartsgeneeskunde 
Rest mij nog alle collega’s te bedankten waarmee ik heb samengewerkt in mijn 
tijd bij huisartsgeneeskunde. Het zijn er te veel om een persoonlijk woordje van 
dank over te schrijven. Mijn kamergenoten waar ik met veel plezier, en soms 
zelfs vriendschap, heb samengewerkt wil ik hier wel persoonlijk noemen: Als 
eerste natuurlijk Judith Sieben die vanaf 1999 tot 2005 de kamer met mij deelde 
en waarmee het contact zich ontwikkelde van collega naar vriendin. Straks ben 
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jij een van mijn para-nimfen en zullen we wederom een (werk)kamer met elkaar 
delen. Ik hoop dat het net zo vertrouwd zal voelen als ik gewend ben met jou in 
mijn aanwezigheid……….. Jochen Cals was de tweede kamergenoot in mijn 
PREVASC periode. We praten vast wel weer eens gezellig na………. Yvonne 
Winants, ik heb je inbreng altijd als zeer waardevol en welkom ervaren. 
De cirkel is rond……….. 
Hoewel het erg voorspoedig leek te lopen is het bij mij niet altijd 
vanzelfsprekend gegaan. Het is een enorme veldslag geweest om juist de 
laatste fase van dit proefschrift tot een acceptabel einde te brengen. Iedereen 
om mij heen, familie, vrienden en collega’s, weet dat ik ziek ben en koste wat 
kost doorzet om maar niet toe te hoeven geven dat ik beperkingen heb ten 
gevolge van mijn gezondheid. Reden is voor mij evident: Op mijn leeftijd hoef je 
niet zo voorzichtig met energie om te moeten gaan. Je moet kunnen genieten! 
Opbouwen van een nieuwe fase in je leven en lekker onbezorgd zijn. Jammer, 
zo ligt het bij mij niet…………… Ik ga ervoor een nieuwe functie te vinden 
waarin ik geen beperkingen zal ondervinden van mijn gezondheid en vooral ook 
van betekenis kan zijn voor anderen via zorg en/of wetenschap. Dus waar het 
mee begon, zorg (verpleging) en wetenschap, komt weer terug in deze fase. De 
cirkel is rond…………….. 
Oost west thuis best 
Mijn vrienden, het thuisfront en mijn ouderlijk gezin wil ik graag bedanken voor 
hun steun tijdens de looptijd van het project. Natuurlijk een speciaal woordje 
voor mijn eigen gezin dat bestaat uit Xavier, Rafael en Isha: Zonder jullie zou ik 
dit proefschrift niet eens hebben WILLEN schrijven. Jullie zijn mijn leven………. 
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About the author 
Tanja Maas was born in Nuenen on September 7th, 1972. She moved to Weert 
with her family and completed her secondary education (MAVO) in this town at 
‘Het Bisschoppelijk College’. She completed intermediate vocational nursing 
education (MDGOvp) in Maastricht followed by higher vocational nursing 
education (HBOv, cum laude) in Sittard. Tanja switched her education from 
nursing to Biological Health Science at the Maastricht University (UM). Her 
master’s thesis focused on the influence of the type of infant feeding, human 
milk or artificial formula, on growth in early childhood (0-3 years). It was 
hypothesised that the known difference in milk fatty acid composition would 
influence length, weight and head-circumference increment. She kept working 
part-time as a nurse in community care, maternity care and occasional nursing 
jobs in a home for the elderly or those intellectually disabled. During the last 
year of her university study (1997) she started working as a research nurse for 
the PREVASC project on prevention of asthma in genetically predisposed 
children at high-risk of developing asthma (follow-up from pregnancy to two 
years). She was appointed to carry out home visits to the participating families 
from pregnancy onwards. During these home visits she offered the advisory 
intervention and carried out research measurements. In 1998 she started 
working as research assistant and finally (2000) she was appointed as PhD-
student carrying out the study as presented in the current thesis (PREVASC, 
follow-up from two to six years). At the moment she is thinking about making a 
switch from epidemiological asthma research to a different field of expertise. 
Her personal happiness lies in her life with her husband Xavier Camp and their 
children Rafael and Isha. 
